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In this thesis, I have focussed on a number of clinical aspects of
the pathophysiology of early diabetic nephropathy which have
previously received little attention.
a) Early diabetic nephropathy, hypertension and vascular disease
1. Patients with IDDM, both with normal albumin excretion and
microalbuminuria, have no evidence of a defect of urinary dopamine
excretion. This genetically determined association with essential
hypertension does not, therefore, explain the link between early
diabetic nephropathy and hypertension.
2. In hypertensive patients with IDDM, captopril and nifedipine
retard have a similar effect in reducing blood pressure and albumin
excretion after eight weeks treatment. Captopril, however, retains an
acute effect on renal haemodynamics, resulting in a decreased
filtration fraction, and this may be of specific importance in the
management of patients with diabetic nephropathy.
3. In newly-presenting patients with NIDDM, 26% had abnormal
urinary albumin excretion, this correlating with age, glycaemic
control, systolic blood pressure and generalised vascular disease.
Over the year following diagnosis, 16% of patients had persistent
microalbuminuria.
b) Tubular function in early diabetic nephropathy
Markers of tubular enzymuria and low molecular weight proteinuria
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were measured in patients with IDDM, both with and without
microalbuminuria. Only 8 (38%) of 21 patients with a detectable
urinary beta-thromboglobulin concentration had concurrent abnormal
albumin excretion. Urinary excretion of N-acetyl-beta-D-
glucosaminidase was increased in 22 (63%) of patients with
microalbuminuria and also correlated with glycaemic control and
smoking. Although tubular dyfunction is commonly found in patients
with microalbuminuria, the relatively poor correlation of currently
available markers would seem to limit their value in the detection of
early nephropathy.
c) Hypoqlvcaemia and diabetic nephropathy
In patients with IDDM and normal albumin excretion, acute
hypoglycaemia causes a number of changes in renal function, notably a
significant fall in both effective renal plasma flow and glomerular
filtration rate (GFR) . The fall in GFR is more marked than in non-
diabetic subjects. It is possible that hypoglycaemia may have a role
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SCOPE AND AIMS OF THESIS
7
Introduction
Nephropathy complicating diabetes mellitus is a major cause of
morbidity and mortality. Until the last few years, it was only
possible to diagnose diabetic nephropathy at an advanced and
irreversible stage of the disease process. However, a much earlier
stage of diabetic renal disease has now been identified,
characterised by normal renal function but an increase in urinary
albumin excretion, in comparison with normal subjects. This early
phase of diabetic nephropathy has been termed 'microalbuminuria'.
Microalbuminuria has been shown to be a strong predictor, if
untreated, of progression to advanced renal disease and patients with
microalbuminuria also have a significantly increased prevalence of
generalised macrovascular disease and higher blood pressure than
control subjects with normal urinary albumin excretion.
Studies to date suggest that intervention at the stage of
microalbuminuria may slow, or even prevent, progression to more
severe nephropathy, characterised by persistent proteinuria, with its
inexorable decline towards end-stage renal disease, although long-
term follow-up data is still awaited. The association between
microalbuminuria, hypertension and generalised vascular disease is
still, however, poorly understood and this, in addition to a number
of other areas of potentially considerable clinical importance in the
field of early diabetic nephropathy, have to date received little
attention. In this thesis, I have attempted to identify and explore
further some of these areas.
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Aims of thesis
I have focussed on three major areas of research and attempted to
answer a number of specific questions.
Early diabetic nephropathy, hypertension and vascular disease
a) Does an abnormality of dopamine excretion, a genetically
determined association with essential hypertension, provide an
explanation for the link between microalbuminuria and increased blood
pressure?
b) In hypertensive patients with insulin-dependent diabetes
(IDDM), do different classes of antihypertensive drugs (namely
angiotensin converting enzyme inhibitors and calcium antagonists)
have differing, and possibly specific, effects on blood pressure,
urinary albumin excretion and renal haemodynamics?
c) In newly-diagnosed patients with non-insulin-dependent diabetes
(NIDDM), what is the prevalence and natural history of abnormal
urinary albumin excretion and its associations, particularly with
blood pressure and macrovascular disease?
Tubular function in early diabetic nephropathy
Is tubular enzymuria and increased excretion of low molecular weight
proteins, indicative of tubular dysfunction, of value in the
detection of early diabetic nephropathy, possibly at an earlier stage
of the disease process than that identified by the presence of
microalbuminuria?
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Hvpoqlvcaemia and diabetic nephropathy
Could hypoglycaemia, which is commonly experienced by most patients







1.1 PREVALENCE AND IMPLICATIONS OF DIABETIC NEPHROPATHY
Renal disease (nephropathy) is a major cause of morbidity and
mortality in patients with IDDM. This is particularly so in those
developing the disease at a young age. Diabetes diagnosed before age
31 years has been reported to be associated with nephropathy in over
35% of patients, with 31% of deaths being due to renal disease
(Deckert et al, 1978), excess mortality in patients developing
nephropathy being 3-4 fold compared with those who do not. Another
epidemiological study, finding a similar prevalence of nephropathy of
approximately 40% in patients with IDDM, has suggested that this is
an even more important cause of mortality, death from renal disease
being reported in over 50% of affected patients (Andersen et al,
1983). In terms of resource implications, diabetic nephropathy
currently accounts for over a quarter of all patients entering
dialysis or transplantation programmes for end-stage renal disease in
the United States (Vollmer et al, 1983; Eggers et al, 1984), with
diabetic patients undergoing haemodialysis and transplantation
spending much longer periods in hospital than patients with non-
diabetic renal disease (Shyh & Bayer, 1985). In the United Kingdom,
it has been estimated that around 20% of patients with renal failure
sufficiently severe to merit renal replacement therapy have diabetes
(Berisa et al, 1989), although a recent survey suggests that a third
of such patients die without receiving renal support treatment (Joint
Working Party on Diabetic Renal Failure, 1989).
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1.2 CLINICAL DIAGNOSIS OF DIABETIC NEPHROPATHY
The hallmark of clinical (frank) diabetic nephropathy is excessive
urinary excretion of protein, especially albumin (Parving et al,
1982), characteristically detected on standard dip-stick urine
testing, eg Albustix. This usually indicates a protein excretion in
excess of 0.5 g/24 h (Abuelo, 1983) and most commonly occurs 14 - 19
years after onset of diabetes, new cases of nephropathy being
relatively uncommon after 25 - 30 years of diabetes (Andersen et al,
1983; Borch-Johnsen et al, 1985). Once clinical proteinuria develops,
arterial blood pressure rises and glomerular function declines
progressively and at a constant rate which varies considerably from
patient to patient (Jones et al, 1979; Viberti et al, 1983a). Renal
failure usually occurs 4-5 years after the onset of proteinuria
(Rutherford et al, 1977; Andersen et al, 1978).
1.3 PATHOLOGICAL DIAGNOSIS OF DIABETIC NEPHROPATHY
Characteristic pathological changes in the kidneys of patients with
IDDM have long been recognised. Nodular glomerulosclerosis was
described by Kimmelstiel and Wilson over 50 years ago and was
considered to be pathognomonic of diabetic renal disease (Kimmelstiel
& Wilson, 1936). Other less specific changes are also well
recognised, including diffuse glomerulosclerosis and mesangial cell
proliferation. More recent pathological studies have shown that the
most consistent finding in diabetic nephropathy is thickening of the
glomerular basement membrane (Bergstrand & Bucht, 1959). Although
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glomerular hypertrophy may be present at diagnosis, progressive
thickening of the glomerular basement membrane appears to occur with
duration of disease (Mogensen et al, 1979a; Mauer et al, 1984).
Excessive deposition of glomerular basement membrane-like material
causes mesangial expansion (Osterby, 1973) and encroachment on the
subendothelial space may compromise the glomerular capillary lumen
and blood flow, eventually causing capillary occlusion (Mauer et al,
1981). Although only around 40% of IDDM patients will develop
clinical diabetic nephropathy, most patients will have some
pathological abnormalities within a few years of diagnosis of the
disease (Deckert & Poulsen, 1981). The extent of the pathological
changes does not invariably correlate closely with either duration of
disease or the clinical picture, but it is clear that clinical
nephropathy manifested by frank proteinuria does not generally become
manifest until pathological changes are well advanced (Mauer et al,
1984; Thomsen et al, 1984).
1.4 THE CONCEPT OF EARLY DIABETIC NEPHROPATHY (MICROALBUMINURIA)
It is evident from Section 1.2 that identification of diabetic
nephropathy at the stage of frank proteinuria is too late to
significantly influence morbidity and mortality.
In the last few years, it has been noted that, before the onset of
frank proteinuria and progressive deterioration in renal function,
there is a silent phase, when renal function remains normal,
characterised by increased urinary albumin excretion (Mogensen et al,
1983). In normal subjects, albumin comprises approximately 11% of the
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total urinary protein excretion (Viberti et al, 1983b) but this
proportion rises progressively with increased renal damage. As
mentioned above, standard dip-stick methods of testing for
proteinuria detect only concentrations of protein in excess of
approximately 500 mg/1 (Abuelo, 1983), of which, at this stage of the
disease process, some 50% is albumin (Viberti et al, 1983b). However,
the presence of much lower concentrations of albuminuria also
predicts the later development of frank nephropathy. In 1982, Viberti
reported that, in a group of patients with IDDM who were followed up
for 14 years, a urinary albumin excretion rate (AER) in excess of 30
ug/min predicted the later development of dip-stick positive
proteinuria (Viberti et al, 1982a). Seven out of eight patients in
this category went on to develop frank nephropathy, compared with
only two out of 55 patients with a lower initial AER. A further
series of studies published in the next two years (Parving et al,
1982; Mathiesen et al, 1984; Mogensen & Christensen, 1984) examined
cut-off concentrations of albuminuria between 15 and 70 ug/min,
patients being followed up for varying periods of time from upwards
of six years. In each study the presence of the higher concentration
of albuminuria was highly predictive of the development of
proteinuria.
This increased concentration of urinary albumin excretion, between
normality and that detectable by standard dip-stick testing, has been
given the label 'microalbuminuria'. This has been defined more
specifically, largely to standardise research in the field, by a
concensus of a predominantly Scandinavian group of investigators
(Mogensen, 1987). Thus microalbuminuria is diagnosed on the basis of
a 24-hour urinary albumin excretion of 30 - 300 mg (20 - 20 ug/min)
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in two out of three samples collected over a 6-month period, this
latter proviso being made on account of the considerable day to day
variation which can occur in urinary albumin excretion, depending on
various factors, including exercise and state of hydration (Chachati
et al, 1987). This day to day variation is reported to be as much as
47% in diabetic patients both with and without abnormal albumin
excretion (Feldt-Rasmussen & Mathiesen, 1984).
In addition to being a reliable predictor of frank diabetic
nephropathy in IDDM, microalbuminuria also clearly correlates with
the presence of retinopathy (Barnett et al, 1985) and closely
predicts the majority of early deaths in IDDM, not only from end-
stage renal disease but also from cardiovascular causes (Jensen et
al, 1987; Gatling et al, 1988a). Similarly, in NIDDM, the presence
of microalbuminuria predicts the development of established
nephropathy, albeit to a lesser extent than in the IDDM population.
In one study (Mogensen, 1984) 22% of patients with microalbuminuria
went on to develop persistent proteinuria over a nine year period.
Microalbuminuria in the NIDDM population is also a strong predictor
of increased mortality (Jarrett et al, 1984; Mogensen, 1984), with
more than 50% of this excess being due to ischaemic heart disease
(Mogensen et al, 1984; Schmitz & Vaeth, 1988). There is additional
evidence that an association between increased urinary albumin
excretion and cardiovascular disease is demonstrable in the non-
diabetic population (Yudkin et al, 1988), lending weight to the
theory that albuminuria may be a marker of a more generalised
vascular process (See Section 1.5).
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1.5 THE PATHOGENESIS OF MICROALBUMINURIA
The pathogenesis of microvascular disease in diabetes is not well
understood and many theories have been put forward. With specific
reference to early nephropathy several possible influential factors
have been suggested.
1. Genetic Factors
There are a number of pointers to a possible genetic role in the
aetiopathogenesis of diabetic nephropathy. The first relates to
individual susceptibility to this particular complication. As
discussed above (Section 1.1), nephropathy affects no more than 40%
of patients and, moreover, development of nephropathy is extremely
rare after 25 - 30 years of the disease. This only partly relates to
metabolic control and exposure to hyperglycaemia, suggesting a
genetic influence. Support is also lent to the concept of a
hereditary factor by the evidence that diabetic nephropathy occurs in
familial clusters (Seaquist et al, 1989).
A link between diabetic nephropathy and the HLA antigen B8 has been
suggested (Barbosa et al, 1976) but the most interesting genetic data
pertains to the association between nephropathy and hypertension (see
also Chapter 3). Although it has traditionally been regarded that
hypertension in patients with nephropathy relates directly to renal
damage, the finding of a higher blood pressure in patients with
microalbuminuria, and apparently normal glomerular function, than in
control subjects with normal albumin excretion (Mathiesen et al,
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1984; Wiseman et al, 1984a; Christensen & Mogensen, 1985) suggests
the possibility of a more fundamental association. That this
association may have a genetic component, with a predisposition to
hypertension contributing to susceptibility to nephropathy, has been
suggested by the finding that parents of patients with IDDM who have
proteinuria have a significantly higher blood pressure than those of
patients with normal protein excretion (Viberti et al, 1987).
Furthermore, research into the erythrocyte sodium-lithium counter-
transport system, which is apparently a genetically determined marker
of hypertension (Semplicini et al, 1989), has shown higher rates of
activity in diabetic patients with nephropathy compared with patients
having a similar duration of disease but normal protein excretion
(Krolewski et al, 1988; Mangili et al, 1988). This system is thought
to reflect the activity of the physiological sodium-hydrogen
antiport, which has an important role in the renal reabsorption of
sodium and bicarbonate, and is also involved in the control of cell
growth and replication (Mahnensmith & Aronson, 1985). As discussed in
Section 1.3, glomerular hypertrophy and mesangial expansion are
characteristic pathological findings in diabetic nephropathy.
Further clues to a genetic influence in the aetiology of diabetic
nephropathy are provided by the ethnic variations in the prevalence
of this complication, seen particularly in the population with NIDDM.
The incidence of nephropathy is higher in a number of ethnic
populations, including Japanese and American Indians (Nelson et al,
1989), although the fact that the latter tend to develop diabetes at
an early age and the former are relatively protected from coronary
heart disease (and therefore are more likely to survive for
sufficiently long to develop nephropathy) may be of importance.
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Nonetheless, there do seem to be some genuine differences between
ethnic groups and, in the UK, Asian Indians have a higher prevalence
of microalbuminuria than comparable patients of European extraction
(Allawi et al, 1988).
2. Haemodynamic Factors
The glomerular filtration rate is approximately 25% higher in
patients with short-term IDDM than in non-diabetic control subjects
(Christiansen et al, 1981a) and is also significantly elevated in
patients with longstanding disease who do not have frank proteinuria
(Mogensen, 1972). Even at initial diagnosis an increase in glomerular
filtration rate of some 40% compared with controls has been reported
(Mogensen, 1971). This is accompanied by an elevation in renal plasma
flow, which is a major determinant of glomerular filtration rate,
accounting for around 50 - 60% of the observed increase (Mogensen &
Andersen, 1973; Christiansen et al, 1981b). There is evidence that
these haemodynamic abnormalities are related to the structural
changes seen early in the course of the disease, with kidney size and
glomerular filtration rate being positively correlated (Mogensen &
Andersen, 1973). Micropuncture studies in rats have shown this to be
associated with an elevated transglomerular pressure gradient
(Hostetter et al, 1981a) and further animal studies have shown that
such haemodynamic changes may cause alterations in glomerular
selective permeability, resulting in increased albumin excretion
(Olson et al, 1982). Nephrectomy results in compensatory haemodynamic
mechanisms, with relative hyperfiltration in the reduced population
of nephrons in the remnant kidney (Hostetter et al, 1981b).
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Nephrectomised rat and dog models (Steffes et al, 1978 & 1982) have
been shown to have more rapid development and progression of diabetic
nephropathy than control animals. An anecdotal case report,
suggesting the importance of haemodynamic factors in the human
kidney, described the post-mortem findings in a diabetic patient with
unilateral renal artery stenosis, who only had classical pathological
changes of diabetic nephropathy affecting the kidney supplied by the
normal renal artery (Berkman & Rifkin, 1973).
3. Metabolic Factors
Glycaemic control has long been considered important in the aetiology
of diabetic complications, including nephropathy and an association
is certainly supported by a number of studies (Mogensen et al, 1983;
Hasslacher et al, 1985). However, at the stage of persistent
proteinuria, the degree of proteinuria and renal impairment does not
appear to relate to prevailing glycaemia and most authors have found
that improvement in blood glucose control at this stage does not
influence the rate of progression of the nephropathic process
(Tamborlane et al, 1982; Viberti et al, 1983c). This is discussed
further in Section 1.7.
In patients with microalbuminuria, there does seem to be a
correlation between albumin excretion and glycaemic control (Wiseman
et al, 1984a) and this may at least partly operate through the
haemodynamic changes discussed above. In diabetic patients, a
positive correlation certainly exists between prevailing plasma
glucose concentrations and glomerular filtration rate (Wiseman et al,
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1984b) and, even in non-diabetic subjects, infusion of glucose
results in an increase in glomerular filtration rate (Brochner-
Mortensen, 1973; Christiansen et al, 1981c).
Disturbances of glucagon and growth hormone secretion also occur in
poorly controlled diabetic patients with serum concentrations of both
of these hormones being increased. Infusion of both glucagon (Parving
et al, 1977 & 1980) and growth hormone (Christiansen et al, 1981d &
1982) may, per se, increase glomerular filtration rate. The magnitude
of the haemodynamic changes caused by infusion of these hormones is,
however, less than is observed in IDDM, particularly in the early
stages following diagnosis, and these metabolic factors are,
therefore, unlikely to be the sole cause of the increased glomerular
filtration rate observed in diabetic patients.
The Steno Hypothesis
A recent theory put forward by Deckert and his colleagues in the
Steno Memorial Hospital in Gentofte, Denmark ties together a number
of the possible pathogenetic factors discussed above and also
attempts to provide an explanation for the clear association between
increased urinary albumin excretion and evidence of vascular (notably
coronary artery) pathology discussed in Section 1.4 (Deckert et al,
1989).
The heparan sulphate proteoglycan is the major glycosaminoglycan
component of the basement membranes of the glomeruli (Kanwar &
Farguhar, 1979; Wu et al, 1987), mesangium (Kanwar et al, 1983; Wu et
al, 1987) and endothelial plasma membranes (Robinson & Gospodarowicz,
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1984). In the kidney, heparan sulphate proteoglycan inhibits the
glomerular filtration of albumin (Rosenzweig & Kanwar, 1982; Groggel
et al, 1988) and contributes to the pore size of the glomerular
basement membrane (Tarsio et al, 1988), in addition to inhibiting
mesangial cell growth (Castellot et al, 1985). Elsewhere in the body,
heparan sulphate proteoglycan has important antithrombogenic
properties (Marcum et al, 1984; Pejler et al, 1987), binds
lipoprotein lipase (Williams et al, 1983) and inhibits arterial
smooth muscle proliferation (Castellot et al, 1984). A decreased
glycosaminoglycan component within the glomerular basement membrane
has been demonstrated in diabetic patients with nephropathy
(Parthasarathy & Spiro, 1982; Shimomura et al, 1987), and loss of
heparan sulphate from the glomerular basement membrane leads to the
loss of anionic sites and consequently albuminuria (Rosenzweig &
Kanwar, 1982; Cotran & Rennke, 1983; Groggel et al, 1988). In
addition, its widespread effects elsewhere, which are likely to
promote the development of atherogenesis (Marcum et al, 1984;
Gallagher et al, 1986; Stender & Hjelms, 1987), may at least partly
explain the association between albuminuria and extrarenal vascular
abnormalities.
Deckert proposes that there is a genetically determined polymorphism
of enzymes involved in the metabolism of heparan sulphate
proteoglycan, this having been demonstrated in at least one rat model
(Eriksson et al, 1986). He hypothesises that patients who develop
albuminuria are characterised by enzymes which are particularly
vulnerable to poor glycaemic control. In these patients a critical
reduction in normal heparan sulphate proteoglycan may occur,
resulting in microalbuminuria, glomerular expansion and other
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extrarenal microvascular and macrovascular complications. It is
postulated that such a genetic polymorphism may account for the fact
that only a certain percentage of diabetic patients develop
nephropathy and also might explain why even patients with
persistently poor glycaemic control do not invariably develop renal
disease or other specific vascular complications.
1.6 SCREENING FOR MICROALBUMINURIA
The recognition that a subclinical increase in urinary albumin
excretion (undetectable on standard dip-stick testing) is highly
predictive of later frank nephropathy and other vascular
complications has led to the development of the concept of
microalbuminuria, as discussed in Section 1.4. The wide range in the
timing of the urine samples collected in the initial studies, and
variety of assays used, meant that early definitions of
microalbuminuria were inconsistent. As described earlier, in an
attempt to standardise this, 'The Gentofte Convention on
Microalbuminuria and Incipient Diabetic Nephropathy' in 1985 reached
the consensus definition of microalbuminuria as a urinary albumin
excretion of 20 - 200 ug/min (30 - 300 mg/24 h) in two out of three
timed collections during a 6-month period (Mogensen, 1987).
Even the lower limit of this definition is considerably higher than
the normal albumin excretion rate in healthy subjects. This has been
quoted in different studies as between 2.5 and 26.0 mg/24 h (1.7 -
17.4 ug/min), with a mean of 9.5 mg/24 h (6.4 ug/min) (Viberti et al,
1984) and between 2.3 and 8.3 ug/min, with a mean of 4.3 ug/min
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(Mogensen, 1984).
The recognition that albuminuria also increases with exercise has led
to attempts to use a standardised test to unmask an even earlier
stage of diabetic nephropathy and to exaggerate the increased albumin
excretion in patients with early nephropathy, with a possibly greater
predictive value (Viberti et al, 1978; Viberti & Keen, 1984; Mogensen
et al, 1979b; Vittinghus & Mogensen, 1982). Nonetheless, the
consensus definition at present remains the gold standard for the
diagnosis of microalbuminuria. As for the timing of the urine sample,
a full 24-hour collection probably remains the standard against which
other screening methods must be compared. A timed overnight
collection may be an equally valuable measurement, with a reduced
risk of the problem of incomplete sampling which invalidates many 24-
hour urine collections, although direct comparative data is lacking.
Many studies have attempted to identify a simple test for
microalbuminuria which does not require patients to collect timed
urine samples at home and which would therefore be more practical for
large-scale screening. The albumin concentration in a random urine
specimen does not, however, correlate particularly well with timed
albumin excretion rates. A correlation co-efficient of 0.45 with the
albumin excretion rate in a timed overnight collection has been
reported (Gatling et al, 1985) and random urinary albumin
concentrations of >25 mg/1 and >26 mg/1 have been shown in different
studies to have a sensitivity of 56% and 100% and a specificity of
81% and 85% respectively in predicting an albumin excretion rate of
>30 ug/min (Gatling et al, 1985; Watts et al, 1986). Clearly this
method of screening results in too many false positive results.
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The normal increase in albumin excretion which occurs with exercise,
mentioned above, is exaggerated in patients with diabetes (Mogensen &
Vittinghus, 1975) and this may partly account for the unacceptably
low sensitivity and specificity of random spot urine albumin
measurements in predicting microalbuminuria. On account of this, the
predictive value of the albumin concentration in early morning urine
specimens has been assessed. Such a measurement appears to correlate
better with both the 24-hour urinary albumin excretion (Cowell et al,
1986) and the albumin excretion rate calculated from a timed
overnight urine collection, a correlation co-efficient of 0.90 having
been reported with the latter (Hutchison et al, 1988). An albumin
concentration of >20 mg/1 in an early morning urine specimen has a
sensitivity of 86 - 91% and a specificity of 74 - 97% of predicting
an overnight albumin excretion rate of >30 ug/min (Gatling et al,
1985; Marshall & Alberti, 1986).
The accuracy of such measurements of albumin excretion in early
morning urine samples can be further refined by the measurement of
the urinary creatinine excretion and the calculation of an
albumin:creatinine ratio. Such a correction improves the predictive
value even in random specimens of urine, but in early morning urine
samples, calculation of this ratio is of even greater benefit. The
albumin:creatinine ratio in an early morning urine sample has a
correlation co-efficient of 0.74 with the 24-hour albumin excretion
(Cowell et al, 1986) and 0.91 with the overnight albumin excretion
rate (Gatling et al, 1985). An albumin:creatinine ratio of >3.5
mg/mmol has been reported to have a sensitivity of 88 - 100% and a
specificity of 95 - 99% of predicting an overnight albumin excretion
rate of >30 ug/min (Gatling et al, 1985 & 1988b) . A further study
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found that a cut-off of 2.5 mg/mmol in the albumin:creatinine ratio
allowed clear separation of groups of subjects with microalbuminuria
and normal albumin excretion (Cohen et al, 1987a).
Although the different cut-off values used in the various published
studies, and the variable results reported, makes firm conclusions
difficult, the available evidence does point to the measurement of
the albumin:creatinine ratio in an early morning urine specimen being
the most useful simple screening test for microalbuminuria, suitable
for mass use in the clinical setting.
1.7 TREATMENT OF MICROALBUMINURIA
It is central to the whole concept of microalbuminuria that
intervention at this stage of the nephropathic process may prevent
progression to frank proteinuria and inevitable deterioration of
renal function. Three major strategies have been found to be of
benefit in such patients.
1. Improvement of Glvcaemic Control
The potential role of poor glycaemic control in the causation of
diabetic nephropathy is discussed in Chapter 1.5 (Mogensen et al,
1983; Hasslacher et al, 1985) and hyperglycaemia has been considered
to be integral in the causation of the glomerular hyperfiltration
which is an early feature of diabetic nephropathy (Hostetter et al,
1982). At the stage of incipient nephropathy, there is some evidence
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of an independent correlation between prevailing glycaemia and
albumin excretion, patients with microalbuminuria having poorer
glycaemic control than those with normal albumin excretion (Wiseman
et al, 1984a).
The potential therapeutic benefit of improving glycaemic control in
patients with frank nephropathy is a matter of some debate. One study
has estimated that glycaemic control accounts for approximately one-
third of the progression of established renal disease over time, at
the stage of a reduced glomerular filtration rate (Nyberg et al,
1987). Others, however, have shown that improved glycaemic control at
this stage of the disease process does not have a significant effect
in influencing deterioration of renal function (Tamborlane et al,
1982; Viberti et al, 1983c).
In patients with microalbuminuria, the evidence that improved
glycaemic control has an important role appears to be more
encouraging. Most studies have focussed on the use of the technique
of continuous subcutaneous insulin infusion (CSII), which enjoyed a
spell of popularity in the early 1980's, to tighten glycaemic
control. Using this technique, a reduced rate of both increase in
albumin excretion with time and progression to frank nephropathy has
been demonstrated (Deckert et al, 1984; Feldt-Rasmussen et al,
1986a). Indeed, an actual fall in albumin excretion over a period of
up to 4 years has been reported in patients with microalbuminuria
treated with CSII to achieve improved glycaemic control (Kroc
Collaborative Study Group, 1984; Feldt-Rasmussen et al, 1986b; Dahl-
Jorgensen et al, 1988). A reduction in kidney size during treatment
with CSII has also been shown in patients with microalbuminuria
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(Feldt-Rasmussen et al, 1986b). Even in diabetic patients with
normal albumin excretion, hyperfiltration, which may predispose to
later nephropathy, appears to be reduced during treatment with CSII
(Beck-Nielsen et al, 1985; Wiseman et al, 1985; Christensen et al,
1987).
The use of CSII has largely fallen out of favour because of poor
patient acceptability, the rapid development of ketosis in the event
of pump malfunction and the problem of hypoglycaemia unawareness
associated with excessively tight glycaemic control. The use of
multiple insulin injections to improve glycaemic control, albeit to a
lesser extent than achieved using CSII, did not result in an obvious
reduction in urinary albumin excretion over a 4-year period, compared
with a conventionally-treated control group, in one study (Dahl-
Jorgensen et al, 1988). Nonetheless, evidence that glycaemic control
is important in the early stages of the nephropathic process is
probably sufficiently compelling that optimization of glycaemic
control should be a therapeutic goal in all such patients with IDDM.
Evidence from previous studies with regard to the importance of
glycaemic control in patients with NIDDM and microalbuminuria is
lacking and this is considered further in Chapter 5.
2. Reduced dietary protein intake
Low protein diets are widely used in the management of patients with
chronic renal failure of all aetiologies. Prospective studies have
been conducted in patients with a reduced creatinine clearance and
elevated serum creatinine concentration, treated with a dietary
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protein intake of 0.4 - 0.6 g/kg body weight/day for at least 18
months. Compared with control subjects on unrestricted diets, there
was a significant slowing in the reduction in glomerular filtration
rate and other parameters of deteriorating renal function, with fewer
X patients developing end-stage renal failure (Rosman et al, 1984; Ihle
et al, 1989) .
Relatively few studies have assessed the value of protein restriction
specifically in patients with nephropathy secondary to IDDM. Short-
term use of a 40 g protein diet over a 3-week period in diabetic
patients with persistent proteinuria reduced both the plasma urea
concentration and the urinary protein excretion (Bending et al,
1988). Longer-term studies have also been conducted using protein
restriction of a similar degree in patients with established diabetic
nephropathy. A highly significant fall in the rate of decline in
glomerular filtration rate and in the albumin excretion rate was
demonstrated after a mean period of 33 months of protein restriction
to 0.67 g/kg body weight/day, compared with a similar period of
treatment on a normal protein diet (Walker et al, 1989). A further
small American study showed similar results in a group of patients
with IDDM, proteinuria and reduced creatinine clearance, treated with
a 40 g protein diet over a 12-month period (Evanoff et al, 1987).
Even at the stage of microalbuminuria, protein restriction appears to
be potentially advantageous, at least in the short-term. During a 3-
week crossover study on a 47 g protein diet and on a normal diet
containing approximately twice that amount of protein, albumin
excretion rate and glomerular filtration rate fell significantly
during protein restriction, with no concomitant changes in blood
29
pressure or glycaemic control over the same period (Cohen et al,
1987b). Protein restriction reduces glomerular filtration and
filtration fraction even in diabetic patients with no evidence of
renal disease (Wiseman et al, 1987) and the effect of this form of
treatment in diabetic patients with nephropathy may be specifically
by its influence on renal haemodynamics, resulting in a reduction in
glomerular hyperfiltration.
Although the available evidence does point to a potential benefit of
protein restriction, even in early diabetic renal disease, from a
practical point of view compliance may prove a problem in a group of
patients who are asymptomatic and in whom dietary intake is already
significantly limited.
3. Antihypertensive Therapy
Because of poor patient acceptability of dietary protein restriction
and the difficulties which are often experienced in trying to
optimize glycaemic control, this is probably the most important
therapeutic option in the treatment of early diabetic nephropathy.
Hypertension and diabetic renal disease are inextricably linked and
in patients with frank nephropathy hypertension is a common finding,
with one study reporting that 51% of proteinuric diabetic patients
had a diastolic blood pressure of >95 mm Hg (Parving et al, 1983).
Debate continues as to whether this is a direct consequence of kidney
damage caused by the nephropathic process, an alternative theory
being that the hypertension and nephropathy have a common
determinant, perhaps of a genetic nature (see Section 1.5).
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Whatevever the precise mechanism of the association, treatment of
hypertension in diabetic patients with frank nephropathy has been
clearly shown in several studies to reduce the rate of decline of the
glomerular filtration rate, although it does not stop the progression
in renal impairment completely (Mogensen, 1982; Bjorck et al, 1986;
Parving et al, 1987).
Diabetic patients with microalbuminuria also have a higher blood
pressure than matched controls with normal albumin excretion, even
although only a minority have hypertension as defined by conventional
criteria (Mathiesen et al, 1984; Wiseman et al, 1984a; Christensen &
Mogensen, 1985). Even throughout the range of albumin excretion
within the defined limits of microalbuminuria, the blood pressure
appears to rise significantly as the albumin excretion increases
(Wiseman et al, 1984a).
There is increasing evidence of the value of antihypertensive therapy
in patients with microalbuminuria. In one of the earlier studies, the
albumin excretion rate was seen to fall by more than 50% over a
period of up to 5 years in a group of patients with microalbuminuria
and minimally elevated blood pressure, who were given
antihypertensive treatment in the form of metoprolol, with or without
diuretics (Christensen & Mogensen, 1987). Subsequent studies have
focussed largely on the angiotensin converting enzyme inhibitors,
predominantly because of the theoretical effect of this group of
drugs in reducing intraglomerular pressure. This might be expected to
be particularly beneficial in diabetic nephropathy, in which
glomerular hyperfiltration is a prominent early feature (see Section
1.5) and, at least in diabetic rats, these drugs do seem to reduce
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intraglomerular hypertension at the same time as reducing proteinuria
(Zatz et al, 1986). As a result, it has been suggested that
angiotensin converting enzyme inhibitors may be useful in the
treatment of diabetic nephropathy even in the absence of
hypertension. In studies in diabetic humans with microalbuminuria and
a supine blood pressure of <160/95, a reduction in the albumin
excretion rate, with a concomitant rise in glomerular filtration
rate, has been demonstrated after a 6-month period of treatment with
enalapril, using a placebo controlled, cross-over design (Marre et
al, 1987). Indeed, even in patients with IDDM who had normal albumin
excretion and normotension, there was a significant decline in
filtration fraction, albumin excretion rate and fractional albumin
excretion following a 3-month treatment period with enalapril (Mau
Pedersen et al, 1988). It is still unclear, however, if the results
of these studies are explicable on the basis of a specific action of
angiotensin converting enzyme inhibitors, or are simply a non¬
specific effect of reducing blood pressure. The use of different
antihypertensive agents in the treatment of hypertension in early
diabetic diabetic nephropathy is discussed further in Chapter 3.
Although it is undoubtedly premature, on the basis of one study (Mau
Pedersen et al, 1988), to advocate treating all patients with IDDM
with antihypertensive drugs, increasing evidence would suggest that
strict control of blood pressure in patients with microalbuminuria
can normalise urinary albumin excretion. It is as yet too early to






The research presented in the following chapters takes the form of a
series of clinical studies. The majority of investigations which have
been conducted during the course of these studies are routine and
well-established laboratory tests. In view of this, a brief
description of methodology has been included in the relevant
chapters, with acknowledgement being given to the laboratories
performing the various investigations. In this chapter, I have
confined myself to the more detailed description of techniques which
are either not performed as standard laboratory investigations or are
particularly important to one or more of the studies.
2.2 MEASUREMENT OF URINARY ALBUMIN EXCRETION
- Screening for the Presence of Microalbuminuria
This is relevant to all the studies described in the subsequent
chapters and is clearly of major importance to this thesis.
The background to screening for microalbuminuria has been discussed
in some detail in Section 1.6. Three major techniques are commonly
used for the quantitative measurement of urinary albumin excretion,
all of which have been well validated and are widely accepted. These
are radioimmunoassays (Keen & Chlouverakis, 1963; Miles et al, 1970;
Woo et al, 1978; Jury et al, 1985), enzyme-linked immunosorbent
assays (ELISA) (Fielding et al, 1983; Mohamed et al, 1984) and
immunoturbidimetric assays (Spencer & Price, 1979; Teppo, 1982).
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Overall, radioimmunoassay and ELISA tend to have greatest sensitivity
but can be difficult to automate. Immunoturbidimetry has a slightly
lesser degree of sensitivity, but this is still perfectly adequate to
detect abnormal levels of albumin excretion within the
microalbuminuric range and the relative ease of automating
immunoturbidimetric assays makes this method particularly suitable
for clinical departments where large numbers of samples are
processed.
The method used in the studies described here is an
immunoturbidimetric assay developed by Dr Richard Spooner, Principal
Clinical Biochemist, Gartnavel Hospital, Glasgow, based on previously
published work by Spencer and Price (1979). Urine samples were
assayed within four days of collection and during the period of
storage were kept at 4°C, with one drop (50 ul) of sodium azide
having been added to each 5 ml of urine.
The principle of the immunoturbidimetric assay involves the reaction
of albumin in the test sample with a specific antibody, this
resulting in a turbid solution, the absorbance of which is
proportional to the albumin concentration in the sample. The
necessary reagents were obtained from the AlbuSure QNT kit (Cambridge
Life Sciences, Cambridge, UK) . This kit comprises Anti-Human Serum
Albumin clarified antiserum, polyethylene glycol buffer and six vials
containing standards (with varying concentrations of albumin from 0 -
160 mg/1) for incorporation in each assay run to enable the
calculation of a standard curve. Absorbance of individual samples was
read using a Cobas Bio Analyser, firstly after addition of buffer
alone and secondly 30 min after incubation with the antibody reagent.
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The absorbance difference for each sample was calculated and the
albumin concentration read from the standard curve.
The method described has a sensitivity of 5 mg/1 in determining
urinary albumin concentration over the range of 0 - 250 mg/1. Samples
were tested in duplicate and the co-efficient of variation (CV) for
the assay was calculated on repeat analysis control data, randomly
selected specimens being analysed again on the next assay run. The
inter-assay CV during the relevant period of time was 5.1 - 5.9%.
For the studies described here, albumin excretion was determined on
at least two 24-h urine collections within a 6-month period, thereby
enabling the diagnosis of microalbuminuria using the most clearly
defined criteria (Mogensen, 1987). The exception to this are the
studies described in Chapter 5 and 6, in which the large number of
subjects and, in the case of Chapter 5, the repeated nature of the
sampling, made the collection of timed urine collections unrealistic
logistically. In these studies, the albumin excretion in early
morning urine samples was corrected for creatinine excretion and an
albumin:creatinine ratio was calculated. A ratio of >2.5 mg/mmol was
considered abnormal, this cut-off having been shown in a previous
study to enable clear separation of patients with a urinary albumin
excretion above and below 30 ug/min (Cohen et al, 1987a).
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2.3 MEASUREMENT OF RENAL HAEMODYNAMICS
- Renal Plasma Flow and Glomerular Filtration Rate
These techniques were used in the studies described in Chapters 4
and 7.
Clearance studies to measure renal plasma flow and glomerular
filtration rate were pioneered over half a century ago and have been
well validated over the years. In spite of the introduction of newer
and more advanced methods with which to assess aspects of renal
function, these older clearance methods remain an invaluable tool for
studying renal physiology in human subjects. Haemodynamic parameters
are estimated by measuring the clearance from plasma of stable inert
marker substances which have been infused into the circulation.
Following a suitable equilibration period, the clearance (C) can be
calculated by a standard formula:-
C = U / P x (Urine Flow Rate)
in which U and P represent the urine and plasma concentrations
respectively of the marker substance.
Inulin (or the very similar compound polyfructosan) remains the best
marker substance for measuring glomerular filtration rate. It is a
small enough molecule to filter freely through the glomerulus and it
is excreted only by the kidney with no active tubular secretion or
reabsorption occurring. A marker substance for renal plasma flow must
have the additional property of near complete extraction from plasma
during one pass through the kidney. Para-amino hippuric acid (PAH)
approaches this ideal, with an extraction ratio of approximately 0.9.
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Because this extraction ratio is less than unity, however, renal
plasma flow measured by this technique is a slight underestimate,
conventionally described as the effective renal plasma flow.
1. Effective Renal Plasma Flow
In the protocol described in Chapter 4, an initial intravenous
loading bolus dose of PAH (0.45 g) was given, followed by a standard
infusion of 8.5 g/1 in 0.9% sodium chloride solution at a rate of 2
ml/min throughout the individual studies. In Chapter 7, a different
protocol was used because of anticipated marked acute changes in
effective renal plasma flow occurring during individual studies and
potential problems with the collection of frequent urine samples
during induced hypoglycaemia. Here the clearance of an intravenous
bolus injection of PAH in a dose of 10 mg/kg body weight was measured
at appropriate points in individual studies. Blood samples were
withdrawn before and 5, 7, 10, 15, 20, 30 and 40 min after each
injection of PAH. The effective renal plasma flow was calculated,
assuming two-compartment kinetics, from the area under the curve of
plasma PAH concentrations after each bolus injection.
In both cases, PAH concentrations were measured by a modification of
the colorimetric method of Bratton and Marshall (1939), adapted for
use with a Technicon Autoanalyser (Harvey & Brothers, 1962). Samples,
following appropriate dilution, were first dialysed to allow transfer
of PAH but not proteins into the dialysate. Sodium nitrite was added
to diazotise the PAH and the colour was produced by coupling with N-
(1-napthyl) ethylenediamine hydrochloride. The absorbance, measured
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spectrophotometrically, is proportional to the PAH concentration in
the sample, which can be calculated from a standard curve.
2. Glomerular Filtration Rate
The glomerular filtration rate was calculated by measuring the
clearance of polyfructosan (Inutest; Laevosan, Linz, Austria), a
synthetic multimer of fructose. In all studies this was administered
as an intravenous infusion, at a concentration of 10 g/1 in 0.9%
sodium chloride solution and a rate of 2 ml/min, following an initial
loading bolus injection of 3.5 g. After an equilibration period of at
least 60 min, glomerular filtration rate was calculated during
individual studies from regular measurements of polyfructosan in
blood and urine specimens.
The method used was a modification of that described by Heyrovsky
(1956), adapted for use on a Technicon Autoanalyser (Dawborn, 1965).
Hydrochloric acid was added to samples, which were heated at 60°C to
hydrolyse the polyfructosan to fructose. Dialysis was used to remove
protein and further heating to 60°C, after mixing of the dialysate
with hydrochloric acid and air, produces a colour which can be
measured spectrophotometrically, the peak absorbance corresponding to
the polyfructosan concentration in the sample.
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2.4 MEASUREMENT OF URINARY FREE DOPAMINE
This is of particular relevance to Chapter 3 and urinary free
dopamine excretion was also measured in the studies described in
Chapter 7.
24-h urine collections for measurement of dopamine excretion were
collected into a bottle containing 25 ml of 5 mol/1 hydrochloric
acid, to lower the urine pH to <3 in order to prevent oxidation of
dopamine. Aliquots from the sample were then stored at -40^C until
assay.
It is likely that only free dopamine is physiologically active but up
to 80% of urinary dopamine may be in conjugated form (Kuchel et al,
1979). Free dopamine was therefore extracted with alumina, the
process being based on the method of Anton and Sayre (1964). Dopamine
standards were extracted following the same procedure as for the test
samples, the recovery of dopamine from the extraction process (mean
(SD)) being 69.7 (0.5)%, compared against unextracted standards. Free
dopamine was then measured by high performance liquid chromatography
(HPLC) with electro-chemical detection, using epinine (N-methyl
dopamine) as an internal standard (Jeffrey et al, 1987). Intra-assay
and inter-assay co-efficients of variation were 4% and 6%
respectively. Urinary free dopamine results were expressed as nmol/1
and the sensitivity of the assay was 5 nmol/1.
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CHAPTER 3
EARLY DIABETIC NEPHROPATHY AND HYPERTENSION (1)
URINARY DOPAMINE EXCRETION AND MICROALBUMINURIA
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3.1 INTRODUCTION
The evidence for a genetic factor playing an important role in the
pathogenesis of diabetic nephropathy is discussed in Section 1.5.
Some of the most interesting data pertains to the close association
between diabetic renal disease and hypertension, and there is some
evidence of increased activity of the erythrocyte sodium-lithium
countertransport system (a genetically determined marker of
hypertension) in diabetic patients with nephropathy (Krolewski et al,
1988; Mangili et al, 1988). In this study, the possible role of renal
dopamine, another factor which apparently has a genetically
determined link with hypertension, has been examined in the context
of early diabetic nephropathy.
Endogenous renal dopamine is believed to participate in sodium
homeostasis and appears to function, under physiological conditions,
as a natriuretic hormone (Kuchel et al, 1978). In normotensive
patients with normal renal function, the urinary excretion of
dopamine correlates directly with sodium output under normal
conditions and responds appropriately to salt loading and depletion
(Alexander et al, 1974; Carey et al, 1981).
In patients with advanced diabetic nephropathy, salt and water
overload, in conjunction with hypertension, are characteristic
features. With increasing impairment of renal function, urinary
dopamine excretion progressively declines, concurrent with the
glomerular filtration rate. At the same time, the response to salt
loading is attenuated and it has been suggested that a relative
deficiency of dopamine is an important factor in this abnormal sodium
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handling by the kidney (Casson, 1984). Abnormal sodium retention has
also been recognised at a much earlier stage in the natural history
of IDDM, before the appearance of overt nephropathy (de Chatel et al,
1977). It was therefore of interest to determine whether a defect in
the mobilisation of renal dopamine may be of importance in the
pathophysiology of early diabetic nephropathy. To assess this, the
relationship between sodium and dopamine excretion was examined in a
group of normal male subjects and in two groups of normotensive males
with IDDM, one with normal urinary albumin excretion and the other
with microalbuminuria.
3.2 PATIENTS AND METHODS
A cohort of 48 male patients with IDDM (mean age 33, range 25 - 38
yr) was recruited from the Diabetic Clinic of Edinburgh Royal
Infirmary. None of these patients was hypertensive by WHO criteria
(World Health Organisation, 1986), all having a supine blood pressure
of <160/95. All patients also had a creatinine clearance of >80
ml/min, calculated on a 24-h urine collection. 37 patients (GROUP 1)
had consistently normal urinary albumin excretion, but 11 patients
(GROUP 2) had microalbuminuria, with an elevated urinary
albumin:creatinine ratio (>2.5 mg/mmol) on two or more occasions in
the previous year, in conjunction with an albumin excretion of 30 -
300 mg in at least one 24-h urine collection. A control group (GROUP
3) comprised 40 healthy normotensive males of comparable age, with no
history of renal disease and normal creatinine clearance.
Following careful instruction, all subjects collected a 24-h urine
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sample for measurement of urinary sodium and dopamine excretion. No
dietary restrictions were enforced but subjects were asked to refrain
from alcohol during the collection. Blood pressure was measured using
a standard mercury sphygomanometer, after resting for 5 min, and the
diabetic patients were further assessed for retinopathy (by direct
ophthalmoscopy after mydriasis) and prevailing glycaemic control,
glycated haemoglobin (HbA^) being measured using commercially
available agar plates (non-diabetic reference range 6.0 - 8.0%). The
characteristics of the diabetic and control groups are shown in Table
1. There was a trend towards the diabetic patients with
microalbuminuria (GROUP 2) having a longer duration of diabetes,
poorer glycaemic control and lower creatinine clearance than those
with normal albumin excretion (GROUP 1), although none of these
differences reached statistical significance.
Details of the assays used in the measurement of urinary albumin and
dopamine excretion are given in Chapter 2 (Sections 2.2 and 2.4).
Urinary sodium was measured by flame photometry, and plasma and
urinary creatinine by an automated modification (Chasson et al, 1961)
of the Jaffe method (Jaffe, 1886).
Statistical Methods
The sodium and dopamine data were log-transformed before analysis.
Correlation co-efficients were calculated by least squares and
regression lines compared by F-ratios. Results are expressed as mean






































































































































Results of 24-h urinary sodium and free dopamine excretion are given
in Table 2. It is evident from the sodium excretion data that the
study was performed under salt replete conditions, and both urinary
sodium and dopamine excretion were comparable in the three groups.
Log-transformed sodium and dopamine data for the individual subjects
in the three groups, with regression lines, are shown in Figures 1 -
3. There was, in both the control group and the two diabetic groups,
a significant correlation between sodium and dopamine excretion but
there were no significant differences between the slopes of the
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The positive correlation between urinary dopamine and sodium
excretion in normal subjects has stimulated research into defining a
physiological role for endogenous renal dopamine. It contributes to
the complex feedback mechanism which is responsible for preserving
sodium homeostasis and the renal synthesis of dopamine is linked to
prevailing salt status, apparently acting to promote sodium excretion
(Kuchel et al, 1978). An inability to mobilise dopamine, appropriate
to salt status, has been described in established essential
hypertension (Harvey et al, 1984), a central feature of which may be
a defect in the ability of the kidney to excrete sodium at normal
perfusion pressures (de Wardener & MacGregor, 1982). In addition, in
normotensive first-degree relatives of hypertensive patients (Saito
et al, 1986) and in normotensive negroes (Critchley et al, 1987),
both groups at a high risk of developing essential hypertension, the
direct correlation between urinary sodium and dopamine is lost,
suggesting that an abnormality of dopamine control, presumably
genetically determined, antedates the development of essential
hypertension.
In patients with IDDM, recent research into the erythrocyte sodium-
lithium countertransport system has suggested that there may be a
genetic linkage between the predisposition to hypertension and
diabetic nephropathy (see Section 1.5). Previously, however, a
possible role for a genetically determined defect in renal dopamine
has not been considered in the pathophysiology of early diabetic
nephropathy. A number of observations suggest that patients with IDDM
do not handle sodium normally. A greater prevalence of hypertension
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in diabetic patients, with or without nephropathy, is well recognised
(Fuller, 1985), and blood pressure has also been reported to be
higher in patients who have microalbuminuria than in those who have
normal albumin excretion (Mathiesen et al, 1984; Wiseman et al,
1984a; Christensen & Mogensen, 1985), although no significant
difference was observed between the small groups in this study. In
addition, exchangeable sodium is increased in patients with IDDM
before the development of overt nephropathy or hypertension (Feldt-
Rasmussen et al, 1987), with a correlation between exchangeable
sodium and blood pressure suggesting that sodium retention may play a
major role in the pathogenesis of the rise in blood pressure observed
in the early stages of diabetic renal disease. Reduced sodium
excretion has been demonstrated in patients with IDDM in response to
volume expansion (O'Hare et al, 1986), and tubular sodium retention
occurring at an early stage in the diabetes process could be
implicated in the development of nephropathy and hypertension.
The results of this study, however, do not suggest that these changes
in sodium handling are associated with a defect in the mobilisation
of dopamine, at least at a stage prior to the development of
hypertension or frank nephropathy. Dopamine output over 24 h was
comparable in all of the groups and the correlation between urinary
sodium and dopamine excretion was maintained in the diabetic
patients, even in the presence of microalbuminuria. The similar
regression slopes in the three groups also suggest that the
sensitivity of the dopamine response to salt intake and excretion was
unaltered.
In conclusion, a defect in the mobilisation of dopamine does not
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appear to predate the onset of frank nephropathy, and abnormalities
demonstrated in patients with established renal disease are likely to




EARLY DIABETIC NEPHROPATHY AND HYPERTENSION (2)
A COMPARISON BETWEEN CAPTOPRIL AND NIFEDIPINE IN
HYPERTENSIVE MALE PATIENTS WITH IDDM
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4.1 INTRODUCTION
The association between microalbuminuria and hypertension, and the
increasing evidence of the value of antihypertensive therapy in
patients with early nephropathy, is discussed in Section 1.7. Because
of the theoretical benefit of angiotensin converting enzyme
inhibitors in lowering intraglomerular pressure, most studies have
focussed on this group of drugs and, at least in rats, their use
seems to reduce intraglomerular hypertension and proteinuria (Zatz et
al, 1986). In diabetic humans, angiotensin converting enzyme
inhibitors have been shown to reduce proteinuria in the presence of
frank nephropathy (Bjorck et al, 1986; Parving et al, 1988 & 1989),
microalbuminuria (Marre et al, 1987 & 1988) and even normal albumin
excretion (Mau Pedersen et al, 1988). It remains unclear, however,
whether these findings reflect a specific action of this class of
drugs or simply an effect of blood pressure reduction. Certainly
other antihypertensive agents do appear to have a potentially
beneficial effect in early diabetic nephropathy and the beta blocker,
metoprolol, has been shown to reduce urinary albumin excretion by
more than 50% in a group of patients with IDDM and nephropathy
(Christensen & Mogensen, 1987). A study in hypertensive patients with
NIDDM has suggested that the calcium antagonist, nicardipine, has a
similar effect on protein excretion to captopril (Baba et al, 1989)
although in a further report of normotensive patients with IDDM,
another calcium antagonist, nifedipine, appeared to actually increase
urinary albumin excretion (Mimran et al, 1988).
To date, however, there is a real lack of carefully controlled
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comparative studies of different antihypertensive agents in patients
with IDDM. This study was therefore conducted to assess and compare
both the acute and chronic effects of captopril and nifedipine retard
in a group of hypertensive patients with IDDM.
4.2 PATIENTS AND METHODS
Patients
Ten male patients with IDDM were recruited from the Diabetic Clinic
of Edinburgh Royal Infirmary. Their mean age (range) was 41 (32 - 50)
yr and duration of diabetes was 21 (7 - 32) yr. All had a body mass
2
index less than 26 kg/m and a creatinine clearance (measured in a
24-h urine collection) of >80 ml/min. Six of the patients were
receiving regular antihypertensive drugs at the time of recruitment.
The remaining 4 patients had not previously received specific anti¬
hypertensive therapy but all had at least mild hypertension, which
for the purpose of the study was defined as a supine blood pressure
(after 5-min rest) of >150 (systolic) and/or 90 (diastolic), on at
least three occasions. None of the patients was receiving any regular
medications apart from insulin and antihypertensive drugs. Based on
the urinary albumin excretion in a 24-h urine collection at the time
of recruitment, 2 of the patients had frank diabetic nephropathy
(albumin excretion 630 and 2418 mg/24 h) and 3 had definite
microalbuminuria (albumin excretion 30 - 114 mg/24 h). Of the
remaining 5 patients, all but one had a 24-h albumin excretion of >10
mg, outwith two standard deviations of the mean for the normotensive,
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non-diabetic population, measured in the Clinical Chemistry
Department of Edinburgh Royal Infirmary. Five patients had background
retinopathy and 2 had previously had photocoagulation therapy for
proliferative changes.
Study Protocol
The protocol followed a randomised, double-blind, cross-over design.
During a four-week run-in period only placebo tablets were
administered and those patients previously treated with
antihypertensive agents discontinued these drugs at the start of this
run-in period. Thereafter, patients were randomised to receive either
captopril (Squibb Ltd, Hounslow, UK) in a dose of 25 mg twice daily
or nifedipine retard (Bayer Ltd, Newbury, UK) 20 mg twice daily, for
a period of eight weeks. Placebo treatment was then re-introduced for
four weeks prior to the second active eight-week treatment limb of
the study with either captopril or nifedipine retard. Throughout the
24-week period of the study, patients were seen at two-weekly
intervals for measurement of blood pressure, using a Hawksley random
zero sphygmomanometer, after resting for at least 5 min. At four-
weekly intervals, 24-h urine samples were collected for measurement
of urinary albumin excretion and venous blood was withdrawn for
estimation of plasma renin activity.
At the beginning and end of each active treatment limb patients were
admitted and the acute effects of a single dose of the drug (either
captopril 25 mg or nifedipine retard 20 mg) on renal function were
assessed.
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Measurements of Renal Function
Effective renal plasma flow and glomerular filtration rate were
calculated by measuring the clearance of para-amino hippuric acid
(PAH) and polyfructosan, administered by a constant intravenous
infusion after an initial loading dose, as described in Section 2.3.
These measurements of renal haemodynamics were made during two 30-min
periods before the administration of the drug and four consecutive
30-min periods thereafter. The basal effective renal plasma flow and
glomerular filtration rate were calculated as the mean of the two
clearance measurements before drug adminstration and the acute effect
of the drug on renal haemodynamics was assessed by calculating the
mean of the measurements during the third and fourth periods
thereafter (between 60 and 120 min after drug administration).
Throughout the acute studies, patients were given 200 ml tap water
orally every hour in order to maintain a diuresis.
In order to exclude any effect of the prevailing plasma glucose
concentration on renal haemodynamics, euglycaemia was maintained
throughout the acute studies using a Biostator (Miles Laboratories,
Slough, UK) , which incorporates a glucose sensor and computer-
controlled glucose delivery system. All patients were admitted at
0800 h having omitted their usual morning insulin and taken only
soluble insulin on the previous evening. Following admission, a
constant infusion of soluble insulin (Human Actrapid, Novo Nordisk,
Crawley, UK) in 0.9% sodium chloride solution was commenced in a dose
of 0.35 mU/kg/min and the Biostator was programmed to maintain a
plasma glucose throughout the period of the study of 5.0 mmol/1, by
means of a variable infusion of a 20% glucose solution. Renal
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haemodynamic measurements were not commenced until the plasma glucose
concentration was stable at the required level.
Other Laboratory Methods
Urinary albumin excretion was measured on 24-h samples collected at
four-weekly intervals throughout the 24-week period of the study and
also on the timed urine collections during the acute studies. An
immunoturbidimetric assay was used as described in Section 2.2.
Plasma renin activity was assessed using a commercially available
radioimmunoassay kit, involving the generation of angiotensin I under
standard conditions (Campagne Oris, Gif-Sur-Yvette, France). Glycated
haemoglobin (HbA^) was measured, at the end of the run-in period and
each of the active treatment limbs, using commercially available agar
plates, the laboratory non-diabetic reference range being 6.0 - 8.0%.
Statistical Methods
Results, unless stated otherwise, are given as mean (SE). Blood
pressure and urinary albumin excretion data during the two treatment
limbs were compared by paired t tests. The albumin data was log-
transformed before analysis because of the wide spread of results
which was not normally distributed. During the acute studies, data
from before and after drug administration were also compared by
paired t tests, after first determining the presence of any
significant trends by performing two-way analysis of variance.
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4.3 RESULTS
After breaking the randomisation code at the completion of the study
it was found that six patients had commenced treatment with
nifedipine retard and four with captopril. One patient was withdrawn
from the study having had a transient ischaemic attack during the
first week of the second period of placebo therapy between the first
and second active treatment limbs, although his blood pressure at
this time was only slightly elevated. Glycaemic control for the group
did not change significantly during the course of the study, the mean
glycated haemoglobin being 10.6 (0.5)% at the end of the run-in
period on placebo treatment, 10.0 (0.5)% at the end of the eight-week
period on nifedipine retard and 10.1 (0.5)% following the captopril
limb of the study. Plasma renin activity was similar during the first
and second placebo periods and did not rise during treatment with
nifedipine retard. As would be expected, there was a significant rise
to 4.3 (6.0) ng-Ang 1/1 whilst taking captopril (compared with 1.1
(0.3) ng-Ang 1/1 on nifedipine retard; p<0.05).
Chronic effects of nifedipine retard and captopril
Blood pressure data is shown in Table 1. The effect of the two drugs
was similar and at the end of the nifedipine retard limb of the study
the mean blood pressure for the group was 132 (4)/ 85 (3), compared
with 131 (5)/ 86 (2) at the end of the period of treatment with
captopril (p=NS). Nifedipine retard did not exert its maximum anti¬
hypertensive effect until after the fourth week of therapy, however,
and at the mid-point of the two treatment limbs blood pressure was
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significantly lower on captopril (130 (5)/ 84 (2) vs 139 (6)/ 91 (3)
on nifedipine retard, mean arterial pressure 99 (2) vs 105 (3);
p<0.05). A tendency for blood pressure to fall over time was also
evident and at the end of the second placebo period the systolic
pressure was significantly lower that that measured at the end of the
run-in period (138 (4)/ 95 (3) vs 147 (6)/ 99 (4); p<0.01 for
difference between systolic values).
Urinary albumin excretion was closely similar during the two active
treatment limbs, the median (range) being 18.5 (8 - 1785) mg/24 h at
the end of the period on nifedipine retard and 17 (12 - 1665) mg/24 h
on captopril (p=NS). Albumin excretion was lower during both active
treatment limbs than in the run-in period, when the median value was
30 (7 - 2418) mg/24 h, although this trend, which is likely to





































































































































Acute effects of nifedipine retard and captopril
Following the first dose of both nifedipine retard and captopril
there was an acute fall in blood pressure, this being greater after
captopril. At the end of the eight-week period of treatment with each
drug, a small acute reduction in mean arterial pressure was still
observed after nifedipine retard, but not after captopril (Figure 1).
Effective renal plasma flow increased significantly after both the
first and last doses of captopril but not nifedipine retard (Figure
2). There was, however, no difference in the baseline measurements of
effective renal plasma flow between the first and last doses of
either drug and therefore the antihypertensive therapy per se did not
influence this aspect of renal haemodynamics chronically. Changes in
glomerular filtration rate varied considerably between individuals,
but there was a non-significant trend towards an acute reduction in
this parameter following the first and last doses of both drugs
(Figure 3). The filtration fraction fell significantly after the
first dose of both drugs but, at the end of the eight-week treatment
period, an acute change in the filtration fraction only occurred
after administration of captopril (Figure 4). Albumin excretion did
not change significantly during any of the acute studies.
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Figure 1
Acute changes in mean arterial pressure (MAP) in response to
captopril (o) and nifedipine retard (®), following first dose of drug
(a) and after eight weeks treatment (b).
























Acute changes in effective renal plasma flow (RPF) in response to
captopril (o) and nifedipine retard (•), following first dose of drug
(a) and after eight weeks treatment (b).








Acute changes in glomerular filtration rate (GFR) in response to
captopril (o) and nifedipine retard (•), following first dose of drug





















Acute changes in filtration fraction in response to captopril (o) and
nifedipine retard (•), following first dose of drug (a) and after
eight weeks treatment (b).

































In this study, captopril and nifedipine retard were found to have a
similar effect, after an eight-week period of adminstration, in
lowering blood pressure in a group of hypertensive males with IDDM
and varying degrees of albuminuria secondary to diabetic nephropathy.
Nifedipine retard, however, was slower to exert its maximum
antihypertensive effect than captopril. There was also a tendency for
both drugs to reduce urinary albumin excretion compared with pre-
treatment values, with no difference being found between the two in
this respect. This latter finding contrasts with a previous report in
a small group of normotensive patients with IDDM and microalbuminuria
(Mimran et al, 1988), which did not employ a cross-over design. In
this study, increased urinary albumin excretion (by an average of
40%) was reported following treatment for six weeks with nifedipine,
although captopril reduced the albumin excretion rate. The only other
directly comparative study between angiotensin converting enzyme
inhibitors and calcium antagonists in diabetic subjects was conducted
in patients with NIDDM (Baba et al, 1989), similar effects on renal
function being reported following four-week treatment periods with
enalapril and nicardipine.
In an attempt to more closely assess the comparative action of the
two drugs on the kidney, acute studies were incorporated at the
beginning and end of each active treatment limb, during which the
effects of a single dose of the drug on renal haemodynamics was
measured. The acute antihypertensive effect of both nifedipine retard
and captopril was much greater after the first dose of each drug than
at the end of the eight-week period of treatment, when the effect of
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captopril on blood pressure was not significant. Both drugs had a
similar effect in tending to reduce the glomerular filtration rate,
this finding contrasting with that of the only previous study to
assess haemodynamic responses to these two drugs (Mimran et al,
1988). Unlike nifedipine retard, however, captopril had an acute
renal vasodilating effect, with a rise in effective renal plasma
flow persisting even at the end of the period of treatment on the
drug. As a result of these changes, a significant fall in the
filtration fraction was still evident as an acute reponse to the
final dose of captopril and this was the most striking difference
between the action of the two drugs on renal haemodynamics. These
changes in filtration fraction are comparable to those found in the
small group of patients studied by Mimran et al (1988). Although
caution is required in using the filtration fraction as a direct
indicator of intraglomerular pressure (Carmines et al, 1987), this
finding would support the theory that angiotensin converting enzyme
inhibitors have a specific action in reducing intraglomerular
hypertension, which is thought to be an important feature in the
early stages of diabetic renal disease (see Section 1.5). This theory
certainly has support from research in rats (Zatz et al, 1986) and a
direct intrarenal action of captopril is particularly suggested in
this study by the fact that the acute reduction in the filtration
fraction at the end of the captopril treatment limb occurred without
a significant coincidental fall in systemic blood pressure. Such an
effect of systemic blood pressure may, however, have accounted for
the changes in renal haemodynamics observed following the first dose
of both captopril and nifedipine retard.
A number of previous studies have suggested that angiotensin
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converting enzyme inhibitors may have a specific reno-protective
action, thought to be secondary to their putative effect on
intraglomerular pressure. In diabetic rats, captopril was more
effective than combined therapy with three other antihypertensive
agents (hydralazine, reserpine and a thiazide diuretic) in preventing
the development of albuminuria and histological changes of diabetic
nephropathy (Anderson et al, 1989). In studies in non-diabetic humans
with hypertension and chronic renal disease, captopril has been
reported to be more effective than a number of other commonly used
antihypertensive agents, including nifedipine, in slowing both
decline in renal function and reducing protein excretion, in spite of
achieving blood pressure control comparable with the other agents
(Ikeda et al, 1989; Ruilope et al, 1989). A number of studies in
diabetic patients with varying degrees of nephropathy have also found
a fall in urinary albumin excretion in response to angiotensin
converting enzyme inhibitors and have suggested that this is related
to a reduction in intraglomerular hypertension (Taguma et al, 1985;
Mimran et al, 1988; Mau Pedersen et al, 1988; Parving et al, 1989).
However, in this study, no significant difference in albumin
excretion was found between captopril and nifedipine retard, during
eight-week treatment periods with each drug, in spite of the fact
that only captopril was associated with changes in renal
haemodynamics suggestive of a direct effect on intraglomerular
pressure. It would seem, therefore, that further evidence is required
before attributing the effects of angiotensin converting enzyme
inhibitors on urinary albumin excretion to this mechanism.
In conclusion, nifedipine retard and captopril have been shown to
have a similar effect in reducing blood pressure in hypertensive
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have a similar effect in reducing blood pressure in hypertensive
patients with IDDM. After eight weeks treatment with each drug,
captopril, but not nifedipine retard, retained an acute haemodynamic
effect in reducing the filtration fraction, supporting the theory
that angiotensin converting enzyme inhibitors may have a specific
glomerular action. Although this could be important in protecting the
kidney against progressive renal disease, in this study both
captopril and nifedipine retard reduced urinary albumin excretion to
a comparable extent, suggesting that the antihypertensive effect of
the drugs per se may be the most important factor. It is
acknowledged, however, that because of the relatively small number of
patients in this study, there is the possibility of a Type 2
statistical error. The results, although largely in keeping with
previous research in this field, therefore have to be interpreted
with some degree of caution.
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5.1 INTRODUCTION
Although most of the available data about microalbuminuria pertains
to the population with IDDM, this is also an important complication
of NIDDM, being a predictor of both frank nephropathy (Mogensen,
1984) and also premature death from ischaemic heart disease (Jarrett
et al, 1984; Mogensen, 1984; Mattock et al, 1988, Schmitz & Vaeth,
1988) (see Section 1.4).
A prevalence of frank proteinuria of 12% has been reported in a large
population of patients with NIDDM in the USA (Klein et al, 1988) and
a cumulative incidence of proteinuria of 25% during the 20 years
after the diagnosis of NIDDM has been estimated (Ballard et al,
1988). In contrast to patients with IDDM, abnormal protein excretion
develops in many patients in the first few years after the
development of NIDDM (Fabre et al, 1982; Marshall & Alberti, 1989)
and a significant prevalence of microalbuminuria has been documented
at the time of diagnosis (Damsgaard & Mogensen, 1986; Uusitupa et al,
1987; Ballard et al, 1988). It has been suggested that this is mainly
a functional phenomenon, consequent upon the osmotic load associated
with uncontrolled hyperglycaemia (Uusitupa et al, 1987; Schmitz et
al, 1989), but previously the natural history of urinary albumin
excretion following the diagnosis of NIDDM has not been reported in
detail. In this study, the prevalence of microalbuminuria (and its
association with other clinical parameters) was identified at
diagnosis in a large group of patients with NIDDM and then assessed
throughout the first year of treatment of hyperglycaemia.
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5.2 PATIENTS AND METHODS
149 newly-diagnosed, previously untreated, patients with NIDDM were
studied. They presented consecutively over a 9-month period to the
Diabetic Clinic of Edinburgh Royal Infirmary and, in each case, a
full history was obtained and clinical examination performed at the
time of the initial clinic visit to determine the presence of
macrovascular disease. Cerebrovascular disease was defined clinically
as a history of stroke or transient ischaemic attack; ischaemic heart
disease as a history of angina pectoris or myocardial infarction
and/or ECG changes of myocardial ischaemia; and peripheral vascular
disease as a history of intermittent claudication, rest pain,
gangrene or amputation and/or the absence of both posterior tibial
and dorsalis pedis pulses in at least one foot. Blood pressure was
measured with a standard mercury sphygmomanometer after 5-min rest
and retinopathy was assessed by direct ophthalmoscopy following
mydriasis. Body mass index was calculated from measurements of height
and weight. Exclusion criteria from the study were as follows: a
history of preceding renal disease of any aetiology; plasma
creatinine >150 umol/1; frank proteinuria; or urinary tract infection
confirmed by culture of a midstream urine sample (collected on all
patients). Early morning urine samples were collected and analysed to
assess albumin excretion as described in Section 2.2, results being
expressed as an albumin:creatinine ratio. Random plasma glucose and
glycated haemoglobin (HbA^) concentrations were measured on a venous
blood sample, the former by a Yellow Springs glucose analyser and the
latter using commercially available agar plates, the laboratory non-
diabetic reference range being 6.0 - 8.0%.
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regression models were fitted to correct for the effect of other
variables, notably age. Linear regression was not appropriate in the
analysis of trends in urinary albumin excretion over the 12 months of
the study, as the majority of patients did not have a detectable
trend. Instead, this data was assessed by calculating the Spearman
rank correlation of the median albumins creatinine ratio with the





































































































































































































1. At Initial Presentation
At initial presentation, 110 (74%) of the 149 patients had a normal
urinary albumin concentration (GROUP 1) but 39 (26%) had an albumin:
creatinine ratio of >2.5 mg/mmol (GROUP 2). Clinical characteristics
of the two groups are shown in Tables 2 and 3. Patients with
microalbuminuria were older and had a higher random plasma glucose
concentration, glycated haemoglobin and systolic blood pressure.
There was also a strong association between elevated urinary albumin
excretion at initial presentation and evidence of macrovascular
disease, most strikingly peripheral vascular disease. Following
correction for the effect of age (Tables 2 and 3), only the
association with peripheral vascular disease clearly remained,
although retinopathy and glycated haemoglobin fell only just short of
significance as independently associated variables. Following further
regression to correct for the combined effect of age, sex, blood
pressure and glycated haemoglobin, there was still a strong trend
towards an association between an abnormal urinary albumin:creatinine
ratio at initial presentation and both peripheral vascular disease







































































































































































2. After 12-month Follow-up Period
Clinical characteristics of the patients with consistently normal
urinary albumin excretion (GROUP A) and those with persistent
microalbuminuria (GROUP B) are shown in Tables 4 and 5. Eighteen
(86%) of the group with persistent microalbuminuria also had an
elevated albumin:creatinine ratio at initial presentation. A
significant association with age was again observed, but following
correction for this, there were no statistically significant
associations with any of the other clinical characteristics assessed.
There was, however, a strong trend towards an association between
persistent microalbuminuria and macrovascular disease, 45% of the
patients with persistent microalbuminuria having evidence of
ischaemic heart disease, cerebrovascular disease or peripheral
vascular disease, compared with only 25% of those with normal urinary
albumin excretion. No association was found between urinary albumin
excretion and the glycated haemoglobin concentration, either at
initial presentation or after 6 months treatment. In contrast, in the
10 patients who had an initially elevated urinary albumin:creatinine
ratio, but subsequently normal albumin excretion, the initial
glycated haemoglobin was higher (14.4 (2.5)%) than in either of the 2
main groups (p <0.05), indicating a greater hyperglycaemic stimulus
(and presumably greater osmotic effect) prior to treatment of
diabetes being instituted. Calculation of Spearman rank correlations
failed to demonstrate any significant influence of the degree of
microalbuminuria, as assessed by the median urinary



































































































































































































































Spearman rank correlations for the median urinary albumin:creatinine
ratio during the first year after diagnosis of NIDDM and other
clinical features.
Age 0.18
Body mass index -0.10
Systolic blood pressure 0.04
Diastolic blood pressure 0.04
Random plasma glucose at initial presentation 0.12
Glycated haemoglobin at initial presentation 0.05
Glycated haemoglobin after 6 months treatment 0.02
No correlation reached statistical significance
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5.4 DISCUSSION
The prevalence of increased urinary albumin excretion at initial
presentation of NIDDM is similar in this study to that previously
reported from Finland (Uusitupa et al, 1987). The earlier study did
not, however, find an association with age, glycaemic control, blood
pressure or macrovascular disease, although the study population was
younger than that reported here. An association between urinary
albumin excretion and age has previously been noted in patients with
longstanding NIDDM (Ballard et al, 1988; Schmitz & Vaeth, 1988), and
the current findings would suggest that age may also be an important
factor in the association between microalbuminuria and blood pressure
which has been reported in patients with NIDDM of longer duration
(Fabre et al, 1982; Schmitz & Vaeth, 1988; Marshall & Alberti, 1989).
An association between microalbuminuria and macrovascular disease in
NIDDM has been recognised, with increased urinary albumin excretion
apparently being an independent predictor (Mattock et al, 1988;
Schmitz & Vaeth, 1988). In this study it is seen that such an
association is evident even at the time of diagnosis, 47% of patients
with an increased urinary albumin excretion at initial presentation
having some clinical evidence of macrovascular disease, compared with
only 23% of those with a normal urinary albumin excretion.
It has been suggested that abnormal urinary albumin excretion at the
time of presentation with NIDDM is simply a manifestation of renal
hyperfiltration secondary to uncontrolled hyperglycaemia (Uusitupa et
al, 1987; Schmitz et al, 1989) and a fall in both glomerular
filtration rate and urinary albumin excretion has been demonstrated
/
85
in a small group of patients following improved glycaemic control
(Schmitz et al, 1989). In the larger study reported here, however, it
was possible to identify different subgroups of patients who had
increased urinary albumin excretion at initial presentation. In the
10 patients who reverted thereafter to normal urinary albumin
excretion it seems reasonable to propose that a functional mechanism
secondary to hyperglycaemia was operational. These 10 patients had
higher glycated haemoglobin concentrations at presentation than
either those with normal urinary albumin excretion throughout the
year of study or those with persistent microalbuminuria, although
similar glycaemic control was evident in all groups after 6 months of
diabetic treatment. Eighteen patients, however, in addition to 3 who
had an initially normal urinary albumin:creatinine ratio, had
persistent microalbuminuria throughout the year of study. In these
patients the degree of hyperglycaemia did not appear to be a major
determining factor, with the glycated haemoglobin both at initial
presentation and following 6 months of diabetic treatment being
closely similar to that found in patients with a normal urinary
albumin excretion throughout. Age was a definite associated factor
and there was also a trend towards a higher prevalence of
macrovascular disease (particularly peripheral vascular disease and
ischaemic heart disease) in patients with persistent microalbuminuria
from diagnosis. The relationship between increased urinary albumin
excretion and generalised vascular disease is discussed further in
Sections 1.4 and 1.5, and in Chapter 8.
In conclusion, persistent microalbuminuria is present from initial
presentation in 16% of patients with NIDDM and in most cases this
would appear to be a specific diabetes-related complication.
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CHAPTER 6
TUBULAR FUNCTION IN EARLY DIABETIC NEPHROPATHY




Microalbuminuria is essentially a measure of increased glomerular
leakage and decreased selectivity (see Section 1.4), but tubular
dysfunction is also an identifiable feature at the stage of early
diabetic nephropathy. This has been demonstrated by the finding in
diabetic patients of increased urinary concentrations of a number of
small protein molecules, of a size freely filtered by the glomerular
membrane but normally reabsorbed through the renal tubules. Proteins
which have been suggested as potentially useful in the detection of
early diabetic renal damage include beta-2-microglobulin (Hermansson
& Ludvigsson, 1980; Poortmans et al, 1982; Ellis D et al, 1983),
alpha-l-microglobulin (Walton et al, 1988; Martin et al, 1990), kappa
light chains (Walton et al, 1988) and retinol-binding protein
(Bernard et al, 1982; Gibb et al, 1989). One small protein which has
not previously been evaluated as a potential marker for early
diabetic nephropathy is beta-thromboglobulin (BTG). This is a
platelet-specific protein which is located in the alpha granules and
released during platelet activation (Ludlam & Cash, 1976). BTG is
normally present only in very low concentrations in the urine, but
increased urinary excretion has been reported in patients with IDDM
(van Oost et al, 1983), particularly in those with frank nephropathy,
in whom a correlation has been observed between plasma creatinine and
urinary beta-thromboglobulin concentrations (Hopper et al, 1986).
A further urinary marker of tubular function, of possible value in
the identification of early diabetic nephropathy, is N-acetyl-beta-D-
glucosaminidase (NAG) (Whiting et al, 1979; Ellis EN et al, 1983;
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Brouhard et al, 1985; Watts et al, 1988; Gibb et al, 1989; Martin et
al, 1990), although its precise role remains to be defined. NAG is a
lysosomal enzyme present in renal tubular cells. It is a much larger
molecule than albumin and does not normally appear in the glomerular
filtrate. Increased excretion of this protein therefore appears to be
a manifestation of loss of integrity of the tubular membrane.
In this study, the urinary excretion of BTG and NAG was measured in
patients with IDDM, both with normal albumin excretion and
microalbuminuria. The association was examined between the excretion
of these markers of tubular dysfunction, albumin excretion and a
number of other clinical parameters.
6.2 PATIENTS AND METHODS
Patient Selection and Assessment
The study cohort comprised 132 patients with IDDM, recruited from the
Diabetic Clinic of Edinburgh Royal Infirmary. None of the patients
were hypertensive as defined by WHO criteria (World Health
Organisation, 1985), all having a supine blood pressure of <160/95 mm
Hg, measured using a standard mercury sphygmomanometer after 5-min
rest, and all had a plasma creatinine concentration of <150 umol/1.
None had a past history of known renal disease nor were taking any
drugs which might cause proteinuria, and none had haematuria or
proteinuria on standard dip-stick testing of urine. The presence of
clinically apparent retinopathy was assessed in each patient by
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direct ophthalmoscopy following mydriasis and if present was
classified as background or proliferative. Proliferative retinopathy
was defined as the presence of soft exudates (cotton wool spots),
active neovascularisation or scarring from previous photocoagulation
therapy; background retinopathy was identified by the presence of
microaneurysms, haemorrhages or hard exudates. Details of drug
therapy and smoking habit were obtained; those who were smoking five
cigarettes or more daily at the time of the study were defined as
'smokers'.
97 of the participating patients had no evidence of diabetic
nephropathy (GROUP 1), with a urinary albumin:creatinine ratio,
measured on at least three occasions during the previous two years in
early morning specimens of urine, consistently being within the
normal range (see Section 2.2). The 35 other patients (GROUP 2) had
been identified previously as having microalbuminuria on the basis of
an elevated urinary albumin:creatinine ratio of >2.5 mg/mmol in two
or more early morning specimens of urine within the preceding year.
Clinical details of the two groups are given in Table 1. The patients
with microalbuminuria (GROUP 2) were significantly older, had a
longer duration of diabetes, a higher mean glycated haemoglobin
concentration and a greater prevalence of retinopathy than those with





































































































































































Study Protocol and Laboratory Methods
All of the patients collected a sample of the first urine voided
immediately after rising, which was subsequently divided into three
aliquots. As described in Section 2.2, urinary albumin excretion was
measured, within four days of collection, in one of these aliquots
stored at 4°C. The other two samples, for determination of urinary
BTG and NAG excretion, were stored until analysis at -20°C. A venous
blood sample was collected for estimation of glycated haemoglobin
(HbA^) and plasma creatinine concentrations. HbA^ was measured using
commercially available agar plates, the laboratory non-diabetic
reference range being 6.0 - 8.0%.
Urinary BTG was measured by standard radioimmunoassay, using an
adaptation of the technique for measurement of plasma BTG described
by Bolton et al (1976). The normal urinary concentration of BTG is
approximately 0.5% of the plasma concentration (Dawes et al, 1978)
and the sensitivity of the assay can be improved by the use of a
greater dilution of antiserum and radio-labelled tracer, with delayed
addition of the tracer. Unextracted urine was incubated at 4°C for 24
12 5
h with antiserum, raised in rabbits, agarnst purifred BTG. I-
labelled BTG (0.1 ng/ml) was then added, this concentration resulting
in binding of approximately 50% of the tracer. After a further 24 h,
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antibody-bound BTG was separated from free BTG and the I actrvity
in the precipitate containing the antibody-bound BTG fraction was
measured. The detection limit for the assay was 0.1 ng/ml, with the
intra- and inter-assay co-efficients of variation both being
approximately 14%.
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Urinary NAG was measured using a commercially available colorimetric
assay supplied by Thames Genelink, Deeside, UK. The assay uses the
principle that a chromogenic substrate, 2-methoxy-4-(2-nitrovinyl)
phenyl-2-acetamido-2-deoxy-beta-D-gluco-pyranoside, is hydrolysed by
NAG to release 2-methoxy-4-(2-nitrovinyl) phenol which, on addition
of an alkaline buffer, produces a colour which can be measured at a
wavelength of 505 nm (Yuen et al, 1984). The inter-assay co-efficient
of variation was less than 6% and results were expressed as a ratio
of urinary NAG:creatinine, the reference range in normal individuals
being 1.0 - 24 umol/mmol.
Statistical Analysis
Chi-square and t tests were used, where appropriate, to determine the
association of urinary BTG and the urinary NAG:creatinine ratio with
the other variables. Multiple regression analysis was performed to
assess the relative importance of the associations between the
urinary NAG:creatinine ratio and the urinary albumin:creatinine
ratio, blood pressure, smoking status, retinopathy, glycaemic
control, age and duration of diabetes.
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6.3 RESULTS
In the early morning urine specimen provided for the study, only 21
of the patients with microalbuminuria (GROUP 2) actually had an
albumin:creatinine ratio of >2.5 mg/mmol. This apparent disparity, in
a group of patients already identified as having microalbuminuria,
can be explained on the basis of the recognised day to day
variability in urinary albumin excretion in individual patients with
diabetes (Feldt-Rasmussen & Mathiesen, 1984; Chachati et al, 1987).
Urinary BTG was above the level of detection of the assay (0.1 ng/ml)
in 21 patients in total, of whom 13 (62%) were in GROUP 2. However,
only 8 patients with a detectable urinary BTG (38%) also had an
elevated albumin:creatinine ratio in the specimen of urine provided
for the study. A detectable urinary BTG was associated with a longer
duration of diabetes, 15 (71%) of the 21 patients having had diabetes
for 10 years or more. The number of patients with a detectable
urinary BTG was too small to reasonably assess the presence or
absence of an association with any of the other clinical parameters
considered.
The urinary NAG:creatinine ratio was elevated in a total of 55
patients. 22 (63%) patients in GROUP 2 had an elevated urinary
NAG:creatinine ratio, and this association with microalbuminuria was
significant (chi-square=8.79, p<0.01). Individual and mean urinary
NAG:creatinine values for GROUP 1 and GROUP 2 are shown in Figure 1.
The association between the urinary NAG:creatinine ratio and an
abnormal urinary albumin:creatinine ratio in the sample collected for
the study was even stronger, 16 out of the 21 patients (73%) having a
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result above the normal reference range (chi-sguare=12.25, p<0.001).
When other clinical parameters were considered, a significant
correlation was observed between the urinary NAG:creatinine ratio and
prevailing glycaemic control, estimated by the glycated haemoglobin
concentration, as shown in Figure 2 (r=0.48, p<0.01). The urinary
NAG:creatinine ratio was elevated in 20 (57%) of the 35 patients
with background or proliferative retinopathy, compared with 35 (37%)
of patients without retinopathy (Figure 3) and this association with
retinopathy also attained significance (chi-square=4.3, p<0.05).
Similarly, an increase in the prevalence of an abnormal
NAG:creatinine excretion was observed in smokers, as shown in Figure
4 (chi-square=12.7, p<0.001). No such association was observed
between smoking habit and elevation of the urinary albumin:creatinine
ratio in this study. There was a trend towards the mean urinary
NAG:creatinine ratio increasing with duration of diabetes, with the
lowest mean concentration seen in patients with a duration of
diabetes <2 yr and the highest in patients with a duration of 10 - 20
yr. This trend did not, however, achieve statistical significance. No
significant association was determined between the urinary
NAG:creatinine ratio and either age, sex, systolic or diastolic blood
pressure.
Multiple regression analysis was performed to determine the most
important associations between the above variables and the urinary
NAG:creatinine ratio. The co-efficients of each term in the multiple
regression are shown in Table 2 and give an estimate of the
difference in the urinary NAG:creatinine ratio attributable to each
variable, independent of the other variables. Smoking habit,
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glycaemic control and microalbuminuria were all independently
associated. The NAG:creatinine ratio was on average 18.2 umol/mmol
greater in smokers than non-smokers and 13.9 umol/mmol greater in
patients with microalbuminuria compared with those patients who had a
normal urinary albumin excretion. For each incremental rise of 1% in
the glycated haemoglobin concentration, the NAG:creatinine ratio rose
by 3.35 umol/mmol. The presence of retinopathy just failed to achieve
significance as an independently important variable, with age,




Urinary NAG excretion, expressed as the NAG:creatinine (NAG/Cr) ratio
(showing mean value) in diabetic patients with normal albumin
excretion (GROUP 1) and microalbuminuria (GROUP 2). Dashed line























Relationship between urinary NAG excretion and retinopathy. Hatched
areas indicate patients with a urinary NAG:creatinine ratio above the
upper limit of normal.
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Figure 4
Relationship between urinary NAG excretion and smoking status.
Hatched areas indicate patients with a urinary NAG:creatinine ratio
above the upper limit of normal.
100
Table 2
Co-efficients, with 95% confidence limits, from multiple regression
analysis, using the urinary NAG:creatinine ratio (umol/mmol) as the
dependent variable.
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represents variables having a statistically significant independent
association with the urinary NAG:creatinine ratio
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6.4 DISCUSSION
Determination of microalbuminuria, indicative of glomerular
dysfunction, allows the identification of a stage of diabetic
nephropathy sufficiently early to provide the possibilitity of
therapeutic intervention to prevent progression of the nephropathic
process (see Section 1.7). However, the evidence that abnormalities
of tubular function are also a feature of nephropathy provides a
possible alternative approach to identifying patients with diabetic
renal disease at the earliest possible stage, when interventional
measures are likely to have maximum impact. The urinary excretion of
a number of proteins of small molecular weight, which are freely
filtered by the glomerular membrane and are therefore markers of
tubular reabsorption, have previously been studied as possible
indicators of early diabetic nephropathy. An increased urinary
excretion of beta-2-microglobulin has been reported in children and
adolescents with IDDM (Hermansson & Ludvigsson, 1980), although other
studies have failed to demonstrate a consistent abnormality in the
excretion of this protein even in the presence of established
diabetic nephropathy (Viberti et al, 1982b; Mathiesen et al, 1984).
Beta-2-microglobulin has a low stability, both in vitro and in vivo
(Bernard et al, 1982; Martin et al, 1990), which may be a factor in
the discrepant results of these earlier studies, and its role as a
potential marker of early tubular dysfunction therefore appears to be
limited. Some of the other small protein molecules mentioned in the
introduction to this chapter (Section 6.1), such as alpha-1-
microglobulin, kappa light chains and retinol-binding protein, may be
of greater diagnostic value in identifying early nephropathy, but
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further evidence is clearly required before their use in routine
clinical practice could be considered.
Beta-thromboglobulin (BTG) is a platelet-derived protein which
usually occurs as a tetramer with a subunit molecular weight of 8,600
daltons and should therefore filter freely through the glomerular
membrane. Reabsorption in the proximal tubule maintains a constant
concentration of BTG excreted in the urine at approximately 0.5% of
the plasma concentration (Dawes et al, 1978). BTG is released in
response to platelet aggregation and activation (Ludlam & Cash, 1976)
and, indeed, a previous study in diabetic patients used BTG as a
marker to examine the role of platelet activation in microvascular
complications of the disease (Hopper et al, 1986). Although that
particular study did not find any clear correlation between the
urinary BTG concentration and platelet survival, a strong association
was observed between BTG excretion and both an increased plasma
creatinine level and increased urinary beta-2-microglobulin
excretion, suggesting a possible role for BTG in the detection of
renal disease in patients with diabetes. A further study
demonstrated an increase in urinary BTG excretion in non-diabetic
hypertensive patients with renal impairment (Anderton et al, 1980),
but the potential role of an increase in urinary BTG excretion as an
indicator of early diabetic nephropathy had not been examined
previously. The findings in this study, however, indicate that
measurement of the urinary concentration of this protein does not
have an adequate degree of sensitivity, using current assays, to have
a useful role in screening for early nephropathy, even though urinary
BTG excretion was increased predominantly in patients with
microalbuminuria and in those with a long duration of diabetes. In
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assessing tubular function, an alternative approach to measurement of
the urinary excretion of low molecular weight proteins is the
quantification in the urine of the enzyme, N-acetyl-beta-D-
glucosaminidase (NAG). This enzyme, which has a molecular weight of
150,000 daltons, is too large to be filtered through the normal
glomerular membrane although it cannot be excluded that, in the
presence of severe glomerular damage, significant concentrations may
appear in the urine via this route. In the main, however, the
appearance of increased urinary concentrations of NAG is likely to
predominantly reflect tubular damage, with loss of integrity of the
tubular membrane, and increased urinary NAG excretion has previously
been demonstrated in diabetic patients with nephropathy (Whiting et
al, 1979; Ellis EN et al, 1983; Watts et al, 1988; Gibb et al, 1989).
In this study, a clear association between urinary NAG excretion and
microalbuminuria has been demonstrated, significant correlations also
being found with both glycaemic control and smoking habit. The
association with glycated haemoglobin confirms the findings of
previous studies (Ellis EN et al, 1983; Watts et al, 1988; Gibb et
al, 1989) and research in experimental animals has given some insight
into the possible mechanisms determining this association with
glycaemic control. It has been demonstrated in dogs that urinary NAG
excretion is related to the urinary glucose concentration (Rowe et
al, 1985) and increased urinary flow rate (resembling the osmotic
diuresis secondary to hyperglycaemia) has been shown in the rat to be
associated with reduced tubular absorption of proteins (Chan &
Straus, 1980). It seems likely that similar mechanisms may be
operational in the human diabetic kidney. The observed association
between urinary NAG excretion and smoking adds to the increasing body
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between urinary NAG excretion and smoking adds to the increasing body
of evidence that smoking in patients who have diabetes may have a
pathogenic role in damaging the microcirculation of various organs,
including the kidney (Muhlhauser, 1990), although the mechanism of
this remains to be elucidated.
In conclusion, urinary excretion of BTG, in common with a number of
other low molecular weight proteins, does not appear to be of value
as a sensitive indicator of early diabetic nephropathy. Measurement
of urinary NAG excretion may complement the quantification of urinary
albumin excretion in the detection of early nephropathy but, in the
light of current evidence, identification of microalbuminuria, rather
than measures of tubular dysfunction, remains the 'gold standard' as
an indicator of potentially reversible renal disease in diabetic
patients. Further longitudinal studies will, however, be necessary
to assess fully the true significance of abnormal urinary excretion
of the various markers of tubular dysfunction.
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CHAPTER 7
HYPOGLYCAEMIA AND RENAL FUNCTION
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7.1 INTRODUCTION
In numerical terms, hypoglycaemia is an immense problem in patients
with IDDM. Around one-half of insulin-treated patients will have at
least one episode of hypoglycaemia in any month, and in any one year,
even conservative estimates suggest that 8 - 13% of patients will
experience severe hypoglycaemia, requiring external help to
resuscitate them (Potter et al, 1982; Casparie & Elving, 1985;
Matthews et al, 1986). Some patients, notably those who have lost the
ability to perceive the early warning symptoms of hypoglycaemia
(hypoglycaemia unawareness) , have recurrent episodes of severe
hypoglycaemia and often the blood glucose concentration has been in
the hypoglycaemic range for a considerable length of time before
they are effectively treated.
Acute insulin-induced hypoglycaemia in humans is a potent stimulus to
autonomic neural activation and the secretion of a number of
hormones, including catecholamines, angiotensin II (Trovati et al,
1988) and vasopressin (Fisher et al, 1989; Thompson et al, 1989).
Profound haemodynamic and haemostatic changes occur during
hypoglycaemia (Hilsted et al, 1980 & 1984; Frier et al, 1983) and the
secretion of catecholamines in association with stimulation of the
sympatho-adrenal system plays an important role in determining these
(French et al, 1955; Frier & Hilsted, 1985). Both myocardial
contractility and cardiac output increase significantly (Hilsted et
al, 1984; Fisher et al, 1987) and overall there is a fall in vascular
resistance. Considerable differences in regional blood flow have,
however, been observed in several major organs and vascular systems,
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including the skin (Hilsted et al, 1982), skeletal muscle (Middleton
& French, 1974; Hilsted et al, 1984), brain (Neil et al, 1987) and
hepato-splanchnic circulation (Beam et al, 1952; Hilsted et al,
1984).
Several of these physiological responses to hypoglycaemia could be
detrimental, particularly in those patients subjected to repeated
prolonged and severe episodes, and may potentially have a role in the
aetiology of the end organ damage which is a feature of the
microvascular complications of diabetes. The possible effects of
hypoglycaemia on the kidney have not, however, previously been
studied. In this chapter, I have examined the changes in renal
haemodynamics and other indices of kidney function during acute
insulin-induced hypoglycaemia, both in patients with IDDM and in
non-diabetic control subjects, in order to establish whether
hypoglycaemia may in any way be implicated in either the causation or
progression of diabetic nephropathy.
7.2 PATIENTS AND METHODS
Patient Selection
Eight male patients with IDDM were recruited from the Diabetic Clinic
of Edinburgh Royal Infirmary. The mean age of the patients was 29
(range 24 - 40) yr and all had a normal body mass index (19 - 25
kg/m ). Their mean duration of diabetes was 8 (range 2 - 15) yr and
the mean (SD) glycated haemoglobin (HbA^) at the time of study was
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9.0 (2.4)%. None of the patients were hypertensive, or receiving
antihypertensive medication. Similarly, none had evidence of any
specific microvascular complications of diabetes, in particular
nephropathy, with all having a normal plasma creatinine concentration
(<100 umol/1) and normal 24-h urinary albumin excretion (<30 mg) in
each of two collections. All of the patients were non-smokers and
none were taking any medications apart from insulin. A control group
comprised 8 healthy non-smoking, non-diabetic male volunteers, all of
normal weight and with a mean age of 30 (range 23 - 39) yr.
Study Protocol
Subjects were admitted at 0800 h on the day of the study, having
fasted since 2200 h on the previous evening. Ingestion of tea or
coffee was not permitted for 12 h before the study. The diabetic
patients administered only soluble insulin within the 24-h period
prior to admission, with the last insulin dose being taken prior to
an evening snack. On arrival in the laboratory, intravenous cannulae
were inserted into both antecubital fossae, one for blood sampling
and the other for administration of insulin and other drugs. In the
diabetic patients, an intravenous infusion of 5% glucose solution was
commenced, in addition to 50 ml of 0.9% sodium chloride solution
containing 50 U soluble insulin (Human Actrapid, Novo Nordisk,
Crawley, UK), administered via a 3-way connector. Infusion rates were
adjusted as necessary to maintain the plasma glucose concentration
within the range of 5.0 - 10.0 mmol/1 during the hour following
admission. The infusion was then discontinued and acute hypoglycaemia
was induced by an intravenous bolus injection of Human Actrapid in a
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dose of 0.125 U/kg body weight. In the control subjects, no glucose
and insulin infusion was required to maintain euglycaemia, but an
identical bolus dose of soluble insulin was administered to induce
hypoglycaemia.
Following administration of the insulin bolus, heart rate, blood
pressure and capillary blood glucose were monitored at 5-min
intervals. The onset of an acute autonomic reaction to hypoglycaemia
was identified by a sudden increase in heart rate, widening of the
pulse pressure and the onset of sweating, in conjunction with a
capillary blood glucose concentration of <2.5 mmol/1. Subsequent
sampling of blood and urine was measured from this time point
(designated 'time=R' in the subsequent results and figures), thus
eliminating individual variability in the time from the
administration of the insulin bolus to the onset of the acute
autonomic reaction.
Measurements of Renal Function
Adequate hydration was ensured in all subjects by fluid loading with
oral tap water (10 ml/kg body weight) at the time of admission, and
then replacing the volume of urine passed subsequently during the
study by giving an equivalent volume of tap water to drink. Fluid
lost through sweating and insensible losses were not specifically
replaced. In addition to this oral hydration, an intravenous infusion
of a 20% mannitol solution was administered continuously at a rate of
50 ml/h throughout the study to maintain a diuresis, aiming for a
urinary flow rate of 7 - 8 ml/min.
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Effective renal plasma flow was estimated by the measurement of
clearance of para-amino hippurate sodium (PAH; Merck, Sharp and
Dohme, Hoddesdon, UK), as described in Section 2.3. An intravenous
bolus injection of PAH was given at three time points (30 min prior
to insulin administration, time=R and R+60 min) with blood samples
for PAH measurement being taken before each injection and then on
seven subsequent occasions up to 40 min. The plasma concentration of
PAH was <0.3 g/1 before each IV bolus injection. The intra-individual
co-efficient of variation for measurement of effective renal plasma
flow using this technique was 9.4%.
Glomerular filtration rate (GFR) was estimated from clearance of
polyfructosan (Inutest; Laevosan, Linz, Austria), administered as a
constant infusion after an initial intravenous bolus loading dose
(see Section 2.3). Blood and urine samples were collected at four
time points (30 min prior to insulin administration, 10 min after
insulin administration, R+60 min and R+120 min) and measurement of
polyfructosan concentrations in these specimens allowed calculation
of GFR, (1) in the basal period; (2) over the time of the acute
hypoglycaemic reaction; and (3) in the recovery period. The intra-
individual co-efficient of variation using this technique was 13.4%.
Urinary concentrations of dopamine (see Section 2.4), albumin (see
Section 2.2) and sodium (measured by flame photometry) were also
calculated from each urine specimen.
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Measurements of Hormone Excretion and Laboratory Methods
Blood samples were withdrawn before insulin was administered and at
R, R+15 min, R+30 min, R+45 min, R+60 min, R+90 min and R+120 min for
measurement of plasma glucose, plasma renin activity, adrenaline,
noradrenaline and angiotensin II concentrations. Plasma glucose was
measured by a glucose oxidase method using a Yellow Springs glucose
analyser. Plasma renin activity was calculated using a commercially
available radioimmunoassay kit method, involving the generation of
angiotensin I under standard conditions (Campagne Oris, Gif-Sur-
Yvette, France). Plasma adrenaline and noradrenaline (Ball et al,
1981) and plasma angiotensin II (Kappelgaard et al, 1976) were
measured, using well-established radioenzymatic assays, in the MRC
Blood Pressure Unit, Western Infirmary, Glasgow.
Statistical Analysis
Results, unless otherwise stated, are given as mean (SE). The data
for all subjects were analysed by one-way analysis of variance, with
paired t tests and the Wilcoxon Rank Sum test being used to compare
basal values with those during the period of the autonomic reaction
to hypoglycaemia and during the recovery phase.
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7.3 RESULTS
All of the subjects experienced a typical autonomic reaction to
hypoglycaemia. The onset of the reaction occurred at a mean of 35
(range 22 - 54) min after administration of the bolus insulin
injection in the diabetic patients and 24 (range 22 - 28) min after
insulin administration in the control group. In the control sujects,
the nadir of plasma glucose occurred at time=R in each individual and
this was also the case in three of the diabetic patients, with the
nadir attained at R+15 min in the remaining five patients.
Metabolic and Hormonal Changes
Plasma Glucose
In the control subjects, the mean plasma glucose fell from 4.6 (0.2)
mmol/1 before insulin administration to 1.3 (0.2) mmol/1 at time=R
(p<0.01), with a characteristic biphasic recovery ensuing. By R=120
min the glucose concentration was restored to basal levels at 4.4
(0.2) mmol/1. In the diabetic patients, plasma glucose fell from 6.2
(0.7) to 1.7 (0.2) mmol/1 at time=R (p<0.001) and 1.6 (0.2) mmol/1 at
R+15 min (p<0.001) with recovery thereafter to 5.1 (0.6) mmol/1 at
R+120 min (p=NS compared with basal value). There was no significant




Plasma glucose response following administration of insulin (arrow)
in diabetic (o) and non-diabetic (•) subjects. B=basal and R=onset of
acute autonomic reaction.
* indicates p<0.05 between groups.
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Plasma Adrenaline
In the control subjects, the mean plasma adrenaline concentration
attained a peak of 6.6 (0.4) nmol/1 at R+15 min, this representing a
significant increase from basal values (p<0.01). In the diabetic
patients, the peak value (again at R+15 min) was 1.7 nmol/1 (p<0.01
vs basal), but compared with the non-diabetic group, this increase in
response to hypoglycaemia was attenuated, with the adrenaline
concentration being significantly lower between time=R and R+45 min
(Figure 2).
Plasma Noradrenaline
In the diabetic patients, the minor increase in plasma noradrenaline
from a baseline value of 1.3 (0.4) nmol/1 to a peak level of 1.8
(0.3) nmol/1 at R+15 min did not attain statistical significance. In
the control subjects, noradrenaline concentrations were significantly
higher than in the diabetic group at each time point and, in
addition, the increase from basal (2.8 (0.30) nmol/1) to the peak
value (4.6 (0.6) nmol/1) was also significant (p<0.01) (Figure 3).
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Figure 2
Plasma adrenaline response following administration of insulin
(arrow) in diabetic (o) and non-diabetic (•) subjects. B=basal and
R=onset of acute autonomic reaction.
* indicates p<0.05 between groups.
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Figure 3
Plasma noradrenaline response following administration of insulin
(arrow) in diabetic (o) and non-diabetic (•) subjects. B=basal and
R=onset of acute autonomic reaction.
* indicates p<0.05 between groups.
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Plasma Renin Activity
Plasma renin activity rose in the diabetic patients to a peak of 1.08
(0.17) ng-Ang 1/1 at R+15 min (p<0.01 vs basal), remaining
significantly elevated until R+30 min and then returning to the basal
value by R+120 min. In the control subjects, plasma renin activity
remained significantly elevated (p<0.01) above baseline values until
R+60 min and there was a non-significant trend towards concentrations
being higher than in the diabetic group throughout (Figure 4).
Plasma Angiotensin II
Plasma angiotensin II concentrations did not rise significantly in
the diabetic patients (peak value of 7.4 (1.5) ng/1 at R+60 min vs a
basal level of 5.1 (0.9) ng/1 (p=0.065)), in contrast to the control
group, in which an increase from 4.4 (0.4) ng/1 to a peak of 15.1
(4.1) ng/1 at R+30 min was observed (p<0.01), with a subsequent fall
to basal values. Again there was a trend towards a greater response
in the non-diabetic subjects, which just failed to reach significance
because of the wide individual variation in responses (Figure 5).
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Figure 4
Plasma renin activity (PRA) response following administration o
insulin (arrow) in diabetic (o) and non-diabetic (•) subjects
B=basal and R=onset of acute autonomic reaction.
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Figure 5
Plasma angiotensin II response following administration of insulin
(arrow) in diabetic (o) and non-diabetic (•) subjects. B=basal and
R=onset of acute autonomic reaction.
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Renal Function
In the diabetic patients, effective renal plasma flow fell from 674
(106) ml/min in the basal period to 540 (198) ml/min during the
period of hypoglycaemia (p<0.01), returning to normal in the recovery
period. A similar response was observed in the control subjects, with
a reduction in the effective renal plasma flow from 625 (38) to 485
(27) ml/min during hypoglycaemia (p<0.01). The values at each of the
three time-points were lower in the control group, this difference
reaching significance at the time of hypoglycaemia (p<0.01) (Figure
6). The magnitude of the fall in response to hypoglycaemia did not
differ between the two groups (Figure 7).
Glomerular filtration rate (GFR) fell in the diabetic patients from a
basal value of 143 (23) to 110 (36) ml/min during the period of
hypoglycaemia (p<0.02), again returning to normal during the recovery
phase. In the control subjects, the GFR values at each time point
were significantly lower (Figure 6) and the overall fall in response
to hypoglycaemia (from 118 (6) to 95 (4) ml/min) was also less than
that observed in the diabetic group (Figure 7).
The correlation between GFR and effective renal plasma flow also
differed between the two groups. In the diabetic patients, GFR and
effective renal plasma flow were closely correlated both in the basal
period (r=0.75, p<0.05) and during the period of hypoglycaemia
(r=0.96, p<0.001). The changes in GFR and effective renal plasma flow
occurring during hypoglycaemia were also well correlated (r=0.78,
p<0.05). In contrast, in the non-diabetic control subjects, these
correlations fell well short of significance.
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Figure 6
Effective renal plasma flow (RPF) (a) and glomerular filtration rate
(GFR) (b) during acute hypoglycaemia in diabetic (o) and non-diabetic
(•) subjects.

























Change in effective renal plasma flow (RPF) (a) and glomerular
filtration rate (GFR) (b) in response to acute hypoglycaemia in
diabetic (GROUP 1) and non-diabetic (GROUP 2) subjects.
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The effects of acute hypoglycaemia on urine volume and urinary
excretion of sodium, dopamine and albumin are shown in Table 1 for
the diabetic patients and Table 2 for the control subjects. Both
urinary volume and albumin excretion rate fell significantly during
hypoglycaemia in the diabetic but not in the control group. Neither
fractional nor absolute urinary sodium excretion changed
significantly in the diabetic patients but a significant fall in
urinary dopamine excretion was observed which did not correlate with
urinary flow (r=0.20, p=NS) and was not dependent on changes in GFR,
renal plasma flow or urinary sodium excretion. In contrast, in the
non-diabetic control subjects, urinary sodium excretion fell during































































































































































































Activation of the autonomic nervous system and the hormonal secretion
associated with acute hypoglycaemia in humans have a profound effect
on the vascular perfusion and function of several organs (Beam et
al, 1952: Middleton & French, 1974; Hilsted et al, 1982 & 1984;
Fisher et al, 1987; Neil et al, 1987) and the intravenous insulin
bolus technique described in these studies is likely to maximally
stimulate this neuro-hormonal activation. Patients with IDDM, who had
no clinical evidence of nephropathy, had a fall in effective renal
plasma flow and glomerular filtration rate of 20% and 23%
respectively in response to acute hypoglycaemia, the reduction in
glomerular filtration rate being significantly greater than that
observed in non-diabetic control subjects. Both effective renal
plasma flow and glomerular filtration rate were higher in the basal
state in the diabetic patients, this being a well recognised feature
of diabetes, particularly in the presence of poor glycaemic control
(Mogensen, 1971 & 1972; Ditzel & Junker, 1972). In addition, a close
correlation was identified in the diabetic patients, but not in the
control subjects, between the changes in glomerular filtration rate
and renal plasma flow during hypoglycaemia, suggesting that in IDDM
the glomerular filtration rate may be more highly dependent on renal
blood flow than in non-diabetic subjects.
Adrenaline and angiotensin II, two of the principal hormones which
are known to affect renal blood flow, were stimulated to a lesser
extent in the diabetic group than in the non-diabetic subjects. It
is recognised that the catecholamine response to hypoglycaemia may be
diminished in patients with IDDM of long duration (Hoeldke et al,
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1982; Bolli et al, 1983; Adamson et al, 1984), which might at least
partially explain the reduced adrenaline response. Both renal plasma
flow and glomerular filtration rate fell significantly, however, in
spite of these reduced hormonal responses. It may be, therefore, that
direct stimulation of the efferent sympathetic nerves as part of the
autonomic response to hypoglycaemia, rather than the specific effects
of the hormones, is the major determinant of the changes in renal
haemodynamics observed. The fall in plasma glucose per se may also be
of importance. A significant fall both in glomerular filtration rate
and renal plasma flow has been demonstrated in diabetic patients when
the blood glucose concentration was reduced from the hyperglycaemic
to the normoglycaemic range, without any simultaneous change in
plasma catecholamine concentrations (Mogensen et al, 1978). This is
apparently not explicable on the basis of changes in plasma volume or
sympathetic activation occurring in response to hyperinsulinaemia
(Mogensen et al, 1980; Christiansen et al, 1981b).
The secretion of vasopressin in response to acute hypoglycaemia is
known to be markedly enhanced in IDDM (Fisher et al, 1989; Thompson
et al, 1989) and the significant fall in urine volume observed in the
diabetic patients during hypoglycaemia, but not in the control
subjects, is likely to be explicable on the basis of this augmented
vasopressin response to hypoglycaemia. The rapid reduction in
urinary flow rate in response to hypoglycaemia may also underlie the
significant fall in urinary albumin excretion rate in the diabetic
group. The elevated basal urinary albumin excretion rate in both
groups is probably related to the prevailing diuretic conditions, as
it has been shown previously that albumin excretion rises
significantly in response to water loading, falling again when the
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urinary flow rate returns to normal (Viberti et al, 1982c).
Urinary dopamine excretion fell in response to hypoglycaemia, but a
reduction in sodium excretion only occurred in the non-diabetic
subjects. The absence of a fall in urinary sodium excretion in the
patients with IDDM is perhaps surprising, as there is usually a close
correlation between dopamine and sodium excretion (Alexander et al,
1974; see also Chapter 3). A reduced sodium excretion might also have
been anticipated on the basis of the action of the insulin
administered to induce hypoglycaemia, as insulin inhibits the renal
excretion of electrolytes (Nizet et al, 1971; DeFronzo et al, 1975)
and enhances sodium reabsorption in the renal tubules (Wiesmann et
al, 1977). A possible explanation for this observed difference
between diabetic and non-diabetic subjects is the absence of a
significant rise in plasma noradrenaline in response to hypoglycaemia
in the diabetic group. Noradrenaline promotes sodium retention, via
alpha receptors in the proximal tubules (McMurray et al, 1988), this
action being independent of any haemodynamic effects.
In conclusion, the studies described here have demonstrated reduced
renal perfusion and glomerular filtration rate in response to acute
hypoglycaemia, more marked in patients with IDDM. These changes in
renal haemodynamics and function are superimposed upon the well-
documented changes in plasma viscosity (Frier et al, 1983; Hilsted et
al, 1984) and platelet activation (Hilsted et al, 1980; Dalsgaard-
Nielsen et al, 1982) which also occur in response to hypoglycaemia.
It is likely that these combined changes are potentially deleterious,
with the overall effect being to initiate, or at least enhance, a
tendency towards tissue ischaemia. Hypoglycaemia may therefore be a
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factor in the causation, or possibly more importantly in the
progression, of diabetic renal disease, particularly in those
patients with hypoglycaemia unawareness who may be exposed to
frequent and often prolonged hypoglycaemic episodes.
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CHAPTER 8
GENERAL DISCUSSION AND FUTURE RESEARCH
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It is not surprising, in such a major new area of potentially
considerable clinical importance, that a substantial amount of
research has been published in the time since the studies presented
in this thesis were initiated. In this final chapter, I have
attempted to discuss the findings of my own studies in the context of
other relevant recently published work, where possible suggesting the
future direction of research which may prove fruitful in enhancing
our understanding of early diabetic nephropathy.
Early diabetic nephropathy, hypertension and vascular disease
In Chapter 3, I examined the possibility that a defect in dopamine
excretion, which appears to have a genetically determined link with
essential hypertension, may be a factor in the development of early
diabetic nephropathy. The finding of a preserved relationship between
urinary sodium and dopamine excretion in patients with
microalbuminuria suggests that such a defect does not predate the
onset of nephropathy in predisposed patients with IDDM. Although
future research could increase the sensitivity of this study by
measuring the dynamic response of dopamine excretion to sodium
loading, it seems likely that it is necessary to look elsewhere to
find a genetic factor which is of aetiological importance in the
development of both diabetic nephropathy and hypertension. As
discussed in Section 1.5, the sodium-lithium countertransport system
has already received considerable attention as such a potential
genetic link and research in this field has continued, although the
most recent studies have done little to clarify the situation.
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A higher sodium-lithium countertransport activity has been reported
in parents of diabetic patients with nephropathy, when compared with
parents of patients with normal urinary albumin excretion (Walker et
al, 1990). In the same study, a significant correlation was noted
between blood pressure in the patients with nephropathy and their
parents. It was suggested that these findings constituted additional
evidence that genetic factors associated with a predisposition to
hypertension are relevant in determining susceptibility to diabetic
nephropathy. However, a further Scandinavian study failed to show any
difference in either blood pressure or sodium-lithium counter-
transport activity between groups of parents of diabetic patients
with and without nephropathy (Jensen et al, 1990). Indeed in this
study, sodium-lithium countertransport activity did not differ even
between the patient groups and the authors reached the opposite
conclusion to that of Walker et al. It is perhaps of particular
relevance that it has been very recently shown, on detailed
examination of the kinetics of sodium-lithium countertransport, that
the mechanism for increased activity in diabetes appears to be
completely different from that found in essential hypertension, again
suggesting that this genetic marker of hypertension does not provide
the link with diabetes and diabetic nephropathy (Rutherford et al,
1992). The sodium-proton pump has also been the subject of recent
attention and it has been suggested that measurement of the sodium-
hydrogen exchange rate may be of more direct relevance in the field
of diabetic nephropathy and hypertension than sodium-lithium
countertransport activity (Barbe et al, 1992). Additional data in
this area will doubtless follow in the next few years.
Further recent research has suggested that patients with early
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diabetic nephropathy have a generalised increased sensitivity to the
vasoconstrictive effects of noradrenaline and this could be relevant
in the development of nephropathy (with enhanced vasoconstriction of
efferent arterioles contributing to intraglomerular hypertension) and
also systemic hypertension (Bodmer et al, 1992). The precise nature
of this apparent hypersensitivity to endogenous vasoconstrictors
remains to be elucidated but it may be genetically determined and
further research in this field could prove fruitful in helping to
explain the link between diabetic nephropathy, hypertension and
generalised vascular disease.
In Chapter 4, the issue of antihypertensive therapy in hypertensive
patients with IDDM was considered, captopril and nifedipine retard
being shown to have a similar effect on reducing blood pressure and
urinary albumin excretion over an eight-week period of treatment,
although captopril maintained an acute effect on renal haemodynamics,
independent of its action on systemic blood pressure. A number of
other recent studies have now also examined the actions of different
antihypertensive agents in the diabetic population. Treatment with
captopril and thiazide diuretics in normotensive patients with
microalbuminuria has been reported to reduce the albumin excretion
rate in comparison with controls, without there being a significant
effect on blood pressure (Mathiesen et al, 1991). This is suggested
by the authors to be indicative of either a fall in intraglomerular
pressure as a result of a direct effect of captopril on efferent
arteriolar resistance or, alternatively, a specific action of the
drug on the intrinsic selectivity of the glomerular membrane,
resulting in a slow decline in the permeability of the glomerular
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barrier to protein. A further study in hypertensive patients
demonstrated that reduced protein excretion whilst taking angiotensin
converting enzyme inhibitors was maintained over a 3-year treatment
period (Hermans et al, 1992).
Exercise-induced microalbuminuria has been suggested as an earlier
marker of diabetic nephropathy than increased urinary albumin
excretion measured at rest (see Section 1.6) and captopril has also
been shown to have an effect on reducing the rise in albumin
excretion in response to exercise, again without having any
significant effect on the systemic blood pressure response (Romanelli
et al, 1989).
There have still been relatively few comparative studies between
different antihypertensive agents in diabetic patients. In
hypertensive patients with IDDM and advanced nephropathy, protein
excretion was found to be less after an eight-week treatment period
with captopril, compared to metoprolol, but the reduction in systemic
blood pressure was also greater on captopril, making the
interpretation of any specific intrarenal effect of the drug
difficult (Bjorck et al, 1990). In a further group of patients with
nephrotic syndrome secondary to diabetic nephropathy, lisinopril and
diltiazem were reported to have similar effects in reducing protein
excretion (Bakris et al, 1990). In patients with early nephropathy, a
recently published multi-centre study from Australia found
perindopril and nifedipine to have a comparable action in reducing
blood pressure and urinary albumin excretion over a treatment period
of 12 months and it was of note that, in both treatment groups,
albumin excretion only fell in patients in whom there was also a
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significant fall in blood pressure (Melbourne Diabetic Nephropathy
Study Group, 1991).
It seems reasonable to conclude from the available data that the
controversy of whether or not angiotensin converting enzyme
inhibitors are specifically reno-protective, secondary to a direct
intrarenal action over and above their effect on reducing systemic
blood pressure, remains to be resolved.
There has recently also been increasing interest in 24-h ambulatory
blood pressure monitoring. Early evidence suggests that, in diabetic
patients with microalbuminuria, not only is the mean blood pressure
higher than in controls with normal albumin excretion, but there is
additionally a significant reduction in the normal nocturnal dip in
blood pressure (Berrut et al, 1992; Hansen et al, 1992). This may be
of particular importance as, certainly in non-diabetic patients with
essential hypertension, there is evidence that loss of the nocturnal
dip is associated with a greater left ventricular mass and an
increased risk of cardiovascular complications (Pickering et al,
1990; Verdecchia et al, 1990). In the light of these findings it
would seem that, to provide maximum information, further studies of
different antihypertensive agents in diabetic patients will require
to consider changes in 24-h blood pressure profiles, rather than
simply alterations in one-off random measurements.
In Chapter 5, I have specifically focussed on patients with NIDDM, a
group in which the link between microalbuminuria and generalised
vascular disease has been shown to be particularly strong. 26% of
patients had an elevated urinary albumin excretion rate at initial
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presentation with NIDDM and this correlated strongly with both age
and the presence of generalised macrovascular disease. Even after
glycaemic control was achieved, 16% of patients had persistent
microalbuminuria during a follow-up period of one year from
presentation, presumably indicating established pathology. A further
study in newly-presenting, normotensive patients with NIDDM has
demonstrated an elevated glomerular filtration rate to be present in
45% (Vora et al, 1992), suggesting that hyperfiltration may be an
important pathophysiological factor in the development of nephropathy
in NIDDM, as has also been postulated to be the case in IDDM
(Hostetter et al, 1982).
The close association between microalbuminuria in NIDDM and the
development of generalised vascular disease has attracted most recent
research interest, however. Patients with NIDDM who have increased
urinary albumin excretion have been noted to have more atherogenic
lipid profiles than normoalbuminuric controls, with higher plasma
levels of VLDL-cholesterol and VLDL- and LDL-triglyceride, along with
reduced HDL-cholesterol concentrations (Niskanen et al, 1990).
Rheological studies have also demonstrated evidence of a
hypercoagulable state, endothelial dysfunction and increased free
radical activation in patients with microalbuminuria, all factors
which have been suggested to be of potential importance in
determining the excess of vascular disease in this group (Schmitz et
al, 1990; Collier et al, 1992; Stehouwer et al, 1992).
The potential role of insulin in the pathophysiology of diabetic
complications has also been the focus of some recent attention. Many
patients with NIDDM have insulin resistance and hyperinsulinaemia,
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and Reaven has proposed that diabetes per se may be just one part of
a syndrome complex which includes obesity, hypertension, lipid
abnormalities and a predisposition to vascular disease (Reaven,
1988). It has further been suggested that hyperinsulinaemia and
abnormalities of lipoprotein metabolism may have a direct role in the
aetiology of hypertension (Reaven, 1991; Pezzarossa et al, 1992). A
recent preliminary study has additionally indicated that
hyperinsulinaemia may be an important factor in the development of
impaired natriuresis, hyperfiltration and microalbuminuria in
patients with NIDDM (Sambarato et al, 1992).
Tubular function in early diabetic nephropathy
In Chapter 6, I have examined the possible role of markers of tubular
dysfunction in the identification of early diabetic nephropathy,
measuring urinary excretion of beta-thromboglobulin and
N-acetyl-beta-D-glucosaminidase in groups of patients with IDDM,
both with and without microalbuminuria. In common with other
investigators, my findings suggest that, although abnormalities of
tubular function are commonly found in the presence of
microalbuminuria, the available markers may not be of adequate
sensitivity to be of great value in the detection of diabetic
nephropathy at the earliest possible stage.
In the last two years there has been only a limited amount of further
published work in this field. It has, however, been suggested that
one of the initial events in the development of diabetic nephropathy
may be increased peritubular capillary leakage, leading to
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interstitial oedema and early tubular dysfunction (Pinter & Atkins,
1990) and some very recent preliminary research lends support to this
theory. Patients with IDDM and normal urinary albumin excretion, who
had serum markers of endothelial dysfunction, also had evidence of
increased free radical activation and abnormal tubular function,
compared to both diabetic patients without evidence of endothelial
dysfunction and also normal non-diabetic control subjects, although
there was no difference in urinary albumin excretion between the
three groups (Yagoob et al, 1992a & 1992b). These findings suggest
that endothelial dysfunction, possibly related to oxidant injury, may
affect the postglomerular, peritubular capillaries at an early stage,
initiating the nephropathic process and resulting in tubular
enzymuria and increased excretion of low molecular weight proteins as
a consequence of ischaemic damage and disruption of tubular cells. If
further research supports these findings, there could be a
considerable resurgence of interest in tubular function in diabetic
patients.
Hvpoqlvcaemia and diabetic nephropathy
In the final experimental studies described in Chapter 7, I have
examined the effect of acute hypoglycaemia on renal function, both in
patients with IDDM and in non-diabetic control subjects. The most
striking findings during hypoglycaemia were a significant fall in
both effective renal plasma flow and glomerular filtration rate, the
reduction in the latter parameter being both greater and more
directly dependent on renal blood flow in the diabetic group.
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Hypoglycaemia is extremely common in patients with IDDM and recently
increased attention has been given in the literature to the fact that
many patients lose the warning symptoms of the onset of
hypoglycaemia, putting them at risk of prolonged and more severe
episodes. In one UK survey, reduced hypoglycaemia awareness was
reported in 23% of insulin-treated patients attending a hospital
diabetic clinic, predominantly in those with a long duration of
diabetes and hence the highest prevalence of specific vascular
complications of diabetes (Hepburn et al, 1990). Interest in this
area has been enhanced by the suggestion that the use of human
insulin may be implicated in the causation of altered hypoglycaemia
awareness (Teuscher & Berger, 1987), resulting in an increased
prevalence of severe hypoglycaemia (Egger et al, 1991). The debate
which has ensued is outwith the scope of this thesis but what has
become clear as a result of this increased publicity in both the
medical and lay press is the fact that many insulin-treated diabetic
patients experience frequent hypoglycaemia, which can often be
asymptomatic and at other times severe and prolonged.
In view of its prevalence and associated physiological effects, it is
perhaps surprising that the possibility that hypoglycaemia may be of
importance in either the initiation or progression of specific
microvascular complications of diabetes has not been researched more
extensively. There seems little doubt that the reduced blood flow to
a number of organs observed during hypoglycaemia, including the
kidneys as described here, could be potentially damaging. This is
particularly the case when considered in conjunction with the
widespread rheological changes which occur during hypoglycaemia (see
Section 7.4), all of which would tend to favour microvascular
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thrombosis. With specific reference to the kidney, these potential
detrimental effects of hypoglycaemia could be examined further by
studying the renal responses to acute hypoglycaemia in patients who
already have evidence of nephropathy and also by carefully assessing
renal function in a group of patients who have experienced recurrent
severe hypoglycaemia, in comparison with matched controls in whom
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Resume
Alors que la microalbuminurie indique une lesion
glomerulaire dans la nephropathie diabetique, des ano¬
malies tubulaires interviennent aussi dans la maladie
renale diabetique a son stade precoce. L'excretion urinaire
de la beta-thromboglobuline (BTG) et de la N-acetyl-
beta-D-glucosaminidase (NAG) a ete mesuree chez
132 patients diabetiques de type 1 (insulino-dependants)
normo-tendus, sans maladie renale manifeste, parmi les-
quels 35 avaient une microalbuminurie et les autres
avaient une elimination urinaire de l'albumine normale.
Sur les 21 patients qui avaient une concentration urinaire
en BTG detectable, seulement 8 (38 %) avaient un taux
d'albuminurie anormal associe. L'excretion de la NAG
etait elevee chez 22 patients (63 %) sur les 35 avec micro-
albuminerie ; des associations significatives ont aussi ete
identifiees entre l'excretion urinaire de NAG et le tabac
(x2 = 12,7, p < 0.001) et l'hemoglobine glycosylee (r =
0,49, p < 0.01). En conclusion, la mesure de la BTG
urinaire n'est pas d'une sensibilite suffisante pour detecter
une maladie renale diabetique a son stade precoce, mais
le taux de NAG urinaire pourrait etre utile dans la
detection de la nephropathie diabetique a un stade
potentiellement reversible.




While microalbuminuria indicates the glomerular
damage of early diabetic nephropathy, tubular abnor¬
malities also occur at an early stage of diabetic renal
disease. Urinary excretion of beta-thromboglobulin
(BTG) and N-acetyl-beta-D-glucosaminidase (NAG) was
measured in 132 normotensive Type 1 (insulin-dependent)
diabetic patients with no evidence of overt renal disease,
of whom 35 had microalbuminuria and the remainder
had normal urinary albumin excretion. Of 21 patients in
whom there was a detectable urinary BTG concentration,
only 8 (38 %) had a concurrently abnormal urinary
albumin excretion. NAG excretion was elevated in 22
(63 %) of the 35 patients with microalbuminuria ; signi¬
ficant associations were also identified between urinary
NAG excretion and smoking habit (x2 = 12.7, p < 0.001)
and glycated haemoglobin (r = 0.49, p < 0.01). It is
concluded that measurement of urinary BTG is not of
sufficient sensitivity to be of value in the detection of
early diabetic renal disease, but measurement of urinary
NAG may be of value in the detection of diabetic
nephropathy at a potentially reversible stage.
Key Words : Type 1 diabetes. Diabetic nephropathy. Microal¬
buminuria. Beta-thromboglobulin. N-acetyl-beta-D-glucosamini-
dase.
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INTRODUCTION
Microalbuminaria, defined as a urinary albumin
excretion rate of 20-200 ug min-1, is an indicator
of early diabetic renal disease, and predicts pro¬
gression to clinical nephropathy (1-4). In a Type 1
diabetic population microalbuminuria has been asso¬
ciated with male gender, hypertension, advanced
retinopathy and neuropathy, indicated by abnormal
vibration sensation (5, 6). Increased urinary excre¬
tion of albumin is predominantly a measure of
glomerular leakage, but tubular dysfunction is also
a feature of early diabetic nephropathy. Increased
urinary concentrations of small protein molecules,
including beta-2-microglobulin (7-9), alpha-l-micro-
globulin (10, 11) and kappa light chains (10), which
are freely filtered across the glomerular membrane,
have been demonstrated in diabetic patients. It is
possible that these proteins, and others such as
retinol-binding protein (12, 13), may be of value
in the early detection of diabetic renal damage.
Beta-thromboglobulin (BTG) is a platelet-spe¬
cific protein which is located in the alpha granules
and released during platelet activation. It occurs
as a tetramer with a subunit molecular weight of
8 600 daltons and is normally present in very low
concentrations in the urine. Urinary BTG was found
to be increased in patients with Type 1 diabetes,
when compared with normal controls (14), and its
urinary excretion was significantly higher in patients
who had nephropaty, with a correlation being obser¬
ved with plasma creatinine and beta-2-microglobulin
(15). The potential value of this urinary protein as
a marker for early nephropathy has not been
investigated previously.
Urinary N-acetyl-beta-D-glucosaminidase
(NAG) is a lysosomal enzyme which is a much
larger molecule than albumin and, although present
in renal tubular cells, does not normally appear in
the glomerular filtrate. Urinary NAG excretion has
been studied previously in diabetic patients and
may be of some value in identifying early diabetic
nephropathy (11, 13, 16-19), although its precise
role remains to be defined. In the present study,
the urinary excretion of BTG and NAG was mea¬
sured in a group of Type 1 diabetic patients with
and without microalbuminuria. The association bet¬
ween urinary BTG and NAG and albumin excretion
was examined and the relationship was determined
between the urinary concentrations of these proteins
and age, sex, duration of diabetes, blood pressure,
glycaemic control, smoking status and presence of
retinopathy in these diabetic patients.
METHODS
132 Type 1 diabetic patients were recruited from the
Diabetic Clinic at the Royal Infirmary, Edinburgh.
Patients were excluded if they had hypertension as defined
by WHO criteria (> 160/95 mm Hg), a past history of
renal disease, and haematuria or proteinuria on routine
testing of urine with Multistix (Ames, Slough, UK),
which identifies those with a urinary protein concentration
of > 300 mg 1 approximately. No patients had a plasma
creatinine concentration > 150 umol l"1 or were taking
any drug which might cause proteinuria. Of the parti¬
cipating patients, 97 (Group A) had no evidence of
diabetic nephropathy, with at least three previous esti¬
mations of urinary albumin excretion consistently being
within the normal range. The 35 other patients (Group B)
had been identified previously as having microalbuminuria
with an elevated urinary albumin/creatinine ratio of
> 2.5 mg mmoD1 in two or more first morning specimens
of urine within the preceding year, this level having
previously been shown (20) to predict an albumin excre¬
tion rate of > 30 ug min-1.
The presence of clinically apparent retinopathy was
assessed in each patient by direct ophthalmoscopy through
dilated pupils and if present was classified as background
or proliferative. Proliferative retinopathy was defined as
the presence of soft exudates (cotton wool spots), active
neovascularisation or scarring from previous photocoa¬
gulation therapy ; background retinopathy was identified
by the presence of microaneurysms, haemorrhages or
hard exudates. Seated blood pressure was recorded, after
resting for 10 minutes, using a standard mercury sphyg¬
momanometer. Details of drug therapy and smoking
habit were obtained ; those who were smoking five
cigarettes or more daily at the time ot the study were
defined as « smokers ». No attempt was made to further
quantify the number of cigarettes smoked. Clinical details
of the two groups are given in Table 1. The patients in
Group B were older, had a longer duration of diabetes,
a higher mean glycated haemoglobin concentration and
a greater prevalence of retinopathy.
On the day of attendance at the clinic, venous blood
was withdrawn for estimation of glycated haemoglobin
and plasma creatinine, and all patients collected a sample
of the first urine voided immediately after rising, wich
was subsequently divided into three aliquots. Urinary
albumin excretion was measured, within 48 hours of
collection, in one of these aliquots stored at 4 °C, with
the other two samples, for determination of urinary BTG
and NAG concentrations, being stored until analysis at
—20 °C. Urinary albumin concentrations were measured
by an immunoturbidometric assay (21) (Cambridge Life
Sciences, Cambridge, UK) and urinary creatinine by the
Jaffe reaction. BTG was measured by immunoassay (22),
with the normal urinary concentration being less than
0.1 U ml-1, and urinary NAG was determined by a
colorimetric assay using a chromogenic substrate, 2-
Methoxy-4-(2'-nitrovinyl) phenyl-2-acetamido-2-deoxy-
Beta-D-gluco-pyranoside (23) (Thames Genelink, Dee-
side, UK). A urinary NAG/creatinine ratio of
& 25 pmol h"1 mmol"1 is considered abnormal, using this
commercially available method. Glycated haemoglobin
was estimated by electroendosmosis using agar plates
(laboratory normal range 6.0-8.0 %).
Statistical Analysis
Chi squared and t-tests were used, where appropriate,
to determine the association of BTG and the NAG/
creatinine ratio with the other variables. Multiple regres¬
sion analysis was also performed to assess the relative
importance of the associations between urinary NAG/
Vol. 16, n" 5, 1990 URINARY BTG AND NAG IN DIABETES 443
Table I. — Clinical details of diabetic patients with normal urinary albumin excretion (Group A) and with microalbuminuria
(Group B)
Group A (n = 97) Group B (n = 35) Difference
Age (years and range) 34 (14-63 yrs) 41 (1-44 yrs) p < 0.02
Duration of diabetes (years and range) 11 (6 mo-48 yrs) 19 (1-44 yrs) p < 0.001
Sex 52 M : 45 F 22 M : 13 F NS
Glycated haemoglobin ( %) 9.5 (2.1) 11.2 (2.1) p < 0.001
Plasma creatinine (mmol 1') 79.2 (12.4) 84.4 (13.3) NS
Systolic BP (mm Hg) 120 (17) 127.2 (22.2) NS
Diastolic BP (mm Hg) 74 (10) 74 (10) NS
* Smoking status (No ( %) pts)
6 (19 %)— Smokers 23 (24 %) NS
— Non-smokers 72 (76 %) 25 (81 %)
* Retinopathy (No ( %) pts)
14 (41 %)— Absent 79 (81 %)
— Background 15 (15 %) 14 (41 %)
-— Proliferative 3 (3 %) 6 (18 %)
— Retinopathy (Total) 18 (19 %) 20 (59 %) p < 0.001
Mean (SD) where appropriate
* Data on smoking habit not available for 6 patients and on retinopathy for 1 patient.
creatinine ratio and urinary albumin/creatinine ratio,
blood pressure, smoking status, retinopathy, glycaemic
control, age and duration of diabetes.
RESULTS
Of the 35 patients previously identified as having
microalbuminuria, only 21 had an albumin/creati¬
nine ratio (ACR) of > 2.5 mg mmol-1 in an early
morning specimen of urine provided at the time
of study. This apparent disparity can be explained
by the recognised day to day variability in urinary
albumin excretion in individual patients with dia¬
betes (24, 25). Urinary BTG was above the level
of detection of the assay (0.1 U ml-1) in only
21 patients in total, 13 of whom (62 %) belonged
to the group with established microalbuminuria
(Group B), although only 8 of these patients (38 %)
also had an elevated ACR in the specimen of urine
provided for the study. Urinary BTG was associated
with a longer duration of diabetes : 15 patients
(71 %) with a detectable urinary BTG had diabetes
for 10 years or more. The number of patients with
a detectable urinary BTG was too small to establish
an association with either retinopathy, smoking
habit or glycated haemoglobin concentration.
The NAG/creatinine ratio was elevated in
55 patients. 22 patients (63 %) with microalbumi¬
nuria had an elevated NAG/creatinine ratio, inclu¬
ding 16 (73 %) of those who had an elevated ACR
at the time of study (Fig. 1). A significant corre¬
lation was observed between the urinary NAG/
creatinine ratio and glycated haemoglobin (Fig. 2).
Complete data on the NAG/creatinine ratio and
retinopathy was not available on two patients and,
for smoking habit, data was missing on six patients.
However, an association was evident between uri¬
nary NAG/creatinine excretion and both of these
parameters, with the NAG/creatinine ratio being
elevated in 20 (57 %) of 35 patients with clinically
apparent background or proliferative retinopathy,
compared with 35 (37 %) of patients without reti¬
nopathy (x2 = 4.3, p < 0.05). A similar increase
in the prevalence of abnormal NAG/creatinine
excretion was observed in smokers (20 (69 %) of
29 patients) compared with non-smokers (31 (32 %)
of 97 patients) (x2 = 12.7, p < 0.001). No asso¬
ciation was observed between smoking habit and
elevation of the urinary ACR. When the patients
were grouped according to duration of diabetes
(Fig. 3), the mean urinary NAG/creatinine ratio
was noted to rise progressively from the group with
a duration of disease of less than 2 years to that
with a duration of 10-20 years, although a corre¬
lation was not found between the NAG/creatinine
ratio and the duration of diabetes considered as a
continuous variable. No significant association was
determined between the urinary NAG/creatinine
ratio and either age, sex, systolic or diastolic blood
pressure.
Multiple regression analysis was performed to
determine the most important associations between
the above variables and the NAG/creatinine ratio.
The coefficients of each term in the multiple regres¬
sion are shown in Table II and give an estimate
of the difference in the NAG/creatinine ratio attri¬
butable to each variable independent of the other
variables. Smoking habit, glycaemic control and the
presence of microalbuminuria were all indepen¬
dently associated, but the presence of clinically
apparent retinopathy just failed to achieve signi-
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Fig. 1. — Relationship between urinary excretion of NAG and albumin, both expressed
as a ratio against urinary creatinine. Bars indicate mean values.
ficance as an independently important variable.
Thus the NAG/creatinine ratio was on average
18.2 umol h-1 mmol-1 greater in smokers than non-
smokers and 13.9 umol h-1 mmol-1 greater in
patients with microalbuminuria compared with those
patients who had a consistently normal urinary
albumin excretion. For each incremental rise of
1 % in the glycated haemoglobin, the NAG/crea¬
tinine ratio rose by 3.35 umol h-1 mmol-1. The
coefficients for age and duration of diabetes are
given per year, and for blood pressure per mm Hg ;
the association with these parameters was not sta¬
tistically significant.
DISCUSSION
The ability to identify patients with early diabetic
nephropathy, by the detection of microalbuminuria,
has provided the possibility of earlier therapeutic
intervention to delay progression of the renal
disease, but the identification of the abnormal
urinary excretion of other proteins has been pursued
in an attemps to identify patients at an even earlier
stage of diabetic renal disease than can be detected
by microalbuminuria. Several proteins of small
molecular weight have been studied as possible
indicators of early diabetic nephropathy. An increa¬
sed urinary excretion of beta-2-microglobulin has
been reported in children and adolescents with
Type 1 diabetes (9, 17), but other studies have
failed to demonstrate an abnormality even in the
presence of established diabetic nephropathy (26,
27). The low stability of beta-2-microglobulin (11,
12), both in vitro an in vivo, may partly explain
these discrepant results, and the role of this protein
as a potential marker of early tubular dysfunction
appears to be limited. Alpha-l-microglobulin, kappa
light chains and retinol-binding protein may be of
greater diagnostic value, but further studies are
required.
The platelet-derived protein, beta-thromboglo-
bulin (BTG), has a low molecular weight and should
therefore filter freely through the glomerular mem-
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Fig. 2. — Relationship between urinary NAG!creatinine ratio and HbAt.
Table II. — Coefficients, with 95 % confidence limits, from multiple regression analysis,
using the NAG/creatinine rato as the dependent variable
Age (change per year) 0.09 (— 0.18, 0.36)
Duration of diabetes (change per year) — 0.38 (— 0.77, 0.01)
Systolic blood pressure (change per mm Hg) 0.01 (— 0.17, 0.19)
Smoking habit (yes/no) 18.2 (10.7, 267)
Retinopathy (yes/no) 5.40 (— 2.53, 13.73)
Glycated haemoglobin (change per 1 %) 3.35 (1.92, 4.78)
Microalbuminuria (yes/no) 13.9 (6.5, 21.3)
brane. Reabsorption in the proximal tubule main¬
tains a constant concentration of BTG excreted in
the urine of approximately 0.5 % of the plasma
concentration (28). BTG is released in response to
platelet aggregation and activation (29), and a
previous study of diabetic patients used BTG as a
marker to examine the role of platelet activation
in microvascular complications (15). Although that
particular study did not find any correlation between
urinary BTG and platelet survival, a strong cor¬
relation was observed with plasma creatinine and
Beta-2-microglobulin, suggesting a possible role for
BTG in the detection of renal disease in patients
with diabetes. A further study demonstrated an
increase in urinary BTG excretion in non-diabetic
hypertensive patients with renal impairment (30)
but to our knowledge the possible role of BTG as
an indicator of early diabetic nephropathy has not
been examined previously. In the present study,
although urinary BTG excretion was elevated in a
higher proportion of the diabetic patients with
microalbuminuria and in those with a long duration
of diabetes, the results do not suggest that mea¬
surement of the urinary concentration of this protein
has an adequate degree of sensitivity to replace or
even complement urinary albumin excretion as an
indicator of early diabetic nephropathy.
An alternative approach to the identification of
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Fig. 3. — Relationship between urinary NAGIcreatinine ratio and duration of diabetes.
Bars indicate mean values.
early diabetic nephropathy is the measurement of
the urinary enzyme, N-acetyl-beta-D-glucosamini-
dase (NAG). This enzyme, which has a molecular
weight of 150 000 daltons, is too large to be filtered
through the normal glomerular membrane although
it is possible that in the presence of glomerular
damage significant concentrations appear in the
urine via this route. However, increased urinary
excretion of NAG is likely to be predominantly
caused by tubular damage, and increased urinary
NAG concentrations have previously been demons¬
trated in diabetic patients who had either frank
proteinuria or microalbuminuria (13, 16-18). The
present study has confirmed this association, and
similar correlations were found between the urinary
NAG/creatinine ration and both glycaemic control
and smoking habit. It was not possible to confirm
an association with the presence of diabetic reti¬
nopathy because of the small number of patients
affected by retinopathy detected clinically on direct
ophthalmoscopy.
The association of the urinary NAG/creatinine
ratio with glycated haemoglobin confirms the fin¬
dings of previous studies (13, 17, 18). It has been
demonstrated in dogs that urinary NAG excretion
was related to the urinary glucose concentration
(31) and, in the rat, increased urinary flow rate
(resembling the osmotic diuresis secondary to hyper-
glycaemia) was associated with reduced tubular
absorption of proteins (32). It is possible that similar
mechanisms are operational in the human diabetic
kidney wich would explain the observed association
with glycaemic control.
The observed association between the urinary
NAG/creatinine ratio and smoking adds to the
increasing body of evidence that smoking may have
a pathogenic role, in diabetic patients, in damaging
the microcirculation of various organs, including
the kidney (33). When the effects of smoking and
glycaemic control were excluded by the use of
multiple regression analysis, a significant correlation
was still demonstrable between urinary NAG excre¬
tion and microalbuminuria.
The present study has shown that urinary BTG,
in common with various other low molectular weight
proteins, is not of value as a sensitive indicator of
early diabetic nephropathy. Urinary NAG excretion,
which can be estimated by a simple kit method,
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may complement the measurement of urinary albu¬
min excretion in the detection of early nephropathy,
although further studies will be necessary before
abnormalities of tubular function can be considered
as a substitute for microalbuminuria as the most
useful indicator of potentially reversible renal
damage in diabetic patients.
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The Natural History and Associations of
Microalbuminuria in Type 2 Diabetes
During the First Year After Diagnosis
A.W. Patrick, P.J. Leslie, B.F. Clarke, B.M. Frier
Diabetic Department, Royal Infirmary, Edinburgh, Scotland
The prevalence of microalbuminuria was assessed in 149 consecutive, newly-diagnosed
and untreated patients with Type 2 diabetes, 129 of whom were followed up for 1 year,
with at least three urine specimens being obtained during this period. At initial presentation,
39 (26 %) patients had a urinary albumin to creatinine ratio (ACR) of > 2.5 mg mmol-1
and compared with patients who had a normal ACR, they were older (64 (11) (SD) vs 58
(11) yr, p< 0.002), with higher random blood glucose (14.4 (4.5) vs 12.3 (4.4) mmol I-1,
p < 0.02) and glycosylated haemoglobin (13.0 (3.1) vs 11.3 (2.7)%, p<0.01) concen¬
trations. An elevated ACR was also associated with a higher systolic blood pressure (149
(22) vs 140 (22), p < 0.05) and the presence of macrovascular disease, particularly
peripheral vascular disease (p < 0.001), with this association persisting after adjustment
for the effect of age. Ten patients reverted to normal albumin excretion on improving
blood glucose control, this group having a significantly higher glycosylated haemoglobin
concentration at initial presentation than the group with a persistently elevated ACR (14.4
(2.5) vs 12.0 (3.0) %, p < 0.05). The 21 (16 %) patients with a persistently elevated ACR
from diagnosis of Type 2 diabetes were older than those with normal albumin excretion
throughout (64 (7) vs 58 (10) yr, p< 0.02) and it is probable that these patients have
abnormal albumin excretion secondary to established renal pathology.
keywords Type 2 diabetes Microalbuminuria Glycosylated haemoglobin
Diabetic complications Vascular disease Nephropathy
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Introduction
Diabetic nephropathy is a major cause of mortality in
Type 1 diabetes, particularly in those patients who
develop the disorder early in life.1 Although the relative
risk of death from renal disease is apparently much lower
in older patients,2 between 32 % and 90 % of all
diabetic patients undergoing dialysis therapy have Type 2
diabetes.3-4
Abnormal urinary excretion of protein has been
reported in up to 50 % of patients with Type 2 diabetes,5
and develops in many patients soon after diagnosis.5'6
The presence of microalbuminuria in this group is
associated with macrovascular disease,7-8 and predicts
the development of frank proteinuria7 and increased
mortality.7-9 In contrast with a recent study of Type 1
diabetic patients,10 a significant prevalence of micro¬
albuminuria has been documented in Type 2 diabetes at
diagnosis.11-13 It has been suggested that this is a largely
functional phenomenon, consequent upon the osmotic
load presented by untreated hyperglycaemia,12,14 but the
presence of microalbuminuria may also indicate a long
prodromal period of asymptomatic hyperglycaemia prior
to diagnosis. The natural history of abnormal urinary
Correspondence to: Dr A.W. Patrick, Lecturer in Medicine, Department
of Medicine, Royal Liverpool Hospital, PO Box 147, Liverpool L69
3BX, UK.
albumin excretion following diagnosis has not previously
been reported in detail in patients with Type 2 diabetes.
The aims of the current study were to assess the
prevalence of microalbuminuria, and associations with
other clinical features, in a cohort of patients with Type
2 diabetes, at initial presentation, and to examine the
natural history of this phenomenon during the first year
of treatment of hyperglycaemia.
Patients and Methods
The study group comprised 149 newly diagnosed,
previously untreated patients (87 male, 62 female)
presenting consecutively to the diabetic clinic of Edin¬
burgh Royal Infirmary over a period of 9 months. In each
case an initial diagnosis of Type 2 diabetes was made
on the basis of clinical presentation, biochemical data,
and the absence of ketosis. Details of current drug
therapy were recorded, a full history was obtained and
a careful clinical examination was performed to determine
the presence of macrovascular disease. Cerebrovascular
disease was defined as a history of stroke or transient
ischaemic attacks; ischaemic heart disease as a history
of angina pectoris or myocardial infarction and/or ECG
evidence of ischaemia; and peripheral vascular disease
as a history of intermittent claudication, rest pain,
gangrene or amputation and/or the absence of the
posterior tibial and dorsalis pedis pulses in at least one
902 0742-3071/90/100902-07 $05.00
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foot. Blood pressure was measured in the arm using a
standard mercury sphygmomanometer after the patient
had been seated for 5 min, and fundi were examined,
using direct ophthalmoscopy after mydriasis, to assess
retinopathy. This was defined as the presence of micro¬
aneurysms, haemorrhages, exudates or proliferative
changes in one or both eyes. Weight and height
were measured and body mass index (BMI) calculated.
Exclusion criteria were known preceding renal disease,
a plasma creatinine concentration of greater than
150 (xmol I"1, the presence of Albustix positive pro¬
teinuria, or urinary tract infection determined by culture
of a midstream specimen of urine collected from all
patients at their initial clinic visit.
The patients were contacted prior to attendance and
asked to provide a specimen of the first urine voided,
immediately after rising, on the morning of the clinic
visit. This was stored at 4 °C until analysis for albumin
was performed, within 72 h of collection. Urinary
albumin concentration was determined by an immuno-
turbidimetric method15 and urinary creatinine was measured
by the Jaffe method. Results were expressed as a ratio
of albumin to creatinine (ACR), and a level of greater
than 2.5 mgmmoh1 was considered abnormal, this
level having previously been shown16 to predict an
albumin excretion rate of > 30 p,g min-1. Venous blood
was withdrawn for estimation of random plasma glucose
and glycosylated haemoglobin which was measured by
electrophoresis using commercially available agar plates
(laboratory normal range: 6.0-8.0 %).
Appropriate treatment was initiated to optimize blood
glucose control, using dietary therapy supplemented by
either sulphonylurea drugs or metformin where indicated.
Patients were reviewed at 1-3 months, 6 months, and
12 months after diagnosis, and more frequently if
indicated on clinical grounds. On each occasion an early
morning sample of urine was collected for measurement
of the ACR and venous blood was taken for estimation
of glycosylated haemoglobin. During the study period,
diabetic treatment was altered where necessary on the
basis of the clinical response to management and the
glycosylated haemoglobin results. Patients with at least
two abnormal ACR measurements (excluding the initial
specimen) in the year following diagnosis were defined
as having 'persistent' microalbuminuria, and in practice
all patients defined in this way had at least three abnormal
results (Table 1). Those with only one abnormal result
were defined as having 'intermittent' microalbuminuria
and the remainder of the patients were considered to
have 'normal' urinary albumin excretion for the purposes
of this study.
Of the initial cohort of 149 patients, 15 were lost to
follow-up within a year of commencing treatment, at
least 2 having died during this period. A further 5 patients
required conversion to insulin therapy within 3 months
of their initial presentation and they were therefore
excluded from further analysis as a diagnosis of Type 2
diabetes was in doubt. The remaining 129 patients were
seen on at least a further three occasions during the year
following diagnosis and urine collections were obtained
Table 1. Number of samples (total and abnormal) and median ACR level during the first year after diagnosis of
Type 2 diabetes in patients defined as having persistent microalbuminuria and intermittent microalbuminuria
Persistent microalbuminuria group ntermittent m icroalbuminuria group
(n=21) (n=20)
Patient Samples Samples Median ACR Patient Samples Samples Median ACR
(total) (abnormal) (total) (abnormal)
1 3 3 38.2 1 3 1 1.5
2 4 3 7.0 2 4 1 <1.0
3 4 4 6.3 3 3 1 <1.0
4 3 3 3.8 4 3 1 <1.0
5 4 4 4.1 5 3 1 <1.0
6 4 4 11.7 6 4 1 <1.0
7 3 3 4.6 7 4 1 2.1
8 3 3 10.8 8 3 1 1.8
9 3 3 5.9 9 3 1 <1.0
10 5 5 3.6 10 4 1 1.7
11 3 3 4.3 11 3 1 <1.0
12 3 3 4.9 12 3 1 <1.0
13 3 3 3.7 13 4 1 1.1
14 4 3 7.8 14 4 1 1.8
15 3 3 13.0 15 3 1 <1.0
16 5 4 4.9 16 3 1 <1.0
17 5 4 5.5 17 3 1 <1.0
18 3 3 3.5 18 3 1 1.8
19 3 3 16.8 19 4 1 1.2
20 3 3 11.2 20 3 1 1.5
21 4 4 27.4
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each time. On the basis of the subsequent ACR measure¬
ments, 88 patients (68 %) were defined as having
normal urinary albumin excretion, 20 (16 %) as having
intermittent microalbuminuria, and 21 (16 %) had persist¬
ent microalbuminuria. Median ACR levels and total
number of specimens examined are given for the latter
two groups in Table 1. All patients in the group defined
as having normal albumin excretion had a median ACR
level of < 1.0 mg mmoh1. Within the group with
persistent microalbuminuria, 18 patients (86 %) had also
been shown to have an elevated ACR at the time of
initial presentation, with only three having had a normal
ACR at their first clinic visit. Of the remaining 21 patients
with an initially elevated ACR, 8 were lost to follow-up
(1 of whom was known to have died during the first year
of treatment), 3 had intermittent microalbuminuria, and
10 had consistently normal albumin excretion thereafter.
Statistical Methods
Univariate comparisons between groups (with and with¬
out abnormal albumin excretion) were made using
Student's t-tests for the continuous data and chi-squared
tests (with Yates' correction) for the categorized data.
Where the numbers in the table were small Fisher's exact
test was used. In order to investigate the confounding
effect of other variables (in particular age) on the above
comparisons, logistic regression models were fitted.
Analysis of trends with the median ACR during the
year following initial presentation was performed in two
ways; by calculating the Spearman rank correlation of
the median ACR with the continuous variables and also
by dividing the ACR into four groups (< 1.0, 1.0-2.5,
2.5—5.0, and > 5.0 mg mmol-1) and examining any
trends across these groups. It is not appropriate to perform
multiple linear regression on these data as 99 of the 129
patients followed up over 1 year had no detectable trend
and therefore the distributional assumptions for multiple
regression would not be satisfied.
Results
At Initial Presentation
Of the 149 patients, 39 (26 %) had an ACR of
> 2.5 mg mmol-1 in the early morning specimen of
urine provided at the time of their first clinic visit. The
clinical characteristics of this group of patients, and those
with a normal urinary albumin excretion at initial
assessment, are shown in Table 2. Patients with microal¬
buminuria at presentation were older (p = 0.002) and
had a higher initial random plasma glucose (p = 0.014)
and glycosylated haemoglobin (p = 0.002). A significant
association was also observed with systolic blood pressure
(p = 0.021) but not with diastolic blood pressure, gender
or BMI. The associations between the initial ACR and
the presence of treated hypertension, retinopathy, and
clinical evidence of macrovascular disease are shown in
Table 3. A strong association was noted with macrovascu¬
lar disease; 18 (47 %) of the microalbuminuria group
had clinical evidence of macrovascular disease compared
with 24 (23 %) of the remaining patients (p = 0.009).
The most striking association was with peripheral vascular
disease (p = 0.001).
Logistic regression was performed to correct for the
effect of age and the adjusted p values are also shown
in Tables 2 and 3. The strong association between an
elevated ACR and peripheral vascular disease was
retained (p = 0.014) but the associations with random
plasma glucose and systolic blood pressure were lost
and those with retinopathy (p = 0.066) and glycosylated
haemoglobin (p = 0.095) fell just short of statistical
significance. Further regression models were fitted to
correct for the combined effect of age, sex, blood
pressure, and glycosylated haemoglobin; peripheral vas¬
cular disease (p = 0.056) and retinopathy (p = 0.090)
approached significance as having an association with
an elevated initial ACR as an independent variable.
Table 2. Clinical characteristics of patients with normal and abnormal urinary albumin excretion at initial
presentation with Type 2 diabetes, showing p values unadjusted and adjusted to correct for the effect of age
Normal Abnormal p p
albumin albumin (unadjusted) (adjusted
excretion excretion for age)
n
Sex (M : F)
Age (yr)
BMI (kg m-2)





64 : 46 23 : 16 1.000 0.985
58 (11) 64 (11) 0.002 —
29.0 (4.9) 28.1 (6.0) 0.368 0.812
12.3 (4.4) 14.4 (4.5) 0.014 0.155
11.3 (2.7) 13.0 (3.1) 0.002 0.095
140 (22) 149 (22) 0.021 0.248
83 (11) 84 (14) 0.721 0.613
Mean (SD) unless otherwise stated.
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Table 3. Presence of other complications in patients with normal and abnormal urinary albumin excretion
at initial presentation with Type 2 diabetes, showing p values unadjusted and adjusted to correct for the
effect of age
Normal Abnormal p p
albumin albumin (unadjusted) (adjusted
excretion excretion for age)
Retinopathy 6 (6) 5 (13) 0.276 0.066
Treated hypertension 15 (14) 9 (24) 0.293 0.243
Peripheral vascular disease 9 (9) 13 (34) 0.001 0.014
Cerebrovascular disease 4 (4) 3 (8) 0.583 0.905
Ischaemic heart disease 16 (15) 6 (16) 1.000 0.519
Total macrovascular disease 24 (23) 18 (47) 0.009 0.207
Number (%).
After Follow-up for I year
The clinical characteristics and associations of the
two groups who were identified as having persistent
microalbuminuria and normal albumin excretion during
the year following diagnosis are shown in Tables 4 and
5. An age difference was again observed, the group with
microalbuminuria being significantly older (p = 0.014).
The only other clinical characteristic which achieved
statistical significance was the BMI, the group with
microalbuminuria having a lower BMI than the group
with normal urinary albumin excretion (p = 0.033), but
this association was lost when results were corrected for
the effects of age. No difference was observed in the
mean glycosylated haemoglobin concentrations between
the two groups, either at initial presentation, or 6 months
later. By contrast, in the 10 patients who initially had
an elevated ACR, but reverted to a normal urinary
albumin excretion on subsequent measurement, a trend
was noted towards a higher random plasma glucose
at presentation (14.9 (4.6) mmol l~') and the initial
glycosylated haemoglobin was significantly higher at
14.4 (2.5) % (mean SD) than for either of these two
groups (p < 0.02 vs group with normal urinary albumin
excretion, and p < 0.05 vs group with persistent
microalbuminuria). A greater number of patients with
persistent microalbuminuria had evidence of macrovascu-
lar disease compared with the group with normal albumin
excretion (45 % vs 25 %). The pattern was similar for
peripheral vascular disease (25 %vs12 %) and ischaemic
heart disease (30 % vs 13 %), but because of the smaller
number of patients, none of these results achieved
statistical significance.
The effect of any trends in the actual value of the
median ACR was examined by calculating Spearman
rank correlations for the continuous variables. Results
are shown in Table 6, with no statistically significant
associations being demonstrated. Further analysis by
Table 4. Clinical characteristics of patients with normal urinary albumin excretion and persistent microalbuminuria
during first year after diagnosis of Type 2 diabetes, showing p values unadjusted and adjusted to correct for the
effect of age
n
Sex (M : F)
Age (yr)
BMI (kg rrm2)





6 months treatment (%)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Normal Persistent p p
albumin microalbuminuria (unadjusted) (adjusted
excretion for age)
88 21
48 : 40 14 : 7 0.445 0.190
58 (10) 64 (7) 0.014 —
29.1 (4.8) 26.5 (5.1) 0.033 0.081
12.6 (4.5) 14.3 (5.2) 0.151 0.204
11.7 (2.8) 12.0 (3.0) 0.623 0.362
8.4 (1.5) 8.5 (1.4) 0.710 0.944
142 (23) 145 (22) 0.621 0.650
84 (12) 82 (12) 0.675 0.964
Mean (SD) unless otherwise stated.
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Table 5. Presence of other complications in patients with normal urinary albumin excretion and persistent
microalbuminuria during first year after diagnosis of Type 2 diabetes, showing p values unadjusted and adjusted to
correct for the effect of age
Normal Persistent p p
albumin microalbuminuria (unadjusted) (adjusted
excretion for age)
Retinopathy 7 (8) 2 (10) 1.000 0.505
Treated hypertension 14 (16) 4 (20) 0.962 0.964
Peripheral vascular disease 10 (12) 5 (25) 0.243 0.537
Cerebrovascular disease 2 (2) 1 (5) 0.473 0.310
Ischaemic heart disease 11 (13) 6 (30) 0.127 0.087
Total macrovascular disease 21 (25) 9 (45) 0.125 0.230
Number (%).
Table 6. Spearman rank correlations for the median ACR
during the first year after diagnosis of Type 2 diabetes and
age, body mass index, blood pressure, random plasma










6 months treatment 0.02
No correlation reached statistical significance.
dividing the median ACR value into four groups also
failed to reveal any clear trends, although the patient
numbers in three of the groups were again small.
Discussion
Despite the accumulating information about abnormal
urinary excretion of albumin in diabetic patients, the
natural history of microalbuminuria in patients with Type
2 diabetes has not been examined prospectively from
diagnosis. In the present study, the prevalence of
increased urinary albumin excretion in newly diagnosed,
untreated Type 2 diabetic patients was of similar magni¬
tude to that reported previously by Uusitupa et a/.12
However, in contrast to this previous report,12 the
abnormal urinary albumin excretion at initial presentation
was found to be associated with age, blood glucose
control, systolic blood pressure, and evidence of macro-
vascular disease. The patients in the present cohort
whose urinary albumin excretion was initially elevated
had a mean age of 64 years and this was equivalent to
the upper limit of Uusitupa et a/.'s study population,
which was restricted to patients within the age range
45-64 years.12 The association with age may therefore
be attributable to the older age group of the patients
in the present study. Other studies of patients with
longstanding Type 2 diabetes have demonstrated that
microalbuminuria is more common in older patients.9-13
Similarly the association with systolic blood pressure in
the newly diagnosed patients reported in the present
study has been described previously in association with
Type 2 diabetes of longer duration,5-6-9-17 although our
findings would suggest that the effect of age may be an
important factor in this association.
The relationship between increased urinary albumin
excretion and macrovascular disease is now well recog¬
nized, not only in Type 2 diabetic patients,8-9 but also
in non-diabetic individuals.18 Cardiovascular disease is
the major cause of excess morbidity and mortality in
Type 2 diabetes19 and the presence of microalbuminuria
appears to be an independent predictor of this.8 In the
present study, 47 % of the patients who had an increased
urinary albumin excretion at initial presentation had
some clinical evidence of macrovascular disease, com¬
pared with only 23 % of those who had a normal urinary
albumin excretion. The most striking association was
with peripheral vascular disease, which is consistent with
a similar observation in Type 2 diabetic patients by
Marshall and Alberti,6 and this association was preserved
even when an adjustment was made to correct for the
influence of age.
Blood glucose control has been shown to correlate
with the urinary albumin excretion rate in patients with
Type 1 diabetes20 and it has been suggested that the finding
of an abnormal urinary albumin excretion at the time of
presentation with Type 2 diabetes is predominantly a
functional phenomenon, related to renal hyperfiltration
occurring secondary to uncontrolled hyperglycaemia.12,14
Schmitz et a/, showed a fall in urinary albumin excretion
and glomerular filtration rate in a small group of newly
diagnosed Type 2 patients after a short period of improved
blood glucose control,14 and in larger groups of Type 1
diabetic patients near-normoglycaemia has also been
demonstrated to reduce urinary albumin excretion.21 The
present study confirms an association between urinary
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Relationship Between Urinary Excretion
of Sodium and Dopamine in Type 1
Diabetic Patients with and without
Microalbuminuria
A.W. Patrick3, R.F. Jeffrey6, A. Collier3, B.F. Clarke3, M.R. Leeb
aDiabetic and Dietetic Department and bUniversity Department of
Clinical Pharmacology, Royal Infirmary, Edinburgh, Scotland, UK
The relationship between urinary sodium and dopamine excretion was investigated in 40
normal males and in 48 normotensive, Type 1 diabetic males, 11 with microalbuminuria
and 37 with normal albumin excretion. In all three groups a significant correlation was
demonstrated and the regression lines were similar. Thus, no evidence was found that a
defect in dopamine mobilization contributes to the early renal pathophysiological changes
of Type 1 diabetes.
key words Type 1 diabetes Microalbuminuria Urinary sodium Urinary dopamine
Introduction
Endogenous renal dopamine is believed to participate in
sodium homeostasis and function under physiological
conditions as a natriuretic hormone.1 The urinary
excretion of dopamine correlates directly with sodium
output under normal conditions and responds appro¬
priately to salt loading and depletion manoeuvres.2,3
Salt and water overload, and hypertension, are charac¬
teristic features of advanced diabetic nephropathy. With
increasing chronic renal failure, urinary dopamine
excretion progressively declines concurrent with glomer¬
ular filtration rate, and the response to salt loading is
attenuated. It has been suggested that a relative deficiency
of dopamine is a factor in the abnormal handling of
sodium by the kidney.4
However, abnormal sodium retention has been recog¬
nized at a much earlier stage in the natural history
of Type 1 diabetes, before the appearance of overt
nephropathy.5,6 It was therefore of interest to determine
whether a defect in the mobilization of dopamine, relative
to salt status, might provide an explanation for early
pathophysiological changes in the condition. Therefore
the relationship between sodium and dopamine excretion
was examined in a group of normal males and in
normotensive, Type 1 diabetic males both with and
without evidence of early diabetic nephropathy (micro¬
albuminuria).
Patients and Methods
A cohort of 48 normotensive, Type 1 diabetic males (age
33, range 25—38, years) was drawn from the Diabetic
Correspondence to: A.W. Patrick, Diabetic Department, Royal
Infirmary, Edinburgh, EH3 9YW, UK
0742—3071/90/010053—04$05.00
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Department of the Royal Infirmary of Edinburgh. All had
a creatinine clearance of >80mlmin_1 but 11 had
evidence of microalbuminuria with an albumin/creatinine
ratio, in an early morning urine specimen, of
>3.0 g mol-1 on at least two occasions in the previous
year. A control group consisted of 40 healthy normotens¬
ive males with normal renal function. The characteristics
of the diabetic and control groups are given in Table
1. In each of the 11 patients defined as having
microalbuminuria, a daily albumin excretion of >30 mg
was confirmed on a 24-h urine collection. Although, in
comparison with the diabetic patients who had normal
albumin excretion, those patients with microalbuminuria
tended to have a longer duration of diabetes, poorer
blood glucose control, and lower creatinine clearance,
none of these differences reached statistical significance.
All subjects were given careful instruction on the
collection of a 24-h urine sample, at home, into a bottle
containing 25 ml of 5 mol I-1 HCI to prevent oxidation
of dopamine. No dietary restrictions were enforced but
subjects were asked to refrain from alcohol during the
collection. Blood pressure was measured, seated, by an
experienced observer using a mercury sphygmoman¬
ometer, and hypertension was defined by WHO classifi¬
cation as a reading above 160/95 mmHg.
Glycosylated haemoglobin was measured using com¬
mercial agar plates, the normal range being 6.0-8.0 %.
Retinopathy was assessed by ophthalmoscopy, after
mydriasis, by two independent observers. Urinary
albumin excretion was measured by an immunoturbidi-
metric method.7 Urinary free dopamine was extracted
onto alumina and assayed by high performance liquid
chromatography with electrochemical detection.8 Sodium
was measured by flame photometry and plasma and
urinary creatinine by the Jaffe method.
The sodium and dopamine data were log-transformed
Accepted 11 September 1989 53
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Table 1. Characteristics of 48 Type 1 diabetic males with and without evidence of early
nephropathy (microalbuminuria) and 40 non-diabetic control subjects with normal renal
function
Diabetic (normal Diabetic Control
albumin (microalbuminuria)
excretion)
n 37 11 40
Age (years) 33 (25-38) 31 (19-44) 26 (20-39)
Blood pressure (mmHg) 128 (11)/77 (7) 124 (16)/78 (8) 126 (10)/74 (8)
Creatinine clearance 122 (25) 102 (19) 110 (12)
(ml min-1)
Duration of diabetes 12 (2-24) 15 (6-28)
(years)





Albumin excretion 10 (3-22) 141 (44-248)
(mg 24-h—1)
Mean (range or SD), or number.
before analysis. Correlation coefficients were calculated
by least squares, and regression lines compared by F-
ratios. Results are expressed as mean (SD) unless
otherwise specified.
Results
It is evident from Table 2 that the study was performed
under salt replete conditions and urinary sodium excretion
was comparable in the three groups. Similarly, there was
no significant difference in urinary dopamine output
between diabetic patients and control subjects. There
was, in both the control group and the two diabetic
groups, a significant correlation between sodium and
dopamine excretion (Table 2). The individual points and
regression lines are shown in Figure 1 for the three
groups. There was no significant difference between the
slopes of the regression lines (Table 2).
Discussion
The positive correlation between urinary dopamine and
sodium excretion in normal subjects has stimulated
research into defining a physiological role for endogenous
renal dopamine. It contributes, with other hormonal and
neuronal influences, to a complex feedback mechanism
which preserves sodium homeostasis. Thus the renal
synthesis of dopamine is linked to prevailing salt status,
and in turn acts to promote sodium excretion.1 An
inability to mobilize dopamine, appropriate to salt status,
has been described in established essential hypertension,9
a central feature of which may be a defect in the ability
of the kidney to excrete sodium at normal perfusion
pressures.10 In addition, in a group of normotensive first-
degree relatives of hypertensive patients, and in a
normotensive population of Negroes, both groups at high
risk of essential hypertension, the direct correlation
between urinary sodium and dopamine was lost, suggest-
Table 2. Twenty-four hour urinary sodium and dopamine excretion in diabetic and control groups
Diabetic (normal Diabetic Control p
albumin (microalbuminuria)
excretion)
n 37 11 40
Urinary sodium 160 (58) 165 (55) 173 (54) NS
(mmol 24-h-1)
Urinary dopamine 1632(437) 1450(294) 1572(453) NS
(nmol 24-h~1)
Correlation coefficients r = 0.44a r = 0.80a r = 0.51b NS
Regression slope 0.38 0.55 0.46 NS
Regression intercept 2.40 1.95 2.17 NS
Mean (SD).
ap < 0.01; bp < 0.001.
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Figure 1. Correlation between urinary dopamine and sodium
excretion with individual points and regression lines for the normal
group (a), the diabetic group with normal albumin excretion (b),
and the diabetic group with microalbuminuria (c)
no difference in blood pressure was observed between
the small groups of the present study. In addition,
exchangeable sodium is elevated in patients with Type 1
diabetes even before the development of overt nephropa¬
thy or hypertension,5'19 with a correlation between
exchangeable sodium and blood pressure, suggesting
that sodium retention may play a major role in the
pathogenesis of the rise in blood pressure observed in
the early stages of diabetic renal disease.19 Reduced
sodium excretion has been demonstrated in patients with
Type 1 diabetes in response to volume expansion, and
tubular sodium retention could be an early functional
change in the diabetic kidney, possibly implicated in the
development of nephropathy and hypertension.20
From our results, however, there is no evidence that
a defect in the mobilization of dopamine exists prior to
the development of hypertension or overt nephropathy.
Dopamine output over 24 h was comparable in all the
groups. The correlation between sodium and dopamine
in urine was maintained in the diabetic patients, even
in the presence of microalbuminuria, and the regression
lines were similar in the three groups, suggesting that
the sensitivity of dopamine response to salt intake and
excretion was unaltered. Indirect evidence in support of
these findings comes from the study of ter Wee and
colleagues who demonstrated identical renal responsive¬
ness to infused dopamine in insulin-dependent diabetic
patients without clinical nephropathy or hypertension,
and in normal control subjects.21
Other possible pathogenic mechanisms include defects
in other vasoactive hormonal systems, such as the
prostaglandin and kallikrein-kinin systems, and increased
responsiveness to the renin-angiotensin system and
catecholamines.5
Further sensitivity could be added to analysis of the
relationship between sodium and dopamine excretion by
dynamic studies assessing the dopamine response to
sodium loading. On the present evidence, however, a
defect in the mobilization of dopamine does not appear
to predate the onset of clinical nephropathy, as indicated
by the presence of frank proteinuria, and abnormalities
demonstrated in patients with established renal disease
are likely to represent a secondary phenomenon related
to the underlying disease process.
ing that an abnormality of dopamine control antedates
the development of essential hypertension.11-12
Recent research into the erythrocyte sodium-lithium
counter-transport system has suggested that there may be
a genetic linkage between the predisposition to essential
hypertension13 and diabetic nephropathy.14 A number
of observations suggest that patients with Type 1 diabetes
do not handle sodium normally. It has been well
demonstrated that there is a greater prevalence of clinical
hypertension in diabetic patients,15 and that blood
pressure is significantly elevated in patients with early
diabetic nephropathy (microalbuminuria) compared with
those having normal albumin excretion,16-18 although
Acknowledgements
We thank R.R. Samson and N. Johnstone for technical




Lee MR. Dopamine and the kidney. In: Lote CH, ed.
Advances in Renal Physiology, London: Croom Helm,
1986: 218-246.
Alexander RW, Gill JR, Yamabe H, Lovemberg N, Reiser
H. Effects of dietary sodium and of acute saline infusion
URINARY SODIUM AND DOPAMINE IN DIABETES 55
ORIGINAL ARTICLES
on the interrelationship between dopamine excretion and 13
adrenergic activity in man. ) Clin Invest 1974; 54:
194-200.
3. Carey RM, Van Loon GR, Baines AD, Ortt EM. Decreased
plasma and urinary dopamine during dietary sodium 14
depletion in man. / Clin Endocrinol Metab 1981; 52:
903-909.
4. Casson IF. Studies on the role of dopamine in renal failure
(PhD Thesis). Leeds: University of Leeds, 1984. 15
5. Drury PL. Hypertension in diabetes mellitus. In: Edwards
CRW, Cary RM, eds. Essential Hypertension as an
Endocrine Disease, London: Butterworths, 1985: 16
301-332.
6. de Chatel R, Weidmann P, Flammer J, et al. Sodium,
renin, aldosterone, catecholamines and blood pressure in 17
diabetes mellitus. Kidney Int 1977; 12: 412-421.
7. Teppo AM. Immunoturbidimetry of albumin and immuno¬
globulin G in urine. Clin Chem 1982; 28: 1359-1361. 18
8. Jeffrey RF, MacDonald TM, Rutter M, et al. The effect of
intravenous frusemide on urine dopamine in normal
volunteers with indomethacin and carbidopa. Clin Sci
1987; 73: 151-157. 19.
9. Harvey JN, Casson IF, Clayden AD, Cope GF, Perkins
CM, Lee MR. A paradoxical fall in urine dopamine output
when patients with essential hypertension are given added
dietary salt. Clin Sci 1984; 67: 83-88.
10. deWardener HE, MacGregor GA. The natriuretic hormone 20.
and essential hypertension. Lancet 1982; i: 1450-1454.
11. Saito I, Takeshita E, Saruta T, Nagano S, Sehihara T.
Urinary dopamine excretion in normotensive subjects with
or without family history of hypertension. / Hypertension 21.
1986; 4: 57-60.
12. Critchley JAJH, Cooper ES, Boye GL, Johnston NR,
Samson RR, Lee MR. Failure of negroes to increase urine
dopamine following an oral sodium load. Br I Clin
Pharmacol 1987; 23: 113P-114P.
Canesse M, Adragne N, Solomon HS, Connolly TM,
Tosteson DC. Increased sodium-lithium countertransport
in red cells of patients with essential hypertension. N
Engl I Med 1980; 302: 712-716.
Mengili R, Bending JJ, Scott G, Li LK, Gupta A, Viberti
GC. Increased sodium-lithium countertransport activity in
red cells of patients with insulin-dependent diabetes and
nephropathy. N Engl / Med 1988; 318: 146-150.
Fuller JH. Epidemiology of hypertension associated with
diabetes mellitus. Hypertension 1985; 7 (suppl 2): II-3-II-
7.
Mathieson ER, Oxenboll B, Johansen K, Svendsen OA,
Deckert T. Incipient nephropathy in type 1 (insulin-
dependent) diabetes. Diabetologia 1984; 26: 406-410.
Christiansen CK, Mogensen CE. The cause of incipient
diabetic nephropathy: studies on albumin excretion and
blood pressure. Diabetic Med 1985; 2: 97-102.
Wiseman MJ, Viberti GC, Mackintosh D, Jarrett RJ, Keen
H. Glycaemia, arterial pressure and microalbuminuria in
type 1 (insulin-dependent) diabetes mellitus. Diabetologia
1984; 26: 401-405.
Feldt-Rasmussen B, Mathieson ER, Deckert T, et al.
Central role for sodium in the pathogenesis of blood
pressure changes independent of angiotensin, aldosterone
and catecholamines in type 1 (insulin-dependent) diabetes
mellitus. Diabetologia 1987; 30: 610-617.
O'Hare JP, Roland JM, Walters G, Corrall RJM. Impaired
sodium excretion in response to volume expansion
induced by water immersion in insulin-dependent diabetes
mellitus. Clin Sci 1986; 71: 403^)09.
ter Wee PM, Van Ballegooie E, Rosman JB, Meijer S,
Donker AJM. The effect of low-dose dopamine on
renal haemodynamics in patients with type 1 (insulin-
dependent) diabetes does not differ from normal individ¬
uals. Diabetologia 1986; 27: 78-81.
56 A.W. PATRICK ET AL.
DlTl ORIGINAL ARTICLES
albumin excretion and the degree of preceding hypergly-
caemia, but in the patients who initially had an increased
ACR, examination of the level of urinary albumin excretion
during the first year of treatment of diabetes revealed
different categories of response. After management of
diabetes was begun, one subgroup of 10 patients reverted
to normal urinary albumin excretion, confirmed at each
subsequent measurement. It could be postulated that a
functional mechanism secondary to hyperglycaemia was
the principal cause of the initially elevated urinary albumin
excretion in these individuals. This premise would be
supported by the observation that the glycosylated haemo¬
globin concentration at presentation was significantly higher
in this group than in the patients who had normal urinary
albumin excretion throughout the period of observation or
in those patients who had persistent microalbuminuria.
After 6 months of treatment, improved blood glucose
control was achieved in all groups of patients with a mean
glycosylated haemoglobin value of 8.5 %.
In the year following diagnosis of diabetes, a total of 21
patients were found to have persistent microalbuminuria,
representing 16 % of the total group followed over this
period of time. This compares with 8.2 % of Type 2
diabetic patients with persistently abnormal urinary
protein excretion from diagnosis reported by Ballard ef
a/.13. Although most (86 %) of these patients could be
predicted by determining an abnormal ACR at diagnosis,
the degree of hyperglycaemia did not appear to be
the major determining factor in this group. Thus the
glycosylated haemoglobin measurements at initial presen¬
tation and after 6 months of treatment were not signifi¬
cantly different from those of the group of patients who
had normal urinary albumin excretion. However, a
definite association with age was observed and a
trend was discerned towards a greater prevalence of
macrovascular disease, particularly ischaemic heart
disease and peripheral vascular disease. The apparent
association between macrovascular disease and urinary
albumin excretion in newly diagnosed Type 2 diabetic
patients is of interest in view of the recent suggestion
that albuminuria is an indicator of widespread vascular
damage, possibly reflecting a genetically determined
abnormality of the heparan sulphate proteoglycan in
the extracellular matrix and basement membrane.22
The present study indicates that persistent microalbu¬
minuria is found in a significant number of Type 2
diabetic patients at the time of diagnosis. While factors
such as blood pressure may be relevant in some
patients,23 in others this finding presumably indicates
a specific diabetes-related complication, possibly
related to the duration of exposure to the diabetic
diathesis. Further study of this group may help to
elucidate the pathophysiology of the vascular compli¬
cations of diabetes.
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The Effects of Acute Insulin-induced
Hypoglycaemia on Renal Function in
Normal Human Subjects
A.W. Patrick3, D.A. Hepburn3, K.J. Craigb, I. Thomson0, C.P. Swainsonb, B.M. Frier3
aDiabetic Department and ''Medical Renal Unit, Royal Infirmary,
Edinburgh, and cMRC Blood Pressure Unit, Western Infirmary,
Glasgow, Scotland
The effects of acute insulin-induced hypoglycaemia on renal function were studied in 8
normal male subjects. Plasma glucose (mean (SE)) fell from 4.6(0.2) to 1.3(0.2) mmol I-1,
the nadir being coincident with the acute autonomic reaction, and returned to the basal
value over the following 120 min. Glomerular filtration rate declined from 118(6) to 95(4)
ml min-1 at the glucose nadir (p<0.01), and during the recovery phase returned to
118(7) ml min"1 (NS compared with basal). Renal plasma flow fell from 625(38) to 485(27)
ml min"1 (p < 0.01), rising to 545(46) ml min"1 during recovery from hypoglycaemia (NS
compared with basal). Following hypoglycaemia, urinary excretion of sodium and dopamine
were reduced significantly, but the albumin excretion rate was unchanged. Plasma
concentrations of adrenaline, noradrenaline, angiotensin II, and plasma renin activity
increased in response to hypoglycaemia. These acute changes in renal function are probably
caused by sympatho-adrenal activation and secretion of catecholamines, but other
hormones, such as angiotensin II, may be contributory.
key words Insulin Hypoglycaemia Glomerular filtration rate Renal plasma flow
Catecholamines Plasma renin activity Angiotensin II
Introduction
Acute insulin-induced hypoglycaemia in human beings
is a potent stimulus to autonomic neural activation and
hormonal secretion. Stimulation of the sympatho-adrenal
system provokes the secretion of catecholamines, which
contribute to the profound haemodynamic and haemo¬
static changes associated with hypoglycaemia.1'2 Myocar¬
dial contractility and cardiac output increase following
hypoglycaemia,3'4 and regional changes in blood flow
have been studied in different vascular beds including
those of the skin,5 skeletal muscle,3'6 the brain,7 and
the hepato-splanchnic system.3-8 Although the overall
vascular resistance declines rapidly it is evident that
considerable regional differences in blood flow occur
and the effect of hypoglycaemia on the perfusion of
many organs and vascular systems is unknown. The aim
of the present study was to examine the effect of acute
insulin-induced hypoglycaemia on the human kidney by
measuring changes in renal plasma flow, glomerular
filtration rate, and other indices of renal function in
normal subjects, and to relate these changes to the
sympatho-adrenal activation and hormonal secretion
which occurs in response to the hypoglycaemic stimulus.
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Subjects and Methods
Subjects
The study was approved by the local Medical Ethical
Advisory Committee and informed consent was obtained
from all subjects. Eight healthy non-diabetic male volun¬
teers were studied (age 30 (range 23—39) years), all of
whom had a normal body mass index. None of the
subjects was taking any medication, or had any intercur¬
rent illness. No dietary restriction or modification was
imposed prior to the study, but the ingestion of tea or
coffee was prohibited overnight and smoking was not
permitted during the study.
Protocol
Subjects were studied in a supine position after an
overnight fast. Intravenous cannulae (Venflon, Viggo,
Helsingborg, Sweden) were inserted into both antecubital
fossae, one for venous blood sampling and the other for
administration of drugs. Each subject was given ordinary
tap water (10 ml kg"1) to drink before commencing the
study and thereafter the urinary fluid loss was measured
and replaced by an equivalent volume of tap water
(approximately 200 ml every 30 min) given orally. Fluid
loss through sweating was not replaced. Mannitol 20 %
(200 g I"1) at a rate of 50 ml h"1 was given by IV
infusion throughout the study period to maintain a
urine flow rate of approximately 7-8 ml min"1. Acute
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hypoglycaemia was induced by an IV bolus injection of
soluble insulin (Human Actrapid, Novo, Basingstoke,
UK) in a dose of 0.125 U kg-body-weight-1. Heart
rate, blood pressure, and capillary blood glucose were
monitored at frequent intervals. The onset of the acute
autonomic reaction (time = R) was indicated by a sudden
increase in heart rate and accompanying changes in
blood pressure, and sampling of blood and urine was
timed from the start of the reaction to eliminate individual
variability in the time taken to develop hypoglycaemia
after the administration of insulin.
Laboratory Methods
Plasma glucose was measured by a glucose oxidase
method using a Yellow Springs Analyser. Plasma renin
activity was calculated by radioimmunoassay of angio¬
tensin I generated under standard conditions (Campagne
Oris, Gif-sur-Yvette, France). Catecholamines9 and angio¬
tensin II10 were measured using radioenzymatic assays.
The timing of drug administration and blood sampling is
illustrated in Figure 1.
Measurements of Renal Function
Glomerular filtration rate (GFR) was estimated from inulin
clearance. A constant infusion of polyfructosam (Inutest,
Laevosam, Linz, Austria) in normal saline (10 g I-1 at a
rate of 120 ml h-1) was commenced after an initial IV
bolus dose of 3.5 g, and a 60-min equilibration period
was allowed. Inulin concentrations were measured by
an auto-analyser after conversion to fructose.11
Effective renal plasma flow was estimated from the
clearance of amino hippurate sodium (Merck, Sharp and
Dohme, Hoddesdon, UK) using a 'single shot' technique.
An IV bolus injection of amino hippurate sodium (PAH)
in a dose of 10 mg kg-body-weight-1 was given at the
start of each clearance period (Figure 1). Blood samples
were taken at 5, 7, 10, 15, 20, 30, and 40 min after the
injection and at the end of each clearance period. Plasma
and urinary PAH were measured by the method of
Bratton and Marshall, modified for use with an auto-
analyser.12 Plasma concentrations of PAH were <0.3 g
I"1 before commencing each clearance period, and the
area under the curve following each IV bolus injection
was calculated assuming two-compartment kinetics.
Timed collections of urine were obtained at intervals
of 30-60 min throughout the study and GFR and renal
plasma flow were calculated: during the basal period;
over the time of the acute autonomic reaction; and
during the recovery phase (from R + 60 min to the
conclusion of the study). The urinary excretion of
dopamine, albumin, sodium, and kallikrein was measured
from each specimen of urine collected. Urinary free
dopamine was extracted onto alumina and assayed by
HPLC with electrochemical detection.13 Sodium was
measured by plasma photometry and albumin by an
immunoturbidimetric assay.14 Kallikrein excretion was
measured by the method of Amundsen eta/.15 and results
were expressed as units of kallikrein activity per minute
(nkat min-1).
Control Studies
To ensure that any changes observed were related to
hypoglycaemia alone, and not caused by any other
component of the study protocol, separate control studies
were performed in two of the subjects under identical
conditions but without administration of insulin. Because
of the obvious absence of hypoglycaemic symptoms, the
nature of these control studies was not concealed from
the subjects.
Statistical Analysis
Results, unless stated otherwise, are presented as mean
(SE). The data for all subjects were analysed by one-way
analysis of variance. The Wilcoxon Rank Sum test was
applied to compare basal values with those at the time
of the autonomic reaction and during the recovery phase,
and a value p < 0.05 was regarded as significant.













Figure 1. Protocol used to test the effect of acute hypoglycaemia on renal function.
The timing of blood (O) and urine (*) sampling is indicated. Time = R indicates
the onset of the autonomic reaction
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Results
All subjects experienced a typical autonomic reaction to
hypoglycaemia with acute onset of sweating, tremor, and
other autonomic symptoms at a mean of 24 (range 22-28)
min after the administration of insulin. In every case the
autonomic reaction was concurrent with the nadir of
plasma glucose. None of the subjects lost consciousness
and administration of glucose was not required.
Metabolic and Hormonal Changes
The mean plasma glucose fell from 4.6(0.2) mmol I-1
to a nadir of 1.3(0.2) mmol I-1 at time = R (p < 0.01).
Thereafter the recovery was biphasic with an initial rapid
rise until R + 15 min, and a slower rise between
R + 15 min and R + 120 min, by which time the plasma
glucose was restored to basal concentrations at 4.4(0.2)
mmol I-1 (Figure 2(a)).
Mean plasma adrenaline rose from a basal value of
0.2(0.04) nmol I-1 to a peak of 6.6(0.8) nmol I"1
at R + 15 min (p < 0.01). At R + 120 min plasma
adrenaline was still significantly elevated at a concen¬
tration of 1.2(0.2) nmol I"1 (p < 0.01 vs basal). A rise
in noradrenaline was also observed, from a basal value
of 2.8(0.3) nmol I-1 to 4.6(0.6) nmol I"1 at time = R
(p < 0.01), returning to the basal concentration by
R + 45 min (Figure 2(b)). Plasma renin activity increased
from a basal value of 0.91 (0.18) ng-Angl I"1 to 1.42(0.18)
ng-Angl I-1 at R + 15 min (p < 0.01) and remained
elevated until R + 60 min, subsequently declining to
basal values at R + 120 min (Figure 2(c)). Angiotensin
II concentrations rose from 4.4(0.5) ng I"1 in the basal
period to a peak of 15.1(4.1) ng l_1 at R + 30 min, and
had returned to the basal value by R + 120 min (Figure
2(d)).
Renal Function
GFR fell from a basal value of 118(6) ml min-1 to 95(4)
ml min"1 during the period of the hypoglycaemic reaction
(p < 0.01), returning to 118(7) ml min-1 in the recovery
phase. Examination of individual results revealed a
consistent response in each subject (Figure 3(a)).
Renal plasma flow fell from a basal value of 625(38)
ml min"1 to 485(27) ml min"1 during the period of the
autonomic reaction to hypoglycaemia (p < 0.01), rising
to 545(46) ml min"1 in the recovery phase (NS compared
with basal). The rapid fall in renal plasma flow occurred
in all 8 individual subjects following hypoglycaemia, but
in 2 subjects a rise in renal plasma flow did not occur
during the recovery phase (Figure 3(b)).
Plasma glucose
Figure 2. Mean response (SE) of (a) plasma glucose, (b) plasma adrenaline (•) and noradrenaline (O), (c)
plasma renin activity, and (d) plasma angiotensin II following injection of intravenous soluble insulin










































Figure 3. Changes in (a) GFR and (b) renal plasma flow following acute
hypoglycaemia in the 8 subjects
The effect of acute hypoglycaemia on the other urinary
measurements is shown in Table 1. Urine volumes did
not fall significantly during the study and similarly there
were no significant changes in the excretion rates of
kallikrein and albumin. Urinary dopamine and both
absolute and fractional sodium excretion were signifi¬
cantly reduced following hypoglycaemia and remained
depressed during the recovery phase.
Control Studies
Blood glucose remained unchanged throughout, with no
significant hormonal responses. Renal function was
unaltered and no significant changes were observed in
any of the other urinary measurements.
Discussion
Acute hypoglycaemia in humans has a pronounced effect
on the vascular perfusion and function of several organs,
which is associated with the activation of the autonomic
nervous system and the stimulated secretion of various
hormones. In the present study the effects of acute
insulin-induced hypoglycaemia on the kidney were
examined in normal human volunteers. During the period
of hypoglycaemia, a transient but substantial reduction
in GFR and renal plasma flow occurred (19 % and 22 %,
respectively, from basal values). As the urine volumes
did not fall significantly during the study, these changes
are likely to represent a true phenomenon, and do not
simply result from problems with bladder emptying or
increased dead space wash-out.
Table 1. Urine volumes and
to acute hypoglycaemia








(ml min-') 7.6 (1.0) 6.7 (0.6) 5.9 (0.6) NS
Absolute sodium
excretion (p.mol min~') 403 (47) 273 (45) 205 (30) < 0.005
Fractional sodium
excretion (%) 2.5 (0.3) 2.0 (0.8) 1.3 (0.6) < 0.01
Dopamine (p.mol min"') 614 (198) 132 (29) 150 (29) < 0.02
Kallikrein
(nkat min-1) 13.9 (1.4) 12.9 (2.4) 8.7 (0.8) NS
Albumin excretion
rate (p,g min~1) 33.1 (13.7) 15.5 (2.8) 18.9 (3.6) NS
Mean (SE).
Significance is tested between the time of hypoglycaemia and basal value.
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The brisk rise in plasma catecholamines in response
to acute hypoglycaemia had a close temporal relationship
to the observed changes in renal function and may have
been responsible for some of these effects, but direct
stimulation of efferent sympathetic nerves per se may
also be of importance.16 Intravenous infusions of either
noradrenaline or adrenaline have been shown to cause
a pronounced reduction in renal blood flow in normal
humans, although no significant changes in GFR were
observed.17 Mqny other hormones are released in
response to hypoglycaemia which may have acute effects
on renal function. Both renin and angiotensin II were
secreted in response to hypoglycaemia and may have
contributed to the observed changes in renal haemo-
dynamics observed in the present study. Angiotensin II
is a potent vasoconstrictor,18 its effects including the
enhancement of sympathetic tone19 and facilitation of
noradrenergic neurotransmission,20 and the intrarenal
infusion of angiotensin II has been shown to cause a
significant reduction in both GFR and renal plasma flow
in diabetic rats with hyperfiItration.21 The increase in
plasma renin activity in response to hypoglycaemia is
probably associated with the stimulatory effect of elevated
concentrations of plasma catecholamines as the rise of
plasma renin activity can be prevented by (3-adrenergic
blockade.22,23 However the release of renin following
hypoglycaemia can occur independently of syfnpatho-
adrenal activation as shown in sympathectomized
humans, in whom catecholamines are not released,24
and can be stimulated by non-adrenergic mechanisms or
haemodynamic changes.
The fall in plasma glucose per se may influence renal
haemodynamics. Mogensen et a/.25 showed a 9 %
reduction in GFR and a 13 % reduction in renal plasma
flow when the blood glucose was reduced from 13.9
mmol I-1 to 6.5 mmol I 1 in 5 patients with Type 1
diabetes mellitus, without a rise in plasma catecholamine
concentrations. In that study it was postulated that the
changes in renal function may have resulted from
increased sympathetic activity in response to a reduction
in plasma volume induced by insulin. Subsequent studies,
however, demonstrated that GFR and renal plasma
flow remained unchanged in diabetic patients during a
hyperinsulinaemic, euglycaemic clamp,26'27 and that
both these variables fell only when blood glucose was
allowed to decline. Conversely, experimental induction
of moderate hyperglycaemia in normal28-29 and in
diabetic human subjects29 has been shown to cause a
significant increase both in GFR and renal plasma flow.
Although alteration of plasma volume has been postulated
as a cause of this phenomenon,30 similar changes could
not be induced by a saline infusion.29
Insulin inhibits the rate of renal excretion of electro¬
lytes,31-32 so the reduction in urinary sodium excretion
observed in the present study was not unexpected.
This effect is partly independent of blood glucose
concentration,31 and in addition insulin is known to
enhance the tubular reabsorption of sodium.33 A close
correlation between the urinary excretion of sodium and
dopamine is recognized in the normal kidney,34 and in
the present study the changes in urinary dopamine
excretion in response to hypoglycaemia paralleled those
of sodium.
The lack of any significant changes in urinary albumin
excretion following hypoglycaemia in normal subjects is
of interest, as it has been suggested that albumin excretion
is increased in Type 1 diabetic patients when the blood
glucose is reduced by insulin infusion, particularly in
those patients who have higher basal albumin excretion
rates,25-27 although Christensen et a/.35 have demon¬
strated a fall in albumin excretion in a group of patients
with diabetes of long duration who had frank proteinuria.
Considerable individual variation was observed in the
present study in the basal urinary excretion of albumin,
with a surprisingly high value being recorded in 2
subjects, but the albumin excretion rate remained low
thereafter during acute hypoglycaemia and in the recovery
period. It is not, however, justified to extrapolate this
observation in normal subjects to diabetic patients, an
investigation of whom is currently in progress.
Many patients with Type 1 diabetes are frequently
exposed to hypoglycaemia and are presumably subjected
to a similar transient modification of renal function.
Diabetic patients who have nephropathy, with varying
degrees of renal impairment, may be more vulnerable to
the rapid changes in renal perfusion which are induced
by hypoglycaemia. Furthermore the rise in haematocrit
and plasma viscosity3,36 and the enhancement of platelet
activation and aggregation37,38 which are precipitated
by hypoglycaemia, may exacerbate pre-existing renal
microangiopathy by potentially enhancing ischaemia.2
Further studies are required to investigate renal function
during acute hypoglycaemia in diabetic patients and the
possible effects of hypoglycaemia on the pathogenesis
and acceleration of diabetic nephropathy.
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Changes in Renal Function During
Acute Insulin-induced Flypoglycaemia
in Patients with Type 1 Diabetes
A.W. Patrick3, D.A. Hepburn3, C.P. Swainsonb, B.M. Frier3
'Department of Diabetes and bMedical Renal Unit, Royal Infirmary,
Edinburgh, Scotland
The effect of acute hypoglycaemia on renal function was examined in eight male patients
with Type 1 diabetes who had normal urinary albumin excretion. Insulin was given as a
bolus intravenous injection (0.125 U kg-1) and plasma glucose fell to a nadir of 1.6 (SE
0.2) mmol I"1, with all patients experiencing an acute autonomic reaction. Renal plasma
flow fell from 674 (106) to 540 (198) ml min"1 during hypoglycaemia (p<0.01) and
returned to 655 (181) ml min-1 (NS vs baseline). Glomerular filtration rate (GFR) declined
from 143 (23) to 110 (36) ml min-1 during hypoglycaemia (p < 0.02), rising to 150 (44)
ml min-1 in the recovery period (NS vs baseline). The urinary flow rate and urinary
albumin excretion rate both fell significantly in response to hypoglycaemia (10.6 (1.2) to
4.7 (1.1) ml min-1; p< 0.002, and 46.2 (10.6) to 26.0 (10.5) p.g min-1, respectively).
Urinary dopamine excretion also declined, from 322 (37) to 211 (29) pmol min-1
(p < 0.005) but sodium excretion was unchanged. Plasma adrenaline concentration (0.2
(0.03) to 1.7 (0.4) nmol I-1; p<0.01) and plasma renin activity (0.49 (0.13) to 1.08
(0.17) ng-Ang I I-1 h-1; p< 0.01) increased during hypoglycaemia, but changes in plasma
noradrenaline and angiotensin II levels did not attain significance. These acute changes in
renal function, observed during hypoglycaemia in diabetic patients, may result from direct
stimulation of the efferent sympathetic nerves to the kidney, complemented by the
hormonal changes induced by hypoglycaemia.
key words Insulin Hypoglycaemia Glomerular filtration rate Renal plasma flow
Catecholamines Angiotensin II Sympathetic nervous system
Introduction
Acute insulin-induced hypoglycaemia in humans stimu¬
lates autonomic neural activation and secretion of various
hormones, including catecholamines, angiotensin II1'2 and
vasopressin.3-4 Profound haemodynamic and haemostatic
changes are associated with hypoglycaemia5-7 and
catecholamines play an important role in determining
these changes. While there is an overall fall in vascular
resistance, considerable differences in regional blood
flow have been observed in several major organs and
vascular systems.2'7-13 In the kidney, a significant
reduction in effective renal plasma flow and glomerular
filtration rate has been demonstrated in response to acute
hypoglycaemia in non-diabetic human subjects.2 The
aim of the present study was to examine the effect of
acute insulin-induced hypoglycaemia on renal function
in Type 1 diabetic patients who had normal urinary
albumin excretion, a group not previously studied.
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Patients and Methods
Patients
Eight male patients with Type 1 (insulin-dependent)
diabetes were recruited from the diabetic clinic at the
Royal Infirmary of Edinburgh. Their age was 29 (range
24—40) yr and all had a normal body mass index.
Duration of diabetes was 8 (2-15) yr and total glycated
haemoglobin at the time of study was 9.0 (SD 2.4) %,
with a laboratory normal range of 5.0-8.0 %. The patients
had no history or clinical evidence of hypertension, and
had no specific diabetic complications. In particular, all
had normal plasma creatinine levels and had a urinary
albumin excretion of < 30 mg in each of two 24-h
collections. Urinary tract infection was excluded in every
patient by culture of a mid-stream specimen of urine.
None of the patients smoked, were taking medication
apart from insulin, or had any intercurrent illness at the
time of study. Ingestion of tea or coffee was not permitted
for 12 h before the study.
The protocol for the study had been approved by the
local medical ethical committee and all participating
patients gave their written consent.
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Protocol
The patients were admitted at 0800 h on the day of the
study, having fasted since 2200 h on the previous
evening. Only unmodified insulin had been administered
during the 24-h period before the study, with the last
insulin dose being administered prior to an evening
snack. Intravenous cannulae (Venflon, Viggo, Helsing-
borg, Sweden) were inserted into both antecubital fossae,
one for blood sampling and the other for administration
of drugs. An intravenous infusion of 50 g I 1 glucose
together with unmodified insulin (Human Actrapid, Novo
Nordisk, Crawley, UK) was commenced to maintain the
plasma glucose concentration in the 5.0—10.0 mmol I-1
range over the subsequent hour. In three patients with a
plasma glucose on admission of > 10.0 mmol I"1 the
insulin infusion was adjusted as necessary to reduce the
concentration below this level. The infusion was then
discontinued and acute hypoglycaemia was induced by
an intravenous bolus injection of Human Actrapid in a
dose of 0.125 U kg-body-weight"1, this technique being
chosen in order to achieve maximal autonomic and
counter-regulatory hormone stimulation. Heart rate,
blood pressure, and capillary blood glucose were moni¬
tored at frequent intervals during the study and the onset
of the acute autonomic reaction (time R) was identified
by the sudden increase in heart rate and sweating.
Subsequent sampling of blood and urine was measured
from this time to eliminate individual variability in the
time taken from the administration of insulin to the onset
of the acute autonomic reaction to hypoglycaemia. Fluid
loading was carried out by giving the patients tap water
to drink (10 ml kg-1) at the time of admission, and the
volume of urine passed subsequently during the study
was replaced orally by an equivalent volume of tap
water. An intravenous infusion of mannitol (200 g I"1)
was also administered continuously at a rate of 50 ml
h"1 throughout the study to maintain a diuresis.
Measurements of Renal Function and
Hormonal Concentrations
Effective renal plasma flow was estimated by the measure¬
ment of clearance of para-amino hippurate sodium
(PAH; Merck, Sharp and Dohme, Hoddesdon, UK). An
intravenous bolus injection of PAH in a dose of 10 mg
kg-body-weight"1 was given at three time-points (30 min
prior to insulin administration, time R and R + 60 min)
with blood samples for PAH measurement being taken
before each injection and then after 5, 7, 10, 15, 20,
30, and 40 min. The effective renal plasma flow was
calculated, using two-compartment kinetics, from the
area under the curve of plasma PAH concentrations
following each IV bolus injection.
Glomerular filtration rate (GFR) was estimated from
clearance of polyfructosan (Inutest, Laevosan, Linz,
Austria), administered as a constant infusion in normal
saline (10 g I"1 at a rate of 120 ml h"1) after an initial
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intravenous bolus dose of 3.5 g. Measurements were
commenced after a 60-min equilibration period, to allow
attainment of steady state plasma levels of polyfructosan.
Blood and urine samples were collected at four time-
points (30 min prior to insulin administration, 10 min
after insulin administration, time R + 60 min and time
R + 120 min) and measurement of polyfructosan concen¬
trations on these specimens allowed calculation of
GFR in the basal period, over the time of the acute
hypoglycaemic reaction and in the recovery period.
Urinary excretion of dopamine, albumin, and sodium
were calculated from each urine specimen. Blood
samples were withdrawn before insulin was administered
and at time R, R + 15 min, R + 30 min, R + 45
min, R + 60 min, R + 90 min, and R + 120 min for
measurement of plasma glucose, plasma renin activity,
catecholamines, and angiotensin II.
Laboratory Methods
Plasma glucose was measured by a glucose oxidase
method using a YSI analyser (Yellow Springs Instruments,
Yellow Springs, OH, USA). Plasma renin activity was
calculated by radioimmunoassay of angiotensin I gener¬
ated under standard conditions (Campagne Oris, Gif-Sur-
Yvette, France). Plasma adrenaline and noradrenaline14
and plasma angiotensin II15 were measured using radioen-
zymatic assays. Blood and urine polyfructosan concen¬
trations were measured by an autoanalyser after conver¬
sion to fructose,16 and PAH was estimated by the method
of Bratton and Marshall, modified for use with an
autoanalyser.17 Plasma concentrations of PAH were less
than 0.3 g I"1 before each IV bolus injection. This
technique for measurement of GFR has an intra-individual
co-efficient of variation (CV) of 13.4 % and for measure¬
ment of renal plasma flow the intra-individual CV
is 9.4 %. Urinary sodium was measured by plasma
photometry and albumin by an immunoturbidimetric
assay.18 Urinary free dopamine was extracted onto
alumina and assayed by HPLC with electrochemical
detection.19
Statistical Analysis
Results, unless otherwise stated, are presented as mean
(SE). Paired t-tests were applied to compare basal values
with values during the period of the autonomic reaction
to hypoglycaemia and during the recovery phase.
Results
All eight patients experienced a typical autonomic
reaction to hypoglycaemia with the onset occurring at a
mean of 35 (range 22-54) min after insulin administration.
The nadir of plasma glucose occurred at time R in three
patients and at time R + 15 min in five patients. Five
patients required an intravenous bolus of 10 g glucose to
accelerate recovery because significant neuroglycopenia
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had developed and/or a plasma glucose level of < 2.0
mmol I"1 persisted after time R + 30 min.
Metabolic and Hormonal Changes
Plasma glucose fell from 6.2 (0.7) to 1.7 (0.2) mmol I-1
at time R (p < 0.001) and 1.6 (0.2) mmol I 1 at time
R + 15 min (p < 0.001) with recovery thereafter to a
level of 5.1 (0.6) mmol I-1 by time R + 120 min (NS
compared with basal value) (Figure 1(a)).
Plasma adrenaline rose from a baseline value of 0.2
(0.03) nmol I-1 to a peak of 1.7 (0.4) nmol I"1 at time
R + 15 min (p < 0.01), falling by time R + 120 min to
0.3 (0.05) nmol I"1 (Figure 1(b)). The minor increase in
plasma noradrenaline from a baseline value of 1.3 (0.4)
nmol I-1 to a peak level of 1.8 (0.3) nmol I 1 at time
R + 15 min was not statistically significant.
Plasma renin activity rose from 0.49 (0.13) ng-Ang I
I"1 h_1 in the basal period to a peak of 1.08 (0.17) ng-
Ang I I-1 Fr1 at time R + 1-5 min (p < 0.01), remaining
significantly elevated until time R + 30 min and then
returning to the basal value by time R + 120 min (Figure
1(c)). Plasma angiotensin II concentrations possibly rose
from a basal value of 5.1 (0.9) ng I-1 to a peak of 7.4
(1.5) ng I-1 at time R + 60 min (p = 0.065), with a fall
to 5.8 (0.6) ng I-1 by time R + 120 min (Figure 1(d)).
Renal Function
Effective renal plasma flow fell from 674 (106) ml min-1
in the basal period to 540 (198) ml min""1 during the
period of hypoglycaemia (p < 0.01), rising to 655 (181)
ml min"1 in the recovery period (NS vs baseline) (Figure
2(a)). GFR fell from a basal value of 143 (23) ml min^1
to 110 (36) ml min-1 during the period of the autonomic
reaction to hypoglycaemia (p < 0.02), rising to 150 (44)
ml min-1 in the recovery period (NS vs baseline) (Figure
2(b)). GFR and renal plasma flow were closely correlated
both in the basal period (r = 0.75, p < 0.05) and during
the period of hypoglycaemia (r = 0.96, p < 0.001). The
changes in GFR and renal plasma flow were also well
correlated (r = 0.78, p < 0.05).
The effects of acute hypoglycaemia on urine volume
and urinary excretion of sodium, dopamine, and albumin
are shown in Table 1. Both urine volume and albumin
excretion rate fell significantly during hypoglycaemia.
Neither fractional nor absolute urinary sodium excretion
changed significantly but a significant fall in urinary
dopamine excretion was observed which did not correlate
with urinary flow (r = 0.20) and was not dependent on
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Figure 1. Mean response (SE) of (a) plasma glucose, (b) plasma adrenaline, (c) plasma renin activity, and (d)
plasma angiotensin II, following intravenous injection of insulin at time 0. R denotes the onset of the acute
autonomic reaction. A significant difference (p < 0.05) from the basal value is shown by *
























Figure 2. Changes in (a) renal plasma flow and (b) GFR in
response to acute hypoglycaemia. A significant difference
(p < 0.05) from the basal value is shown by *
Discussion
In normal humans, the acute activation of the autonomic
(particularly the sympatho-adrenal) nervous system and
the hormonal secretion associated with acute hypoglycae¬
mia have a profound effect on the vascular perfusion
and function of several organs, including the heart,12
the brain,10 the spleen,13 and the kidney.2 Acute
hypoglycaemia induced by an IV bolus injection of
unmodified insulin, as in this study, is likely to maximally
stimulate this neurohormonal activation, in contrast
to stepped hyperinsulinaemic, hypoglycaemic clamp
techniques, which are of greater value in studying
threshold effects.
In the present study, Type 1 diabetic patients who had
normal urinary albumin excretion were shown to have
a fall in effective renal plasma flow and glomerular
filtration rate, by 20 and 23 %, respectively, in response
to hypoglycaemia. Both renal plasma flow and glomerular
filtration rate were higher in the basal state in the
diabetic patients than in a group of non-diabetic subjects
previously studied,2 which is well recognized to be
associated with diabetes and may be maintained by
hyperglycaemia.20-22 In contrast to the findings reported
in non-diabetic subjects,2 a close correlation was ident¬
ified between the changes in glomerular filtration rate
and renal plasma flow. This suggests that in diabetic
patients the glomerular filtration rate may be more highly
dependent on renal blood flow than in non-diabetic
subjects.
Two of the principal groups of hormones which are
known to affect renal blood flow (catecholamines and
angiotensin II) were stimulated to a lesser extent in the
diabetic group in the present study than in the non-
diabetic subjects previously investigated.2 The cate¬
cholamine response to hypoglycaemia may be progess-
ively diminished in patients with Type 1 diabetes of long
duration,23-25 which might partially explain this finding,
despite a significant degree of hypoglycaemia being
achieved in all subjects. Although the hormonal response
was apparently attenuated, a reduction in renal plasma
flow and glomerular filtration rate was still manifest in
the group of diabetic patients. It is possible, therefore,
that direct stimulation of the efferent sympathetic nerves
is the major determinant of changes in renal haemody-
namics occurring secondary to acute hypoglycaemia.
Table 1. Urine volumes and urinary excretion of sodium, dopamine, and albumin in response to
hypoglycaemia
Basal period Period of Recovery P
hypoglycaemia period
Urine volume (ml min-1) 10.6 (1.2) 4.7 (1.1) 7.7 (1.5) <0.002
Absolute sodium excretion (p,mol I-') 262 (38) 250 (43) 303 (50) NS
Fractional sodium excretion (%) 1.3 (0.2) 1.7 (0.3) 1.6 (0.2) NS
Dopamine (prmol min-1) 322 (37) 211 (29) 230 (25) <0.005
Urinary albumin concentration (mg I-1) 4.2 (1.0) 5.4 (1.1) 4.6 (1.1) NS
Albumin excretion rate (|xg min-1) 46.2 (10.6) 26.0 (10.5) 42.6 (9.3) <0.005
Mean (SE).
Significance is tested between time of hypoglycaemia and basal period.
The basal period commenced 30 min before the insulin bolus was given and ended 10 min after insulin injection.
The period of hypoglycaemia commenced at the onset of the acute autonomic reaction (time R), ending at time
R + 60 min. The recovery period extended from time R + 60 min to time R + 120 min.
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The potential role of the fall in plasma glucose per
se does, however, deserve comment in this context.
Mogensen ef a/.26 previously demonstrated a significant
fall both in GFR and in renal plasma flow, in a group
of diabetic patients, when the blood glucose level was
reduced from 13.9 mmol I-1 to 6.5 mmol I-1, without
a simultaneous rise in catecholamine concentrations.
These changes do not appear to be explicable on the
basis of changes in plasma volume or of concurrent
sympathetic activation occurring in response to hyperin-
sulinaemia.27-28
Vasopressin is secreted in response to acute hypoglycae-
mia and this is markedly enhanced in diabetic patients.3'4
The significant fall in urine volume observed in the
diabetic patients during hypoglycaemia is likely to be
explained by this augmented vasopressin response to
hypoglycaemia, rather than simply bladder emptying
problems, as such a reduction was not found in non-
diabetic subjects using identical techniques.2 The rapid
reduction in urinary flow rate in response to hypoglycae¬
mia may also underlie the fall in urinary albumin
excretion rate. The unexpectedly elevated basal albumin
excretion rate is probably related to the prevailing diuretic
conditions, as it has been shown previously that the
urinary albumin excretion rate rises significantly in
response to water loading, falling again when the urinary
flow rate returns to normal.29 Changes in urine volume
may have determined alterations in urinary albumin
excretion which have been reported previously in
response to insulin infusion,30 although others have
suggested that the urinary albumin excretion rate actually
rises in response to a falling plasma glucose concentration
in diabetic patients.26'28
Urinary dopamine excretion fell in response to hypogly¬
caemia but, in contrast to previous findings in non-
diabetic subjects,2 no significant change either in total
or in fractional sodium excretion occurred in the diabetic
patients. A close correlation has been observed between
urinary dopamine and sodium excretion in the normal
kidney,31 and a fall in urinary sodium excretion might
have been anticipated on the basis of insulin inhibiting
the renal excretion of electrolytes32,33 and enhancing
sodium reabsorption in the renal tubules.34 One possible
explanation for this apparent difference between diabetic
and non-diabetic subjects is the absence of a significant
rise in plasma noradrenaline in response to hypoglycae¬
mia in the diabetic group, as noradrenaline promotes
sodium retention, via alpha receptors in the proximal
tubules,35 and this is independent of haemodynamic
effects.
An overall reduction in the prevailing level of blood
glucose control is one of the main therapeutic aims of
diabetic management but a potential risk of such a
strategy is to increase the frequency of hypoglycaemia.
The present study has examined the effects of hypoglycae¬
mia on the kidney in diabetic patients who have no
clinical or biochemical evidence of nephropathy. If these
changes in renal haemodynamics and function are
Dm
superimposed upon the documented changes in plasma
viscosity6,7 and platelet activation5,36 which are known
to occur in response to hypoglycaemia, the combined
effects are potentially deleterious,37 particularly in pati¬
ents who have established renal microangiopathy.
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